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General introduction
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Chapter 1
Adolescents and young adults: defining the age group
Over the past decades there is growing attention for adolescents and young 
adults (AYA) diagnosed with cancer1. Stuck between paediatric and adult 
oncology, AYA cancer patients form a distinct, understudied and underserved 
group in cancer care2,3,4. The definition of the AYA age range focussing on young 
cancer patients has evolved over time. There is international consensus that the 
definition of adolescence in the context of cancer ranges from 15 to 19 years 
and that adolescence has a transition to young adulthood, starting in the early 
twenties5. However, there is no agreement on the upper age limit; 24, 25, 29, 
35 and 39 years have been used6. The US National Cancer Institute defines AYA 
age as 15-39 years at cancer diagnosis, but also proposed that the age range 
should be handled with flexibility, depending on the research question and the 
health care system4,7. Conceptually, definitions can be based on physical and 
psychological development and the accompanying care system (paediatric 
versus adult oncology), aspects of tumour pathology or biology, or on health 
outcomes8,9. In the Netherlands, the definition of the AYA age range ,18-35 years 
at cancer diagnosis, is based on the organisation of the health care system, in 
which there is a clear distinction between paediatric (birth to 18 years) versus 
adult oncology (18 years and older). The upper age limit of 35 years was chosen 
based on cancer epidemiology. Over the age of 30 there is an increasing number 
of patients with common cancers, in particular breast cancer, for which already 
dedicated cancer care teams exist, which is increasingly the case beyond the 
age of 35 years. Furthermore, to start a new dedicated AYA service, the numbers 
should be such that it is worthwhile to instigate age-specific services, as AYA 
patients - in contrast to paediatric cancer patients - are dispersed among several 
hospitals in the Netherlands. This means that the upper age limit should not be 
too low. Therefore, the pragmatic Dutch AYA age definition is 18-35 years at 
diagnosis. 
The AYA cancer patient: what makes them a unique 
group in oncology? 
Epidemiology
Cancer at AYA age is rare. In the Netherlands approximately 2,700 AYA patients, 
aged 18- 35 years,  are diagnosed with cancer annually - around five times the 
number of cases diagnosed in children aged 0-17 years10. The incidence of cancer 
is rising, specifically among those aged 25-39 years and for melanoma, testicular, 
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1thyroid, breast and colorectal cancers. AYAs typically present with either a paediatric malignancy at older age (e.g. acute lymphoblastic leukaemia (ALL), 
brain tumours), a tumour typically of AYA age (e.g. Hodgkin’s disease, germ cell 
tumour, melanoma or thyroid cancer) or with an adult carcinoma at relatively 
young age (e.g. breast and colorectal cancer)11. Lymphomas, breast, melanoma, 
testicular, colorectal and thyroid cancer, female genital tract malignancies, 
bone and soft tissue sarcomas, leukaemias and central nervous system cancers 
account for 95% of the cancers in this age group. The frequency and incidence of 
distribution of cancer types is remarkably different across the age spectrum of 
AYA patients, with -as stated above- more and more carcinomas being diagnosed 
among patients in their thirties. Five-year relative survival rates for AYAs with 
cancer continue to increase in the Netherlands, exceeding 80% for all diseases 
combined10. Although the gains occur for some tumour types more slowly than 
in children and older adults, a fairly good survival is found for most tumour 
types, with a marked exception for e.g. certain leukaemias, central nervous 
system tumours, and some sarcomas (e.g. rhabdomyosarcoma). Potential 
reasons for the relatively lack of progress in survival for some tumour types are 
delay in diagnosis due to unfamiliarity with cancer at AYA age12,13, differences 
in disease biology (cancers that are histologically indistinguishable across the 
age spectrum may be characterised by particular adverse biological features 
in the AYA population (e.g. increasing complexity with age, such as is seen in 
synovial sarcoma)14,15, low clinical trial availability and participation rates16,17, 
lack of knowledge and paediatric sparring partners in adult teams regarding 
typical paediatric cancers, possibly relatively poorer tolerance of chemotherapy 
schedules in AYA as compared to children7,18-20. 
Developmental phase
Adolescence and young adulthood are complex phases of life due to the many 
rapidly occurring developmental, emotional and social transitions. Young people 
aim to achieve many developmental milestones in a rather short time frame such 
as completing education, establishing autonomy, creating their own identity, 
forming (romantic) relationships, pursuing gainful employment, becoming 
financially independent and starting a family21,22. The period of adolescence 
and young adulthood, characterised by physical growth on the one hand and 
psychosocial maturation on the other hand, has three developmental stages. 
Each developmental phase is characterised by different dilemmas. In early 
adolescence (12-18 years) group identity is an important milestone. Adolescents 
find safety and trust in peer groups based on mutual characteristics, which helps 
them to become more detached from their parents. In adolescents with severe 
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illness, there is a risk that this milestone will not be reached, due to absence at 
school where groups usually are formed. This can lead to feelings of alienation 
and problems with forming social networks. The period of late adolescence (19-
22 years) comes with forming personal identity and roles. Severe and chronic 
illness may hinder a person to develop an own identity and the dominant patient 
role may interfere with the achievement of personal, social or educational 
plans. This can result in adjustment problems and diminished self-esteem. 
In young adulthood (23-34 years) partner relationships and intimacy are 
important milestones. Young people who do not achieve these milestones in 
early adulthood may experience isolation23,4. In all three developmental phases 
experimenting with these transitions and dilemmas is very important, however 
still with the support and within the safety net of family and peers. 
Cancer challenges AYAs’ abilities to achieve these milestones, which can lead 
to stagnation of their normal development24. Although AYA cancer patients 
experience challenges similar to those of older and younger patients, including 
short-term (e.g. hair loss, nausea) and long-term effects of cancer treatment 
(e.g. pain, psychological distress, fear of cancer recurrence), these effects 
interfere more severely with daily functioning in combination to age-specific 
challenges of specific developmental phases. Cancer often forces AYAs to 
move back home and become dependent on parents, usually after periods of 
time living independently or while just discovering and experiencing newfound 
autonomy and independence. Changes in physical appearance resulting from 
treatment (e.g. amputation, hair loss or weight change) can negatively impact 
body image (looking not similar to peers) and interfere with self-esteem and 
identity development. Negative body image, low self-esteem, infertility 
concerns, or feeling abnormal due to cancer and its treatment might negatively 
influence AYAs’ readiness and ability to engage in romantic relationships or 
sexual activities. Often, AYAs have concerns about sexuality and procreation, 
which are not always expressed by themselves or addressed by their treating 
physicians and some AYA experience a delay in achieving psychosexual 
milestones (e.g. dating and sexual intercourse), while others may show sexual 
risky behaviour25.  In young adults, emotional and financial burden of a cancer 
diagnosis may have negative impact on the partner relationship leading to 
distress among AYAs and their partners. Isolation and alienation are commonly 
reported among AYAs with cancer, particularly when they miss part of the peer 
group life because of cancer treatments and, therefore, lack experiences being 
shared by their healthy peers. AYAs frequently report difficulties maintaining 
or making new relationships as they feel anxious about fitting into their peer 
group again. On top of these emotional roller coasters, cancer treatment and 
13
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1long-term and late medical effects can lead to serious disruption in education and lead to employment problems (unemployment, returning back to work,  job 
insecurity) which may give AYAs the feeling of being “left behind”. In addition, 
AYA cancer survivors report issues with getting mortgages and insurances, 
and have to deal with financial difficulties. Young adults with young families 
are faced with competing responsibilities in which care for children and lack of 
transportation for hospital visits, may also lead to lower treatment compliance 
levels21. These AYA age-specific topics are nicely shown in figure 1. 
Figure 1: Age-specific topics in the AYA cancer patient population
Part I: Health-related quality of life, psychosocial 
outcomes and adaptations
For decades, the success of cancer treatments has focused on objective 
outcomes such as radiological response, progression-free and overall survival, 
and healthcare-provider perspective of treatment-related toxicities. More 
recently, increasing attention has been given to patient reported outcomes 
(PROs), defined as ‘any report of the status of a patient’s health condition 
that comes directly from the patient, without interpretation of the patient’s 
14
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response by a clinician or anyone else’26, in order to evaluate treatment efficacy. 
PROs include a range of outcomes such as symptoms, functioning and health-
related quality of life (HRQoL). HRQoL is the most widely used PRO and is 
defined as a multidimensional concept that includes the patient’s perception 
of the impact of the disease and its treatment on physical, psychological and 
social functioning. Data on HRQoL in AYA patients are still limited, however, as 
described above, many patients experience a substantial burden of physical and 
psychological symptoms, with an adverse impact on HRQoL. Two recent review 
papers showed that AYA with cancer experience worse HRQoL compared with a 
normative population27,28. HRQoL assessment in clinical practice throughout the 
course of the disease is important as it can facilitate communication, improve 
symptom control and patient satisfaction and reduce hospital admissions29. 
Negative and positive outcomes 
Within the perspective of the developmental phases, the emergence of distress 
or resilience is a function of the extent to which the illness interrupts key 
developmental tasks, and/or the extent to which the young person is able to 
mitigate these hurdles to normal, age-appropriate development30.
Negative outcomes associated with cancer at AYA age
In order to provide optimal age-specific supportive care it is important to get 
insight into the prevalence of AYA (age-specific) HRQoL issues and identify AYA 
patient subgroups that might be more susceptible to poor HRQoL outcomes 
and subsequently might benefit from additional support or interventions. Apart 
from patients’ point of view it is essential that health care professionals are 
aware of which HRQoL issues matter most to AYA cancer patients. Because 
cancer at AYA age is rare, many health care professionals only occasionally have 
to care for AYA patients and therefore may have a lack in their knowledge and 
unintentionally deliver less optimal age-specific care. Two important issues 
AYA cancer patients may be confronted with are fear of cancer recurrence and 
fatigue7; both may have debilitating effects on their HRQoL. Fear of cancer 
recurrence is defined as the “fear, worry, or concern relating to the possibility 
that cancer will come back or progress”31. Previous research showed that 
psychosocial help for fear of cancer recurrence is a key unmet need among AYA2. 
However, less is known about the prevalence and correlates of fear of cancer 
recurrence among AYA. Cancer-related fatigue is one of the most common and 
distressing symptoms reported by cancer patients in general both during and 
after cancer treatment32,33. Little is known about the prevalence, impact, and 
correlates of severe fatigue among AYAs. 
15
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1Positive outcomes associated with cancer at AYA ageNext to a negative impact, AYA cancer patients may also experience positive 
(adaptive) outcomes, like post-traumatic growth and resilience. Post-traumatic 
growth is described as the positive psychological change that appears 
following significantly burdensome or traumatic life events34. Resilience is the 
ability to cope with negative emotions that arise from a stressful experience, 
by identifying and developing resources to function35. Over the past decade 
psychosocial research in AYA has broadened its scope from negative to positive 
aftermath of cancer. It could be hypothesized that both post-traumatic growth 
and resilience might promote HRQoL and buffer negative consequences of 
cancer. Empowerment is also a positive factor that may be associated with 
HRQoL and has been introduced as issue in cancer survivorship research over 
recent years36-39. Empowerment is the feeling of being able to manage the 
challenge of the cancer experience and having a sense of control over one’s 
life40. Empowered AYA cancer patients may be more likely to understand and 
participate in their own care by mobilizing resources and taking actions that 
can reduce distress, enhance strategies for dealing with cancer and improve 
HRQoL36,37. It is therefore important to evaluate which sociodemographic, 
clinical and psychological factors are associated with positive outcomes among 
AYA cancer patients. 
Part II: Supportive and palliative care
AYA cancer patients have often been identified as the “lost tribe”. There is no 
medical “home” for AYAs with cancer as neither paediatric departments, which 
are disease and family-focused, nor adult oncology  departments which are 
mainly disease-focused, are able to provide age-adjusted care to this specific 
group9. This is even more the case for AYA cancer patients who are in a palliative 
trajectory. They may lack the option of family care and may feel too young 
for general palliative and hospice care. It is, therefore, of great importance to 
understand the needs of the AYA cancer patients in different stages of cancer.
Psychosocial and supportive care needs 
The psychosocial and supportive care needs of AYAs tend to be broader in 
scope and intensity compared to younger and older patients, because of the 
many developmental, emotional and social changes and transitions that occur 
in a rather short period of time during this specific phase of life. Data from a 
large national survey of 523 AYA cancer survivors in the USA found that 53% 
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of them reported having six or more unmet information needs (e.g. developing 
another type of cancer, signs of cancer recurrence, late effects of cancer, family 
members’ risk of cancer, financial needs, and fertility issues). Furthermore, 35% 
had unmet service needs, especially with regard to peer support and psychosocial 
supportive care2. Another national survey among 1395 AYA cancer survivors 
in the USA has shown that the most commonly reported unmet needs were 
addressing recurrence concerns (80%), followed by information on late effects 
(78%), family risk of cancer (51%), and fertility information (45%)41. Having 
unmet information or service needs was associated with poorer HRQoL42,43.
Palliative and end-of-life care
The World Health Organization defines palliative care as “an approach that 
improves the HRQoL of patients and their families facing the problem associated 
with life-threatening illness, through the prevention and relief of suffering by 
means of early identification and impeccable assessment and treatment of pain 
and other physical, psychosocial and spiritual problems”44. Palliative care in AYA 
cancer patients is different since AYA have had less time to learn from other 
adverse life experiences to help manage the effects of advanced disease. They 
face many complicated decisions but may lack the fully developed executive 
functioning and abstract thinking necessary for medical decision-making and 
coping with uncertainty45. AYAs can report anticipatory grief over their lives that 
have not yet been lived and they incline to act normal as long as possible. A 
previous study showed that AYAs who die in the hospital tend to use palliative 
care services very late in the course of the disease and often undergo aggressive 
treatment until death is near46. A timely introduction of palliative care would 
have great use in providing physical, psychosocial, and spiritual support. 
Palliative care should be part of the comprehensive cancer care for AYAs47. It 
is important not to assume that AYA patients may be less willing to discuss 
death and other end-of-life issues like nutrition/hydration, sedation, treatment 
cessation and place of death48. Another important aspect of palliative and 
end-of-life care concerns the interprofessional communication. Optimal and 
timely communication between hospital health care professionals and general 
practitioners is essential for a good transition of care. Although this statement 
can be made for all patients who don’t need any further hospital-based care, the 
specific needs and issues that play a role in end stage life of AYA cancer patients 
should be addressed properly. Moreover, end-of-life care for AYA cancer patients 
differs from ‘normal’  adult end-of-life care since AYA do not frequently have 
comorbidities and can therefore have a longer process of dying. 
17
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1Organisation of care for AYA cancer patients in the Netherlands: the Dutch AYA ‘Young and Cancer’ Platform
Over the last decades, the oncology community became aware of the gap in the 
care needs and outcomes of AYA cancer patients1,4. Comprehensive assessment of 
the needs is necessary to optimise services for AYAs. The existing organisational 
models of paediatric and adult (medical) oncology are not ideally suited to 
the complex needs of AYA patients, which require a different, new, patient-
focused multidisciplinary approach1. National AYA programs were formed in 
an attempt to bridge the gap between the two worlds and address unmet care 
needs of this patient group. In the Netherlands, in 2009, the Radboud university 
medical center (Radboudumc) in Nijmegen, in the east of the Netherlands, 
launched the AYA Expertise Platform, in a close collaboration between AYAs and 
professionals49. The main goal of the Platform was to improve the care for and 
the quality of life of AYA cancer patients by offering structural, standardised, 
comprehensive and patient-centered AYA cancer care. An AYA outpatient clinic 
was launched where AYA cancer patients, regardless of their treatment status, 
type and intent of treatment, could address their age specific questions to a 
dedicated multidisciplinary AYA team (nurse, medical oncologist, psychologist 
and social worker). Interviews with AYAs showed that one of the most important 
unmet needs was (digital) peer support. Therefore, in 2010 an online community 
named AYA4 (All Information You’ve Asked for) was developed by and for AYA 
cancer patients treated at the Radboudumc. The online community became 
available for all AYA cancer patients in the Netherlands in 2014.
Aims and content of this thesis
The overall purpose of this thesis is to gain scientific knowledge about the most 
important HRQoL issues, psychosocial outcomes and adaptations and quality 
of care issues among Dutch AYA cancer patients, leading to insights into the 
(further) development of optimal age-specific AYA care. The current thesis can 
be divided in two parts. Part I addresses HRQoL, psychosocial outcomes and 
adaptations. Part II describes supportive and palliative care initiatives. 
18
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Part I: Health-related quality of life, psychosocial 
outcomes and adaptations
The first part of this thesis is focused on HRQoL in general and on specific 
psychological issues AYA cancer patients are confronted with that may affect 
their HRQoL, in particular  fear of cancer recurrence and fatigue. In Chapter 2 the 
ten most important HRQoL issues for AYA cancer patients will be investigated 
and a comparison with the perception of health care professionals  will be made 
to determine whether there is a discrepancy in assessment of disease impact 
between patients and professionals. In Chapter 3 the prevalence, correlates of 
high fear of cancer recurrence and its association with HRQoL in AYA cancer 
patients who visit the multidisciplinary team of the AYA outpatient clinic will 
be explored. In Chapter 4 the prevalence of severe cancer related fatigue in 
AYA cancer patients will be subject of study and will be compared with matched 
population-based controls. This chapter will also report on the impact of severe 
fatigue on HRQoL of AYA cancer patients. In addition, correlates of fatigue 
severity will be studied. 
Next to negative consequences, patients with cancer at AYA age may also 
experience more positive psychosocial outcomes related to personal resilience or 
feelings of empowerment and post-traumatic growth. In Chapter 5 an overview 
of the literature on post-traumatic growth and resilience in AYA cancer patients 
will be given to explore the most important clinical, sociodemographic and 
psychological variables associated with post-traumatic growth and resilience, 
their relationship with HRQoL and possible interventions to improve PTG and/
or resilience. In Chapter 6 the levels and associated factors (demographic, 
clinical and psychological) of empowerment and the association between 
empowerment and HRQoL will be examined in AYA cancer patients. 
Part II: Supportive and palliative care
The second part of this thesis is focused on supportive care aspects among AYA 
cancer patients. In Chapter 7 a study on the secure online support community 
for AYA cancer patients will be described by providing user statistics, 
questionnaire data about usefulness, and a content analysis. As one in five AYA 
patients eventually die of cancer, the availability of age-adjusted palliative care 
including end-of-life care is of utmost importance. In Chapter 8 the experiences 
of bereaved parents concerning the palliative care for their child and (after)
19
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1care for themselves, social support and their psychological wellbeing will be investigated. In addition, the experiences of general practitioners regarding 
the palliative care of a terminally ill AYA cancer patients and their families will 
be studied. Finally, Chapter 9 will provide a summary and discuss the practical 
implications of the findings presented in this thesis and makes recommendations 
for future research. 
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Abstract 
Objectives: To determine health-related quality of life (HRQoL) priorities of 
adolescent and young adult (AYA) cancer patients and examine discrepancies 
between AYA and health care professionals (HCP).
Methods: Dutch AYA cancer patients aged 18-35 years at time of cancer 
diagnosis (N=83) and Dutch HCP (N=34) involved in AYA oncology were invited 
to complete the Quality of Life for Cancer Survivors questionnaire.  
Results: Patients scored significantly lower on negatively formulated HRQoL 
issues (e.g. fatigue, coping difficulties, feeling isolated) and significantly higher 
on positive formulated issues (e.g. support from others, overall physical health, 
happiness) compared to HCP. The most important issues for AYA cancer patients 
were: perceived support from others, distress about initial cancer diagnosis, 
distress for family, overall quality of life and happiness. HCP perceived distress 
about initial cancer diagnosis, distress for family, cancer treatment distress, 
interference of illness with employment/study and fatigue as most important 
for AYA. The top 10 priorities of patients vs. perceptions of HCP overlapped for 
5 of 10 issues. 
Conclusion: AYA cancer patients perceived most HRQoL items as less 
problematic compared to HCP. The discrepancy between patients and HCP 
illustrates the importance of patient participation, i.e. involving patients in 
organizing and prioritizing their own (psychosocial) care. 
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Introduction
Adolescents and young adults (AYA), being diagnosed with cancer at the age of 18 
to 35 years, are a distinct group halfway between paediatric and adult oncology. 
Over the last decades, the incidence of cancer in AYA has increased in Europe 
as well as the United States and Canada 1-3. In the Netherlands about 2700 new 
patients per year are diagnosed with cancer in this age group 4. Although the 
improvement in survival rates of AYA cancers lags behind that of childhood and 
adult cancers, the vast majority of AYA cancer patients will become survivors as 
the overall 5-year survival rate in the Netherlands is 80% 5. 
AYA cancer patients are in a phase of life where they have to reach developmental 
milestones such as completing education, getting intimate relationships, 
pursuing gainful employment or having children 6. Cancer challenges AYAs’ 
abilities to achieve these milestones. Problems concerning self-esteem, 
autonomy, body image, fertility and sexuality may have a negative impact on 
health-related quality of life (HRQoL) of AYA cancer patients 6-8. 
In recent years there is increasing attention to patient-reported outcomes 
(PROs), including HRQoL assessment in AYA cancer patients 9. A PRO is defined 
as information about the status of a patient’s health condition that comes 
directly from the patient, without interpretation of the patient’s response 
by a clinician or anyone else 10. Patients’ HRQoL can be evaluated in multiple 
domains including physical, psychological, social, and spiritual well-being 
11,12. HRQoL measurement in AYA cancer patients allows physicians to better 
understand the complexity of taking care of AYAs with cancer 9,13-15. Validated 
HRQoL questionnaires are mostly analyzed on scale level and although this 
is psychometrically the soundest method, it can cause loss of information. 
Evaluating HRQoL on item level will provide more detailed information about 
which items result in low scale scores and about aspects of HRQoL where AYA 
patients need more (age-specific) support. 
To achieve optimal patient-centred care, it is essential that health care 
professionals (HCP) are able to assess AYAs’ needs and preferences. A previous 
study in Australia showed that most oncology professionals recognized the 
unique nature of the AYA population (defined as cancer patient 15-25 years) 
regarding biological, genetic, epidemiological, psychological, social and 
cultural factors. In that study the results of the HCP were compared with 
previous research on unmet needs among AYA cancer patients. HCP broadly 
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misrepresented the priorities of AYA as being related to survival outcomes, 
concerns about death and dying, and functional well-being. HCP perceptions 
were largely in contrast with the priorities of AYA following a cancer diagnosis, 
which related more broadly to issues associated with normal life stage 
development including peer and family relationships, engagement in education 
and employment, development of autonomy and treatment environment (in- or 
outpatient, facilities, staff) 16. Although this Australian study showed significant 
discrepancies for the younger AYA patients with cancer compared to HCP, it is 
not clear if the discrepancies also exist for young adults diagnosed with cancer 
between 18 and 35 years. One could assume that this age group has reached 
another life phase with different milestones, more responsibilities and more 
independence from parents in comparison to cancer patients aged 15-25 years. 
Moreover, it would be interesting to evaluate whether this incongruence exists 
in the Dutch system with its clear distinction between paediatric and adult 
oncology. 
Assessing HRQoL priorities and providing care according to these priorities 
might lead to higher patient satisfaction and can improve doctor-patient 
partnership and ultimately overall quality of care 17. Therefore, the aims of the 
current study are to: 1) determine the top ten HRQoL priorities on item level 
relevant to AYA cancer patients (according to gender, cancer type, treatment 
intention, partner status and having children); 2) determine whether there is a 
discrepancy between items prioritized by AYA patients and oncology HCP.
Methods
Participants
Patients aged 18 to 35 years at time of cancer diagnosis and who had been seen 
by at least one of the members of the AYA team of the Radboud university 
medical center (Radboudumc) in The Netherlands, were invited to participate in 
this study. The Radboudumc is an expert center in delivering age-specific care 
for AYA cancer patients during and after cancer treatment. The AYA team is a 
dedicated multidisciplinary team including a medical oncologist, clinical nurse 
specialist, medical psychologist, and social worker. Patients consulting the AYA 
team receive standard medical care from their own treating physician in the 
Radboudumc (medical oncologist, haematologist, surgeon, gynaecologist etc.) 
and visit the AYA team for age-specific questions and care needs. In general, 
patients visiting the AYA team represent a group of patients with high disease 
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severity, diagnosed with relatively advanced stage of disease and undergoing 
intensive treatments, and reporting more difficulties with coping. Patients 
with lower stage disease treated solely by surgery, are not often seen by the 
AYA team. For this study, AYA patients were included independently of the 
status of treatment (during or after treatment), the type of treatment (surgery, 
chemotherapy, radiotherapy, immunotherapy/targeted therapy and hormonal 
therapy or a combination), or the number of AYA team visits (some patients only 
had one introduction talk with one of the members of the team and did not 
receive specific care thereafter, whilst others visited members of the AYA team 
more frequently) to depict the real-life heterogeneous sample of AYA cancer 
patients visiting the AYA team. Inclusion commenced January 2012 and ended 
March 2016. 
Dutch HCP involved in AYA oncology were asked at the 2017 annual AYA 
congress on age-specific care to participate in the study. Moreover, an e-mail 
was sent to the HCP members of the Dutch AYA ‘Young and Cancer’ Platform 
in order to ensure maximal participation rate. Background information of the 
HCP was gathered including age, gender, type of oncology HCP, hospital name 
and how many AYA cancer patients they saw per month via self-developed 
questions. HCP were asked to complete the Quality of Life for Cancer Survivors 
questionnaire according to their thoughts of the items that play a role in the AYA 
population after being treated for cancer. 
Procedure
Potential study participants were recruited via letters describing the study and 
inviting patients to participate. Patients who were willing to participate had to 
actively opt-in to the study by providing written informed consent by e-mail to 
a member of the AYA team. Participants were then sent the questionnaire by 
e-mail that could be completed online. The study was deemed exempt from 
full review and approval by a research ethics committee (CMO Regio Arnhem-
Nijmegen, #2016-2872) 
Measures
Sociodemographic and clinical characteristics
Demographic data, including age, sex, partnership, having children, living 
situation, educational level and employment status were gathered by self-report. 
Medical data, including tumour type, disease stage, type(s) of treatment(s) 
received, treatment status at participation (on/off treatment) and time since 
initial diagnosis were extracted from the patients’ medical records by one of the 
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researchers (SK). 
Health-related Quality of Life Questionnaire
AYA cancer patients
The Quality of Life for Cancer Survivors (QoL-CS) questionnaire measures the 
HRQoL of cancer patients. It consists of 41 items on the physical, mental, social, 
spiritual impact of cancer on the life of the patient. Respondents rate themselves 
along an interval rating scale ranging from 0 to 10 for each item. An overall QoL 
score was computed by averaging all 41 items 18. We adapted the questionnaire 
slightly by adding four items (neuropathy = a burning or tingling sensation or a 
feeling of numbness, concerns of dying, concerns about fertility, concerns that 
family members will get cancer). These reflect problems/concerns faced in daily 
clinical practice. The items local recurrence and distant metastases have been 
combined into 1 item. Therefore, the total number of items is 44. Questions can 
be negatively or positively formulated. A negatively formulated question means 
that a higher score illustrates a bigger problem, for example: ‘To what extent 
is sleeping a problem?’ (0=no problem, 10= very big problem). A positively 
formulated question means that a higher score illustrates more benefit, for 
example: ‘How useful do you feel?’ (0=not at all, 10= very useful).   
Statistical analysis
Analyses were performed using SPSS statistical software (version 24, Chicago, 
IL, USA) and two-sided p values of <.05 were considered statistically significant. 
Differences in HRQoL items between two groups were compared with an 
independent t-test and between more than two groups with an analysis of 
variance  (ANOVA). For AYA cancer patients HRQoL items were analysed 
according to five variables: gender (male/female), cancer type (testicular, 
sarcoma, breast, haematologic, gynaecologic and other), treatment intention 
(curative/palliative), partner (yes/no) and children (yes/no). Three items 
(importance of religious activities, importance of spiritual activities and spiritual 
change) were excluded, as they reflect religious aspects and their intrinsic value 
differs per person dependent on cultural and religious background. Clinical 
significance was determined by applying Normans rule of thumb (observed 
difference exceeds 0.5 x mean standard deviation)19.
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Results
Sociodemographic and clinical patient characteristics
In total, 309 letters requesting participation in the study were sent to AYA cancer 
patients visiting one of the members of the AYA team. A total of 89 patients, 
comprising 57% of those who opted to take part in the study (155 patients) 
and 29% of those invited (309 patients) completed the online questionnaire. 
The remainder 66 patients eventually did not fill out the questionnaires after 
they previously agreed to do this. A small part of non-participation was due to 
technical problems when returning the online questionnaires. Six patients were 
excluded due to age criteria: 4 were diagnosed with cancer <18 years and 2 were 
aged >35 years at the time of diagnosis. Table 1 displays sociodemographic, 
disease, and treatment-related characteristics of the final sample (83 patients). 
The mean age at the time of diagnosis was 27.5 (SD=4.6) years with a range 
of 18 to 35 years and a median age at diagnosis of 27 years. The average time 
since diagnosis was 2.1 years (SD=2.6) and 86% of patients received curative 
treatment. Of the participants, 52% were male. The most commonly diagnosed 
cancers were testicular cancer (34%) and sarcoma (19%).
Characteristics health care professionals
Thirty-four HCP derived from 12 hospitals, filled out the QoL-CS questionnaire. 
Among them were 11 medical oncologists, 5 nurse specialists, 11 nurses, 1 social 
worker, 1 physical therapist, 1 rehabilitation specialist, 2 psychologists and 1 
who did not report his/her medical profession. Their mean age was 45 years with 
a range of 23 to 64 years. Of the HCP 12% (n=4) were male. Each of them guided 
a mean of 15 (range 1-70) AYA cancer patients monthly. Four HCP were from 
non-university hospitals. 
HRQoL items
Table 2 shows mean (+SD) scores on HRQoL items for AYA cancer patients and 
HCP. HCP rated physical symptoms like fatigue, appetite, pain, constipation, 
sleep disorders, nausea and neuropathy among AYA cancer patients 
significantly higher compared to what AYA cancer patients reported as their 
own most relevant issues. These differences were clinically relevant. AYA cancer 
patients rated overall physical health and quality of life, happiness, satisfaction, 
usefulness and support from others (all positively formulated questions) 
significantly higher compared to HCP. HCP rated distress about time since 
treatment completion, anxiety, depression, fear of future tests, fear of recurrent 
cancer, fear of dying, problems with personal relationships, sexuality, concerns 
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about fertility, interference with illness of employment/study, feeling isolated, 
uncertainty about the future and life purpose as clinically relevant and more 
important HRQoL items in comparison to AYA cancer patients. 
Table 1: Demographic and clinical data of AYA cancer patients
AYA cancer patients N=83
Gender
Male
Female
43 (52%)
40 (48%)
Age at diagnosis, mean 27.5 (4.6)
Age at survey 29.6 (4.8)
Time since cancer diagnosis 2.1 (2.6)
Cancer diagnosis
Testicular cancer
Sarcoma
Breast cancer
Lymphoma/leukaemia
Gynaecological cancer
Melanoma 
Other *
28 (34%)
16 (19%)
10 (12%)
10 (12%)
9 (11%)
3 (4%)
7 (8%)
Stage
NA
Stage 1
Stage 2
Stage 3
Stage 4
Unknown
9 (11%)
11 (13%)
25 (30%)
13 (16%)
18 (22%)
7 (8%)
Treatment intention 
Curative
Palliative
71 (86%)
12 (14%)
Treatment status at participation
Active 
Completed
22 (27%)
61 (73%)
Treatment type 
Surgery
Chemotherapy
Radiotherapy
Immunotherapy/targeted therapy
Hormonal therapy
Systemic therapy other
70 (84%)
72 (87%)
24 (29%)
13 (16%)
7 (8%)
13 (16%)
Partner
Yes 
No
58 (70%)
24 (29%)
Children
Yes
No
27 (33%)
55 (66%)
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Table 3a shows the top ten of most relevant HRQoL items rated by AYA cancer 
patients and HCP and the overlapping items in the middle column. Support 
from others was ranked as the most important HRQoL item among AYA cancer 
patients, followed by distress about initial cancer diagnosis and distress for 
family. These last two items were ranked as most important by HCP. Only five 
out of ten items were similar for patients and HCP. Six out of ten items of AYA 
cancer patients were positively formulated. Table 3b displays top ten HRQoL 
items rated by AYA cancer patients and HCP for only negatively formulated 
items. It shows that the first three items are similar for both groups (distress 
about cancer diagnosis, distress for family and distress about cancer treatment). 
Six out of ten items overlapped.  
Table 4 depicts the top ten most important HRQoL items for AYA cancer patients 
according to gender, cancer type, treatment intention, partner and having 
children. It shows that male AYA cancer patients scored significantly higher on 
items concerning quality of life, happiness, satisfaction, hopefulness, overall 
physical health and experienced less interference with activities at home. 
The difference between males and females on the item satisfaction was not 
clinically relevant. Between tumour types there were differences on the items: 
quality of life, happiness, cancer treatment distress, overall physical health 
and interference with activities at home. For sarcoma patients these effects 
were more outspoken than for patients with other cancer types. AYA cancer 
patients treated with curative intention scored significantly higher on items 
concerning quality of life, hopefulness and overall physical health in comparison 
Table 1: Continued
Living situation
With parents
On own
With partner
14 (17%)
24 (29%)
44 (53%)
Highest completed education
Low/intermediate vocational education or less
High-level vocational education and/or university
38 (46%)
44 (53%)
Employed/studying
Yes
No 
68 (82%)
15 (18%)
Not all numbers add up to 83 because of missing data
*Other cancer types comprise brain tumour (n=1), sigmoid carcinoma (n=1), oropharyngeal 
cancer (n=1), neuroendocrine tumor (n=1), salivary gland cancer (n=1), adrenal carcinoma (n=1), 
lung cancer (n=1)
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Table 2: Mean scores (SD) on HRQoL items of AYA cancer patients and health care professionals
 
AYA (n=83) Health care professionals (n = 34) P-value
Physical well-being
Fatigue 4.4 (2.7) 7.3 (1.2) 0.000**a
Appetite 1.5 (2.2) 5.1 (2.3) 0.000**a
Pain 2.3 (2.3) 4.3 (2.0) 0.000**a
Constipation 1.8 (2.4) 3.7 (1.8) 0.000**a
Sleep 2.8 (2.8) 5.2 (1.9) 0.000**a
Nausea 1.6 (2.6) 4.8 (2.3) 0.000**a
Menstrual changes 3.7 (3.8) 5.2 (2.5) 0.074
Neuropathy 2.2 (2.5) 4.8 (2.6) 0.000**a
Overall physical health b 6.6 (1.6) 5.7 (1.4) 0.004**a
Psychological well-being
Coping difficulties 4.1 (2.6) 6.2 (1.5) 0.000**a
Quality of life b 7.2 (1.7) 6.2 (1.1) 0.003**a
Happiness b 7.1 (1.9) 6.2 (1.3) 0.012*a
Control b 5.5 (2.6) 5.1 (1.6) 0.411
Satisfaction b 6.8 (1.9) 5.9 (1.3) 0.012*a
Concentration/memory b 5.7 (2.2) 5.0 (1.6) 0.095
Usefulness b 6.4 (2.3) 5.3 (1.6) 0.014*
Appearance 5.0 (3.0) 6.2 (2.0) 0.030*
Self-concept 3.8 (2.8) 6.4 (1.7) 0.000
Distress about initial diagnosis 7.6 (2.5) 8.5 (1.5) 0.054
Cancer treatment distress 6.9 (2.3) 7.8 (1.5) 0.047*
Distress about time since treatment completion 5.5 (2.8) 6.9 (1.4) 0.014*a
Anxiety 3.7 (2.7) 6.5 (1.3) 0.000**a
Depression 3.0 (2.6) 5.0 (1.3) 0.000**a
Fear of future tests 4.7 (2.7) 6.9 (1.4) 0.000**a
Fear of second cancer 4.8 (2.9) 5.7 (2.1) 0.107
Fear recurrent cancer 5.4 (2.5) 7.1 (1.2) 0.001**a
Fear of dying 4.1 (3.2) 6.2 (1.8) 0.001**a
Social well-being
Family distress 7.6 (2.0) 7.8 (1.1) 0.671
Support from others b 8.1 (1.8) 6.2 (1.6) 0.000**a
Personal relationships 3.7 (2.9) 6.6 (1.6) 0.000**a
Sexuality 4.3 (3.3) 7.2 (1.2) 0.000**a
Concerns about fertility 5.0 (3.6) 7.3 (1.8) 0.001**a
Interference of illness with employment or study 6.2 (3.0) 7.8 (1.2) 0.004**a
Home activities 6.5 (2.7) 7.2 (1.2) 0.105
Feel isolated 3.7 (3.0) 6.1 (1.5) 0.000**a
Financial burden 6.3 (3.0) 5.9 (1.6) 0.533
Concerns that family members will get cancer 3.9 (2.8) 4.8 (1.7) 0.097
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Table 2: Continued
Spiritual well-being
Importance of religious activities c 2.1 (3.3) 3.6 (1.9) 0.020*a
Importance of spiritual activities c 1.3 (2.2) 4.4 (2.0) 0.000**a
Spiritual change c 1.8 (2.4) 4.9 (1.8) 0.000**a
Uncertainty future 5.2 (2.9) 6.6 (1.6) 0.010*a
Illness positively changed life b 5.1 (2.8) 6.2 (1.6) 0.028*
Life purpose b 4.5 (3.1) 6.1 (1.6) 0.005**a
Hopefulness b 6.8 (2.2) 7.3 (1.2) 0.169
*p<0.05; **p<0.01
a = clinical relevant
b= Positively formulated item
All other items are negatively formulated: the higher the score, the bigger the problem
c= neutral formulated items because of religious background, not in analysis
Table 3a: Top 10 most important HRQoL issues among AYA cancer patients and health care 
professionals including positive formulated items
Rank AYA cancer patients Overlap with HCP HCP Rank
1 Support from others (M= 8.1)a No Distress initial cancer diagnosis (M = 8.5) 1
2 Distress initial cancer diagnosis (M=7.6) Yes, with rank 1 Distress family (M = 7.8) 2
3 Distress family (M=7.6) Yes, with rank 2 Cancer treatment distress (M = 7.8) 3
4 Quality of Life (M=7.2)a No Interference of illness with employment or 
study (M = 7.8)
4
5 Happiness (M=7.1)a No Fatigue (M = 7.3) 5
6 Cancer treatment distress (M= 6.9) Yes, with rank 3 Hopefulness (M = 7.3)a 6
7 Satisfaction (M= 6.8)a No Concerns about fertility (M= 7.3) 7
8 Hopefulness (M =6.8)a Yes, with rank 6 Sexuality (M = 7.2) 8
9 Overall physical health (M = 6.6)a No Home activities (M = 7.2) 9
10 Home activities (M = 6.5) Yes, with rank 9 Fear recurrent cancer (M  = 7.1) 10
Unique items for AYA cancer patients or HCP are in bold and italics
a = positively formulated questions 
M = mean
AYA= adolescent and young adult
HCP= health care professional
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with patients treated with palliative intent. AYA patients with a  partner scored 
significantly higher on happiness, satisfaction and overall physical health. The 
difference in overall physical health between groups was not clinically relevant. 
There were no differences in top ten item scores when stratified for having 
children or not.   
Discussion
The results of the current study indicate that there is a considerable discrepancy 
in top ten HRQoL items prioritized by AYA cancer patients and HCP. About 
half of HRQoL items rated as important, were similar for patients and HCP. 
AYA cancer patients rated most HRQoL items as less important than HCP, 
indicating that professionals believe that the burden of cancer and treatment 
is larger than is actually perceived by the patients themselves. This holds for 
all four domains (physical, psychological, social and spiritual) of the QoL-CS 
questionnaire. Top ten items for AYA cancer patients are dominated by six 
positively formulated questions, indicating that AYA cancer patients are more 
inclined to emphasize HRQoL items with a positive connotation like happiness, 
satisfaction, hopefulness and social support. This phenomenon, expressing 
Table 3b: Top 10 most important HRQoL issues among AYA cancer patients and health care 
professionals excluding positive formulated items
Rank AYA cancer patients Overlap with HCP HCP Rank
1 Distress initial cancer diagnosis (M=7.6) Yes, with rank 1 Distress initial cancer diagnosis (M = 8.5) 1
2 Distress family (M=7.6) Yes, with rank 2 Distress family (M = 7.8) 2
3 Cancer treatment distress (M= 6.9) Yes, with rank 3 Cancer treatment distress (M = 7.8) 3
4 Home activities (M = 6.5) Yes, with rank 8 Interference of illness with employment or 
study (M = 7.8)
4
5 Usefulness (M = 6.4) No Fatigue (M = 7.3) 5
6 Financial burden (M = 6.3) No Concerns about fertility (M= 7.3) 6
7 Interference of illness with employment or 
study (M = 6.2)
Yes, with rank 4 Sexuality (M = 7.2) 7
8 Concentration/memory (M = 5.7) No Home activities (M = 7.2) 8
9 Control (M = 5.5) No Fear recurrent cancer (M  = 7.1) 9
10 Distress about time since treatment 
completion (M = 5.5)
Yes, with rank 10 Distress about time since treatment 
completion (M = 6.9)
10
Unique items for AYA cancer patients or for HCP are in bold and italics
M= mean
AYA= adolescent and young adult
HCP= health care professional
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positive feelings and thoughts, also called benefit finding, has been previously 
described and is associated with less HCP visits and lower levels of distress 20. In 
our study, stratified analyses showed that male patients, patients being treated 
with curative intent and patients who have a partner valued mainly positive 
formulated HRQoL items higher. 
Our results are in line with previous studies. Thompson et al. found that there 
is a significant gap between the identified health care preferences of AYA with 
cancer (15-25 years) and the understanding of the Australian oncology HCP 
who deliver their care. HCP significantly underestimated the breadth of AYA 
psychosocial concerns in AYA with cancer and had a strong focus on survival and 
physical wellbeing 16. This is interesting because a study among older patients 
(mean age 55 years) found that there is considerable consistency between 
physicians’ and patients’ perceptions of the needs and support that the patients 
received. There was a discrepancy between the actual and the desired level of 
emotional and cognitive support 17. In addition, Snyder et al. concluded that the 
issues cancer patients (mean age 61.5 years) prefer to be addressed, were the 
issues that HCP felt difficult to deal with 21.
A previous study among 294 long-term breast cancer survivors (almost 6 years 
after cancer diagnosis, mean age 50.9 years) using the QoL-CS questionnaire 
showed that survivors experienced, besides negative effects affecting overall 
quality of life, also benefits (hopefulness, having a life purpose, having a 
positive change after treatment) which helped to cope with worse outcomes 
22. In our study we also observed many of these positive effects, indicating that 
resilience and post-traumatic growth can be important consequences in the AYA 
population after cancer treatment 23,24. 
Male AYA cancer patients scored clinically relevant higher on items concerning 
quality of life, happiness, hopefulness, overall physical health and experienced 
less interference with activities at home. This is line with a previous study where 
male gender showed a positive correlation with empowerment, which may 
be explained by the fact that men use more effective problem-focused coping 
strategies 25. It could also be due to the fact that a substantial part of our study 
sample includes male patients with testicular cancer (34%) who, in general, have 
a good prognosis and a relatively short treatment duration. AYA patients with 
partner scored clinically relevant higher on happiness and satisfaction, which 
illustrates the buffering and stabilizing effect of the social support of a partner 26. 
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It is valuable to establish the HRQoL priorities of AYA cancer patients in order 
to prioritize the items where AYA needs specific attention for. The discrepancy 
between top ten HRQoL priorities between AYA and HCP illustrates that we also 
must invest in thorough listening to patients’ needs and training and guidance 
of oncology HCP in delivering age adjusted psychosocial care. The results of 
this study will add in developing and spreading the knowledge about how AYA-
specific care should be organized, mainly regarding topics about perceived 
support from others, distress about initial cancer diagnosis and distress for 
family. It also emphasizes the importance of patient experiences and needs in 
the development of age-specific health care 27. Since 2013 the Dutch AYA ‘Young 
and Cancer’ Platform has been established, in co-participation with AYA cancer 
patients and HCP from university medical centres and large regional centres. 
The main goal of the Platform is to improve the care for and the quality of life 
of AYA cancer patients by developing structural, standardized, comprehensive 
and patient-centred guidelines for AYA cancer care, research and education. 
An e-module has been developed recently to educate students and health care 
professionals in the Netherlands  on age specific topics relevant for AYA cancer 
patients. Better training of HCP can reduce discrepancies between patients and 
HCP supportive care needs.
We acknowledge several limitations of our study. First, AYA cancer patients 
evaluated their own situation and HCP evaluated the HRQoL of the AYA cancer 
patient population in general. Comparing patient-specific versus general data 
could have influenced the results. Data should therefore be interpreted with 
caution. Second, AYA cancer patients were treated in a single centre and 
received multidisciplinary care by a dedicated AYA team, while the HCP were 
from several centres. It could be that HRQoL item scores are better than those 
of AYA cancer patients treated in other centres in the Netherlands without age-
specific care. The patients in the current study sample were diagnosed with a 
relatively advanced stage of disease and were treated intensively, mostly with 
more than one treatment modality. This is an overestimation in disease severity 
of the entire AYA cancer population 28. Both factors limit the generalizability 
of the results of the current study. Third, the QoL-CS questionnaire is not an 
AYA-specific HRQoL questionnaire. It was validated in a sample of cancer 
survivors with a mean age of 49.6 years who were on average 6.7 years after 
cancer diagnosis 18. Therefore, we assume that the QoL-CS questionnaire has 
less discriminative value in our AYA population as our sample was median 2.1 
years after cancer diagnosis. Moreover, studies have shown that the meaning of 
patients’ self-evaluations of their quality of life may not be the same across different 
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points in time, a phenomenon known as response shift. It reflects change that 
occurs because of adaptation to cancer, not true change due to cancer progression 
29. This phenomenon could have influenced our results.  A fourth limitation is the 
low response rate, which is not unusual in studies in young patients with cancer 
but was even lower than in previous questionnaire studies among AYA patients 
(29% response rate in the current study sample versus 43% and 52% in previous 
studies) 30,31. Unfortunately, we do not have information regarding the reasons 
for not participating. Because demographic data were not collected from the 
non-responders, we could not rule out selection bias. A fifth limitation is that 
we have used the QoL-CS questionnaire in a group of oncology HCP. Since the 
QoL-CS questionnaire is validated in cancer survivors 18, one could question 
whether HCP interpret the questions in a similar way and whether HCP could 
estimate the effect on HRQoL items as they might treat only few patients with 
particular types of cancer instead of the broad variety in cancer types of the 
whole AYA population. Sixth, the HCP sample was relatively small and has only 
few physicians. Since data were gathered at an AYA seminar, one could assume 
that HCP in the sample are highly dedicated with care for AYA cancer patients, 
which could skew the data. 
In conclusion, this study showed a incongruence between the views of AYA 
cancer patients and HCP regarding the most important HRQoL items. Overall, 
HCP in this study believed that the burden of cancer and its treatment is bigger 
than actually perceived by the patients themselves. Assessing HRQoL can 
therefore be of clinical importance in order to provide optimal age-specific care. 
The discrepancy between patients and HCP illustrates the importance of co-
creation survivorship care together with patients in particular of this age group. 
Future research should aim at developing an age-specific questionnaire, which 
discriminates between positive and negative HRQoL items and its impact on 
overall HRQoL in AYA cancer patients.
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Abstract
Objective: High fear of cancer recurrence (FCR) is a frequently reported problem 
among cancer patients. Previous research has shown that younger age is 
associated with higher levels of FCR. However, little attention has been given to 
date about how FCR manifests itself among adolescent and young adult (AYA) 
cancer patients. This study explores the prevalence, correlates of high FCR and 
its association with HRQoL in cancer patients in their late adolescence or young 
adulthood. 
Methods: Seventy-three AYA cancer patients, aged 18-35 years at diagnosis, 
consulting the AYA team of the Radboud University Medical Center completed 
questionnaires including the Cancer Worry Scale (CWS), Quality of Life-Cancer 
Survivors (QOL-CS) and Hospital Anxiety and Depression Scale (HADS). Socio-
demographic and medical data was collected by self-reported questionnaire.
Results: Forty-five participants experienced high FCR (62%), which was higher 
than the 31-52% reported in previous studies among mixed adult cancer patient 
samples. Socio-demographic and medical variables were not associated with 
levels of FCR. High FCR was significantly associated with lower levels of social 
and psychological functioning and overall HRQoL and higher levels of anxiety 
and psychological distress.
Conclusion: Results illustrate that FCR is a significant problem amongst AYA 
cancer patients consulting an AYA team, with participants reporting higher levels 
of FCR than cancer patients of mixed ages. Health care providers should pay 
specific attention to this problem by screening and the provision of appropriate 
psychosocial care when needed.
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Introduction
Recently national adolescent, and young adult (AYA) programs have been 
formed in an attempt to bridge the gap between the pediatric and adult 
oncology services and to address the unmet supportive care needs of the AYA 
cancer patient group. Definitions of the AYA have evolved over time and there 
are currently differing perspectives regarding the appropriate definition of the 
AYA age range between countries. In the United Kingdom AYAs are considered 
to be patients aged between 13-24 years. In the United States the spectrum of 
AYA includes patients aged 15-39 years of age, whilst in the Netherlands, where 
the present study was conducted, AYAs are typically defined as patients aged 
18-35 years at cancer diagnosis [1,2]. Regardless of the specific definition of AYA, a 
cancer diagnosis may have profound effects on the lives of AYA cancer patients, 
interfering with the attainment of normal developmental milestones [3]. At a 
time when most AYAs are trying to make future plans for career, relationships 
and children, the future can seem uncertain. Furthermore, cancer-related 
issues such as premature confrontation with mortality, changes in physical 
appearance, increased dependence on parents, disruptions of social life and 
school/employment because of treatment, and potential loss of reproductive 
capacity may become particularly distressing and could negatively impact their 
health-related quality of life (HRQoL) [4,5,3,6]. Because the vast majority of AYA 
cancer patients will go on to be long-term survivors (relative 5-year survival of 
82% [7]), it is important to optimize the quality of their survival.
Due to cancer occurring at a critical phase in life, AYA cancer patients (AYAs) 
have unique physical, psychological and social care needs [8,9]. Nevertheless, 
research involving AYAs aged 15-39 years at diagnosis reports a high number of 
unmet needs amongst AYAs, with psychosocial help for fear of cancer recurrence 
(FCR) as a key unmet need [10]. FCR has recently been defined as the ‘fear, worry, 
or concern relating to the possibility that cancer will come back or progress’ [11]. 
It has also been described as a ‘sword of Damocles’ that hangs over survivors for 
the rest of their lives [12]. While a normal level of FCR is adaptive because it can 
keep a person alert and aware of symptoms [13], high levels of FCR can adversely 
affect a person’s HRQoL and social activities [14,15]. Cancer survivors with high 
levels FCR may engage in excessive monitoring for signs of potential recurrence 
and/or try to cognitively or behaviorally avoid reminders of their cancer [13]. High 
FCR is associated with both more unscheduled doctor appointments as well as 
unwillingness to be discharged from follow-up care [16-19], leading to increased 
health care costs [18]. Furthermore, patients with elevated FCR commonly 
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report difficulties planning for the future [15], which may adversely impact on 
the developmental milestones of young adulthood although this has not been 
systematically investigated. Comparing of the prevalence of FCR across studies 
is difficult due to a lack of a consensus definition of high FCR [11]. However, a 
systematic review of FCR literature [14] suggests that moderate to high levels 
of FCR affect on average 49% of cancer patients and severe FCR affects on 
average 7% [14] and high levels of FCR persist over time when untreated [20]. 
Recent Dutch studies using the Cancer Worry Scale (CWS) report prevalence 
rates for high FCR of 31% in women breast cancer (n=194) [21], 36% amongst 
men with localized prostate cancer (n=283) [22], 38% in colorectal cancer patients 
(n=76) [23] and 52% in gastro-intestinal stromal tumor patients (GIST; n=54) [24]. 
Younger age is the most consistent predictor of increased FCR among cancer 
patients [20,14]. However, the majority of studies are conducted among breast 
cancer patients or mixed-aged adult samples. There is inconclusive evidence of 
the association between FCR and time since diagnosis or objective indices of 
risk of recurrence with some studies finding an association and others not [14]. 
To date, little data is available on the prevalence of FCR in the AYA population 
or the factors associated with increased levels of FCR in this age group. A recent 
study reported a FCR prevalence rate of 85.2% among AYA cancer patients 
aged 15-39 years. However, this study is limited by the fact that it used a single 
non-validated question to assess FCR and that it recruited a self-selected group 
who were users of a cancer survivorship website [25]. Studies involving cancer 
patients of mixed age show that FCR is associated with poorer HRQOL [14], and 
another recent study has shown that in AYA cancer patients this relationship is 
moderated by perceived growth [26]. 
This cross-sectional study explores the prevalence, correlates and association 
with HRQoL of FCR in a sample of consecutively-seen AYA cancer patients. A 
strength of the present study over existing research is that FCR is measured 
with a valid and reliable FCR-specific questionnaire with a cut-off for high FCR 
which has been validated in the Dutch adult cancer patient population [21,23,24]. A 
secondary aim was to compare the reported prevalence of FCR in the present 
sample to that of other studies of Dutch cancer survivors using the same 
outcome measure. Due to the fact that previous literature reports a consistent 
relationship between younger age and FCR, and AYAs experience cancer at a 
vulnerable phase of life where future goals are defined and coping skills need to 
be developed, it was hypothesized that AYAs would report a higher prevalence 
of FCR than has been reported in cancer patients of mixed ages (31-52%), 
participants with high FCR would have significantly lower HRQOL than with 
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those with low FCR and that clinical characteristics would not be significantly 
associated with having high FCR. 
Methods
Participants
Using the Dutch definition of AYA, patients aged 18-35 years at cancer diagnosis, 
who had been seen by at least one of the members of the AYA team of the 
Radboud University Medical Center (Raboudumc) in The Netherlands, were 
invited to participate in this study. The AYA team is a dedicated multidisciplinary 
team for patients aged 18 to 35 years at diagnosis including a medical oncologist, 
clinical nurse specialist, medical psychologist and a social worker. Patients 
consulting the AYA team receive regular medical care from their own treating 
specialist at Raboudumc (oncologist, surgeon, hematologist, dermatologist, 
urologist, gynecologist etc.) and visit the AYA team for age-specific questions 
and care needs. In general, patients visiting the AYA team represent a group of 
patients with high disease severity, diagnosed with relatively advanced stage 
of disease and undergoing intensive treatments, and reporting more problems 
with coping. Patients with lower stage disease (e.g. cervical cancer, melanoma) 
treated solely by surgery, are not often seen by the AYA team. 
In order to depict the real-life heterogeneous sample of AYA cancer patients 
visiting the AYA team this study included, AYA patients independent of their 
treatment status (during or after treatment), type of treatment (surgery, 
chemotherapy, radiotherapy, immunotherapy and hormonal therapy or 
combination), or the number of visits to the AYA team. Inclusion commenced 
January 2012 and ended March 2016.
Procedure
Potential study participants were recruited via letters describing the study 
and inviting patients to participate in the study. Patients willing to participate 
had to actively opt-in to the study by providing written informed consent by 
email to a member of the AYA team. Participants were then sent a single set of 
questionnaires by email that could be completed online. The study was deemed 
exempt from full review and approval by a research ethics committee (CMO 
Regio Arnhem-Nijmegen).
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Instruments
Sociodemographic and clinical characteristics
Demographic data, including age, gender, partnership, having children, living 
situation, educational level, and employment status were gathered by self-
report. Medical data, including tumour type, disease stage, treatment type, 
treatment status (on/off treatment) and time since initial diagnosis were 
extracted from the patients’ medical records by one of the researchers (SK). 
Fear of cancer recurrence/progression
The Cancer Worry Scale (CWS) is used in research to assess concerns about 
developing cancer again (e.g. how often do you worry about developing cancer 
(again)?) and the impact of these concerns on daily functioning ( e.g. have these 
thoughts interfered with your ability to do daily activities?) [21]. The CWS is a reliable 
(Cronbach’s alpha in this study = .89) and valid measure of FCR which has been 
validated in several studies involving Dutch cancer patients [23,24,21,27]. The eight 
items of the CWS are rated on a four-point Likert scale ranging from never (1) 
to almost always (4). Scores range from 8 to 32 [28]. A cut-off scores of 13 or 
more is validated for prostate cancer survivors (sensitivity 86%; specificity 84%)
[22], and 14 or more for breast (sensitivity 77%; specificity 81%)[21] and colorectal 
cancer survivors (sensitivity 86%; specificity 87%) [29] indicating high levels of 
FCR. The present study used a cut-off score of 14 or more to indicate high FCR.
Health-related quality of life
The Quality of Life for Cancer Survivors (QoL-CS) questionnaire was used to 
measure HRQoL. It consists of 41 items on the physical, psychological, social 
functioning and religious impact of cancer on the life of the patient. Respondents 
rate themselves along an interval rating scale ranging from 0 to 10 for each item. 
For subscale scoring purposes, all items were ordered, so that 0 indicated the 
lowest or worst possible HRQoL, and 10 indicated the highest or best possible 
HRQoL outcome. An overall QoL score was computed by averaging all 41 items 
[30]. Strong evidence for the validity and reliability of the instrument has been 
reported [31,32]. Cronbach’s alphas ranged from 0.35 for religious functioning to 0.91 
for the total QoL scale score in this sample.
Psychological distress 
Psychological distress was measured with the Hospital Anxiety and Depression 
Scale (HADS). The HADS is a self-report questionnaire comprising 14 items on a four-
point Likert-scale. Total score and subscales scores can be calculated for depression 
and anxiety (7 items each). Higher scores indicate more anxiety, depression, and 
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psychological distress. Due to a lack of somatic items, the HADS is not confounded 
by the presence of physical symptoms and therefore suited for people with cancer 
[33]. The HADS is reliable [34] (Cronbach’s alpha > 0.77 in this sample) and validated for 
use in different groups of Dutch subjects and in cancer patients [35,36].
Statistical analyses
The present study is a secondary analysis of a data collected to assess HRQOL 
amongst AYA cancer patients. Analyses were performed using Statistical 
Package for the Social Sciences version 22 (SPSS), and two-sided p values of 
<.05 were considered statistically significant. Differences in sociodemographic 
and clinical characteristics, HRQoL and psychological distress between patients 
with low and high levels of FCR were compared using chi-square and t-tests 
(or Mann Whitney U test), where appropriate. Given that a minimal clinically 
important difference for the primary outcome measure (CWS) has not been 
established, clinically meaningful differences were determined with Norman’s 
‘rule of thumb’, using ~0.5 SD difference to indicate a threshold discriminant 
difference in scores [37]. To contextualize the findings of the present study t-tests 
were used to compare mean levels of FCR reported in the present sample with 
the results of other Dutch cancer survivors studies using the CWS, and chi-square 
was used to compare the proportions reporting high FCR with other studies. 
Results
Sample characteristics
In total, 309 letters requesting participation in the study were sent to AYA cancer 
patients visiting one of the members of the AYA team. Eighty-nine participants, 
comprising 57% of those who opted-in to the study (n=155) and 29% of those sent 
mailed invitations (n=309), completed the online questionnaire. Four participants 
were excluded since they were diagnosed with cancer under the age of 18 
years. Twelve patients were excluded from analyses because they had a recent 
recurrence (n=5) or received palliative treatment (n=7), making the item wording 
of the CWS irrelevant to them, resulting in final sample of 73 participants. Table 1 
displays socio-demographic and clinical and treatment-related characteristics of 
the sample. Mean age at cancer diagnosis was 27.4 years (SD=4.9) and average 
time since cancer diagnosis was 1.9 years (SD=2.6). The most common diagnosis 
was testicular cancer (34%), followed by breast cancer (15%) and sarcoma (12%). 
The majority of participants had undergone surgery (84%) and chemotherapy 
(86%), and had completed treatment at time of study (76%).
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Table 1: Characteristics of the study sample stratified by level of FCR
Total N= 73 Low FCR N= 28 High FCR N= 45 P-value
n (%)a n (%)b n (%)c
Gender
Male
Female
36 (49%)
37 (51%)
17 (61%)
11 (39%)
19 (42%)
26 (58%)
0.12
Age at diagnosis (yrs) 27.4 (4.6) 26.3 (4.9) 28.0 (4.4) 0.12
Time since cancer diagnosis (yrs) 1.9 (2.6) 1.9 (3.6) 1.9 (1.9) 0.94
Tumour type
Testicular cancer
Breast cancer
Sarcoma
Lymphoma
Gynecological
Melanoma
Leukemia
Other
25 (34%)
11 (15%)
9 (12%)
8 (11%)
7 (10%)
2 (3%)
2 (3%)
9(12%)
13 (46%)
2 (7%)
4 (14%)
2 (7%)
3 (11%)
0 (0%)
1 (4%)
3 (11%)
12 (27%)
9 (20%)
5 (11%)
6 (13%)
4 (9%)
2 (4%)
1 (2%)
6 (13%)
0.53
Stage
NA
Stage 1
Stage 2
Stage 3
Stage 4
Unknown
8 (11%)
12 (16%)
23 (32%)
11 (15%)
13 (18%)
6 (8%)
5 (18%)
3 (11%)
11 (39%)
1 (4%)
5 (18%)
3 (11%)
3 (7%)
9 (20%)
12 (27%)
10 (22%)
8 (18%)
3 (7%)
0.15
Treatment status
On 
Off
17 (24%)
54 (76%)
6 (21%)
22 (79%)
11 (26%)
32 (74%)
0.69
Treatment type (yes)
Surgery
Chemotherapy
Radiotherapy
Immunotherapy
Hormonal therapy
61 (84%)
63 (86%)
20 (27%)
9 (12%)
6 (8%)
24 (86%)
25 (89%)
5 (18%)
0 (0%)
1 (4%)
37 (82%)
38 (84%)
15 (33%)
9 (20%)
5 (11%)
0.70
0.56
0.15
0.01
0.25
Partner
Yes 
No
52 (72%)
20 (28%)
19 (68%)
9 (32%)
33 (75%)
11 (25%)
0.51
Children
Yes
No
24 (33%)
48 (67%)
8 (29%)
20 (71%)
16 (36%)
28 (64%)
0.49
Living situation
With parents
On own
With partner
12 (17%)
19 (26%)
41 (57%)
7 (25%)
9 (32%)
12 (43%)
5 (11%)
10 (23%)
29 (66%)
0.13
Highest completed education
Low
Intermediate 
High
1 (1%)
32 (44%)
39 (54%)
0 (0%)
14 (50%)
14 (50%)
1 (2%)
18 (41%)
25 (57%)
0.58
Employed or studying
Yes
No
63 (86%)
10 (14%)
24 (86%)
4 (14%)
39 (87%)
6 (13%)
0.91
NA= not applicable  a= % of total participants; b=% of patients with low FCR; c=% of patients 
with high FCR
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Prevalence FCR
Mean score on the CWS for the AYA cancer sample was 14.9 (SD=4.6). Forty-five 
AYA cancer patients (62%) scored 14 or higher on the CWS suggesting a high 
level of FCR. The percentage of AYA cancer patients scoring high on FCR was 
significantly higher than the 31% in breast cancer patients (t=2.8, p=0.007), 36% 
in prostate cancer patients (t=5.4, p=<0.001), 38% in colorectal cancer patients 
(t=4.5, p=0.002), but it did not differ significantly from 52% prevalence reported 
by GIST cancer patients (t=0.7, p=0.47) (Table 2). 
Correlates of High FCR
There were no differences in sociodemographic (age, gender, partner, education, 
living situation, and occupational status) and clinical variables (type of tumor, 
type and phase of treatment, disease stage) between AYA cancer patients with 
high or low levels of FCR (Table 1). However, immunotherapy was significantly 
associated with high FCR (Chi2= 6.7, p=.01).
Association between High FCR, HRQoL and psychological distress
AYA cancer patients with high FCR (CWS ≥ 14) reported worse functioning in 
the psychological domain (t=5.1; p<0.01), and social functioning domain (t=3.6; 
p<0.01), and lower overall HRQoL (t=4.5; p<0.01), compared with those with 
low levels of FCR (Table 3). These differences were clinically relevant as well 
as statistically significant. No differences were found for physical and religious 
functioning. AYA patients with high levels of FCR reported significantly higher 
scores on anxiety (t=-3.5; p<0.01), and total distress (t=-3.0; p<0.01), compared 
with those with lower levels of FCR. These differences were of clinical relevance. 
No significant difference was found for depression. 
Table 3: HRQoL and psychological distress scores according to level of FCR
Total
N=73
Low FCR
N=28
High FCR
N=45
T-value P-value
Quality of Life for Cancer Survivors
Physical functioning 7.5 (1.6) 7.8 (1.7) 7.4 (1.4) 1.1 0.28
Psychological functioning 5.8 (1.5) 6.8 (1.1) 5.1 (1.4) 5.1 <0.01a
Social functioning 5.2 (1.4) 5.9 (1.4) 4.8 (1.2) 3.6 <0.01a
Religious functioning 3.9 (1.2) 4.1 (1.3) 3.7 (1.3) 1.3 0.20
Total 5.7 (1.1) 6.3 (1.0) 5.3 (1.0) 4.5 <0.01a
HADS
Anxiety 6.3 (3.9) 4.4 (3.0) 7.5 (3.9) -3.5 <0.01a
Depression 4.1 (3.5) 3.2 (3.3) 4.7 (3.5) -1.8 0.08
Total psychological distress 10.4 (6.6) 7.6 (5.7) 12.2 (6.6) -3.0 <0.01a
aClinically relevant difference
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Discussion 
The present study is among the first to quantify the prevalence of high FCR in a 
sample of AYA cancer patients, aged 18-35 years at diagnosis who consulted at 
least one of the members of the multidisciplinary AYA team. High levels of FCR, 
were reported amongst 62% of participants in the present sample. Whilst there 
remains debate around definition of high FCR and a consensus definition of 
clinical FCR is currently under development [11], the results of the present study 
confirm our hypotheses that FCR, assessed with the CWS, is a common concern 
among AYA cancer patients and high FCR is more prevalent amongst AYAs than 
cancer patients of mixed ages and stages [24,21,23,22]. Consistent with past literature 
[20,14] and as hypothesised, objective determinants of poor prognosis were not 
significantly associated with FCR in the present sample. 
High prevalence rates of clinical FCR have been reported in other studies 
involving younger patients with a good prognosis. For example, Thewes et al. 
[38] found that 70% of survivors aged 18-45 years at diagnosis with early-stage 
breast cancer reported clinical levels of FCR. Reasons for the higher prevalence 
in younger people with cancer are not well studied but in breast cancer survivors 
motherhood of young children, and the unexpected nature of life-threatening 
illness at an early age have been postulated [39,17]. There is some evidence that 
the relationship between age and FCR may also be, in part, mediated by the 
perceived physical, social or economic consequences of having a recurrence [39], 
anxiety [40,39], coping style [41] and self-efficacy [42]. Due to small sample size it was 
not possible to test mediators of FCR in the present sample, but future studies 
should explore this issue. 
The prevalence of high FCR in the present AYA sample was significantly higher 
than has been previously reported amongst breast, prostate and colorectal 
cancer patients however it did not significantly differ from that reported 
amongst GIST patients [24]. Potential similarities between the GIST and AYA 
samples are that both groups included patients with poor prognosis, whereas 
the other samples included only patients treated with curative intent. Another 
potential explanation is that both AYA cancer and GIST are rare diseases, 
meaning that patients may have fewer social comparators and less information 
available to them, these factors might also contribute to increased uncertainty 
in GIST and AYA. Another possible explanation is that both groups included 
patients receiving novel targeted therapies. Targeted therapies are often 
associated with extended treatment duration and intensive monitoring for signs 
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of treatment response or recurrence over longer periods of time than standard 
cancer treatments, due to the frequent checking for treatment response and/
or recurrence over extended periods these treatments might contribute to 
higher levels of FCR [43]. Further research is required to better understand the 
relationship between novel cancer treatments and FCR.
Consistent with the results of several literature reviews exploring the factors 
associated with FCR, the present study found that higher FCR was associated 
with poorer psychological and social functioning and lower overall HRQoL [14,20]. 
Physical symptoms can serve as triggers for FCR [24] and previous research has 
shown an association between FCR and the presence of physical symptoms 
among people with mixed cancer types [44,14,20]. However, it is noteworthy that in 
the present study no association was found between FCR and physical HRQoL. 
This is in contrast to previous literature [14]. Interestingly, no difference was 
found between the proportions of patients reporting low versus high FCR for 
most conventional treatment modalities, with the exception of immunotherapy 
which was associated with higher FCR in the present sample. 
In considering the results of the present study several potential limitations 
should be acknowledged. To determine the prevalence of FCR in the present 
study the higher (and more conservative) cut-off score for high FCR (13 vs. 14) was 
selected. A lower CWS cut-off score of 11 vs. 12 has been suggested for screening 
purposes [21], and a cut-off score of 12 vs 13 has been used to detect high FCR in 
male prostate cancer patients [22]. Further research is needed to validate both the 
CWS and other common measures of FCR in AYA cancer patients. Given the high 
prevalence of FCR in AYAs, the results of this study underline the importance of 
establishing a psychometrically sound FCR screening questionnaire with a cut-
off score specifically validated for the AYA population. 
The cross-sectional design limits the determination of causal associations 
between the study variables. Furthermore, due to the small sample size it was 
not possible to conduct multivariate analyses adjusting for confounding effects 
or to examine moderating or mediating factors. Although the role of clinical 
characteristics in FCR is inconsistent across studies, future studies involving 
larger samples are needed to determine whether the predictors identified in the 
present study are replicated when their effects are adjusted for the influence of 
age and clinical characteristics such as time since diagnosis, type of treatment, 
treatment status and comorbidities. As this was a secondary analysis data on 
psychiatric morbidity and trait anxiety were not available but future studies 
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might consider including these as covariates to determine to what extent high 
comorbid with or influenced by psychiatric disorder or trait anxiety. 
All participants received multidisciplinary care by a dedicated AYA team within 
an academic hospital setting. AYAs referred to this specialized team often 
present with more complex care needs and therefore it is unclear to what 
extent FCR levels reported in the present sample are representative of the level 
of FCR in the broader population. Patients in this sample were also diagnosed 
with relatively advanced stage of disease (18% in our sample compared to 4% 
stage 4 disease in total Dutch AYA population) and were treated with multiple 
treatment modalities. Lower stage cervical cancer, melanoma, and early-stage 
testicular cancer are usually treated only with surgery. Therefore, the present 
sample might overestimate the disease severity of the entire AYA cancer 
population and may have contributed to the high observed level of FCR in 
the present sample. Both factors may limit the generalizability of our results. 
Another limitation of our study is the low response rate, which is unfortunately 
not unusual in studies of young cancer patients [45], limiting the generalizability 
of our results. Longitudinal, population-based studies are needed to understand 
changes in FCR over the course of the cancer trajectory and to provide insights 
into the predictors of these changes. More research is also needed to identify 
the prevalence and predictors of higher FCR in a large representative sample of 
AYA cancer patients, including those in 15-18 year old age range. 
With regard to instrumentation of HRQoL, the current study relied upon a generic 
instrument with limited use in study samples consisting of young patients. 
There are currently no valid or reliable HRQoL instruments available for the 
entire AYA age range. The QoL-CS was selected because qualitative research 
highlights the need for tools measuring age-specific impact of cancer, such 
as employment challenges, social isolation, sexual and relationship problems 
[46]. Internal consistency of the QoL-CS in the present sample was high for the 
total score (0.91) and good to acceptable for most subscales with the exception 
of religious functioning (0.35). Cultural differences in religiosity between the 
Netherlands and the United States (where the QoL-CS was originally developed) 
might account for this difference. More research is needed to validate existing 
HRQOL instruments specifically for the AYA population. 
Although FCR is a growing area in the psycho-oncology literature relatively few 
studies to date have focused specifically on AYA cancer patients. This study is 
one of the first to explore the issue of FCR in an AYA cancer population using 
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an FCR-specific questionnaire with a validated cut-off. The present study found 
a significantly higher prevalence of FCR in this specific group of AYA cancer 
patients and a higher prevalence than has been reported in previous studies 
involving cancer patients of mixed ages. Based on the results of the present 
study, it is recommended that clinicians give greater attention to FCR in the 
clinical care of AYAs. Where feasible validated screening measures can be 
routinely used to identify problematic levels of FCR [47,21]. Where routine screening 
of FCR is not feasible clinicians should routinely ask about and normalize the 
presence of FCR and use questions to further explore whether FCR is chronic 
or bothersome and if there is a need for help to manage FCR. Patients with 
severe or problematic may benefit from a growing number of evidence-based 
interventions for reducing high FCR [48-50] [51,49,52]. A better understanding of FCR 
in AYA cancer patients will help clinicians identify patients who are in need of 
(psychosocial) intervention and when to most effectively intervene. Existing 
interventions are yet to be evaluated in an exclusively AYA population. However, 
as the theoretical foundations of existing interventions are relevant to all age 
groups, is it very likely that the therapeutic techniques they contain are equally 
relevant to AYA cancer survivors. However, some minor modification of patient 
resources (e.g. peer videos, patient examples in handouts) may make existing 
interventions more appealing and accessible to a younger audience. Given the 
potential impact of FCR on the developmental milestones of AYAs, further 
quantitative and qualitative research is needed to explore the functional impact 
of FCR on the lives of AYA cancer patients and to validate common measures of 
FCR in AYA populations. Future studies may therefore benefit from using multi-
dimensional scales to assess FCR. 
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Abstract
Background: The current study determined the prevalence of severe fatigue 
in Adolescent and Young Adult (AYA) cancer patients (aged 18-35 years at 
diagnosis) consulting a multidisciplinary AYA team in comparison with gender- 
and age-matched population-based controls. In addition, impact of severe 
fatigue on quality of life and related factors of fatigue severity were examined. 
Methods: AYAs with cancer (n=83) completed questionnaires including the 
Checklist Individual Strength (CIS-fatigue), Quality of Life (QoL)-Cancer Survivor, 
Hospital Anxiety and Depression Scale (reflecting psychological distress), and 
the Cancer Worry Scale (reflecting fear of cancer recurrence or progression). 
Results: The vast majority of participants had been treated with chemotherapy 
(87%) and had no active treatment at the time of participation (73.5%). Prevalence 
of severe fatigue (CIS-fatigue score ≥ 35) in AYAs with cancer (48%, n=40/83) 
was significantly higher in comparison with matched population-based controls 
(20%, n=49/249; p < .001). Severely fatigued AYAs with cancer reported lower 
QoL compared to non-severely fatigued AYAs with cancer (p’s < .05). Female 
gender, being unemployed, higher disease stage (III-IV) at diagnosis, receiving 
active treatment at the time of participation, being treated with palliative 
intent, having had radiotherapy, higher fear of recurrence or progression, and 
higher psychological distress were significantly correlated with fatigue severity 
(p < .05). 
Conclusion: Severe fatigue based on a validated cut-off score was highly 
prevalent in this group of AYAs with cancer. QoL is significantly affected by 
severe fatigue, stressing the importance of detection and management of this 
symptom in those patients affected by a life-changing diagnosis of cancer in 
late adolescence or young adulthood.
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Introduction
Compared to adults, a diagnosis of cancer in adolescents and young adults 
(AYAs) between the ages of 18 and 35 years is rare. Advances in early detection 
and improvements in cancer treatments have resulted in an overall 5-year 
survival rate exceeding 80% in AYAs [1]. While AYAs with cancer face challenges 
similar to adult cancer patients, those in the heart of their youth experience 
unique cancer-related challenges in addition to usual age-related developmental 
tasks. The combination of achieving normal developmental milestones and 
simultaneously coping with a life-changing diagnosis of cancer frequently 
leads to psychosocial issues among AYAs with cancer [2]. Several studies have 
documented higher levels of distress and lower quality of life (QoL) in AYAs with 
cancer in comparison with healthy matched peers or adult cancer patients [3-5]. 
Moreover, treatment-related symptoms (e.g. pain and fatigue) and late effects 
(e.g. second cancers and cardiovascular disease) can interfere with a healthy 
body image, establishing social relationships, or attaining levels of autonomy 
and independence. With the expected further gains in overall survival of AYA 
cancer, it is important to address persistent disease- and treatment-related 
symptoms that compromise several domains of QoL.
Cancer-related fatigue (CRF) is one of the most common and distressing 
symptoms reported by adult and childhood cancer patients both during and 
after cancer treatment [6, 7]. The most commonly used definition for CRF is 
formulated by the National Comprehensive Cancer Network (NCCN) and defines 
CRF as “a distressing, persistent, subjective sense of physical, emotional, and/or 
cognitive tiredness or exhaustion related to cancer or cancer treatment that is not 
proportional to recent activity that interferes with usual functioning” [8]. The vast 
majority of studies on the prevalence and severity of CRF have been conducted 
in adult or childhood cancer patients and only a few studies evaluated fatigue 
severity in AYAs with cancer. Moreover, the limited AYA-specific studies did not 
attempt to report on clinically relevant levels of fatigue by using a validated cut-
off for severe fatigue [4, 9]. 
Knowledge on the prevalence of severe fatigue in AYAs with cancer is important, 
as we know from studies in adult cancer patients that severe fatigue is associated 
with more functional impairments, lower QoL, and more distress [6, 10]. For AYAs 
with cancer, the impact of severe fatigue might be even more pronounced because 
it can interrupt developmental milestones such as completing education, finding 
first or pursuing employment, beginning a romantic relationship, or starting a 
66
Chapter 4
family. Understanding factors related to severe fatigue among AYAs with cancer 
will help health care providers identify who is more likely to experience this 
symptom. In addition, it will help researchers to determine potential factors 
that could be addressed in interventions targeting fatigue. 
The present study determined the prevalence of clinically relevant levels of 
fatigue in AYAs with cancer using a validated cut-off for severe fatigue and 
compared the proportion of severely fatigued cases with the proportion of 
severely fatigued cases in a sample of gender- and age-matched population-
based controls. In addition, the impact of severe fatigue on QoL and potential 
sociodemographic, treatment-related, and psychological correlates of fatigue 
severity was explored. A cross-sectional approach was used for this study to 
gather descriptive information about the presence of clinically relevant levels of 
fatigue among AYAs with cancer. 
Materials and methods
Patients
Patients aged 18-35 years at cancer diagnosis and who had been seen by at least 
one of the members of the AYA team of the Radboud university medical center, 
Nijmegen, The Netherlands, were invited to participate in this study. The AYA 
team is a dedicated multidisciplinary team including a medical oncologist, clinical 
nurse specialist, medical psychologist, and social worker. Patients consulting 
the AYA team receive regular medical care from their own treating specialist 
(oncologist, surgeon, haematologist, dermatologist, urologist, gynaecologist, 
etc.) and visit the AYA team for age-specific questions and care needs. In general, 
patients visiting the AYA team represent a group of patients with higher disease 
severity, diagnosed with relatively advanced stage of disease and undergoing 
intensive treatments, and reporting more problems with coping. The AYA team 
does not often see patients with low stage disease treated solely by surgery, 
such as in the case of thin melanomas. 
To depict the real-life heterogeneous sample of AYAs with cancer visiting the 
AYA team, AYAs with cancer were included in this first study on the prevalence 
of severe fatigue regardless of treatment status (during or after treatment), type 
of treatment (surgery, chemotherapy, radiotherapy, immunotherapy, targeted 
therapy, hormonal therapy or combination), or the number of AYA team visits 
(some patients only had one introduction talk with one of the members of the 
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team and did not receive specific care thereafter). Inclusion commenced January 
2012 and ended March 2016.
Population-based controls
Population-based controls were derived from a cohort of panel members 
surveyed by CentERdata, a research institute at Tilburg University collecting data 
from a sample of more than 2000 Dutch households (http://www.centerdata.
nl/en/). This CentERpanel represents the adult Dutch-speaking population with 
respect to demographic characteristics. Population-based controls provided 
self-reported data on age and gender and completed a multi-dimensional 
fatigue questionnaire (Checklist Individual Strength, see measures). They had 
no sickness absence in the workplace (0 days) in the month prior to filling in 
the questionnaires. Further information on the presence of physical or mental 
health conditions in population-based controls was not available.
Procedure
Potential study participants were recruited via letters describing the study 
and inviting patients to participate in the study. Patients willing to participate 
had to actively opt-in to the study by providing written informed consent by 
email to a member of the AYA team. Participants were then sent a single set of 
questionnaires by email that could be completed online. The study was deemed 
exempt from full review and approval by a research ethics committee (CMO 
Regio Arnhem-Nijmegen, #2016-2872).
Measures
AYAs with cancer completed a self-report questionnaire on sociodemographic 
data (i.e., age, gender, partner status, having children, education level, and 
employment status). A member of the AYA team (SK) extracted clinical data (i.e., 
cancer diagnosis, disease stage at diagnosis, time since initial cancer diagnosis, 
type(s) of treatment(s) received, duration of cancer treatment, treatment status 
at participation, and time since completion of cancer treatment) from patients’ 
medical records. AYAs with cancer completed the following questionnaires, 
including a multi-dimensional fatigue questionnaire:
Checklist Individual Strength, subscale fatigue severity (CIS-fatigue). The subscale 
fatigue severity of the CIS consists of eight items scored on a 7-point Likert 
scale. Total CIS-fatigue scores can range from 8 to 56, with scores greater than 
34 indicating clinically relevant levels of fatigue [11]. The CIS-fatigue has been 
used in previous studies examining severe fatigue in cancer patients during 
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and after cancer treatment [12-14]. A cut-off was used to group AYAs with cancer 
into two groups to indicate severely fatigued (≥ 35) and non-severely fatigued 
patients (< 35). 
Quality of Life-Cancer Survivor (QoL-CS). The QoL-CS consists of 41 items scored 
on a 10-point Likert scale and was used as a cancer-specific measure of QoL [15]. 
The impact of cancer diagnosis and treatment is assessed with four subscales, 
i.e., physical, social, psychological, and spiritual wellbeing. In addition to the 
four subscale scores, the total QoL score reflecting the average across all items 
was used in this study. Higher scores indicated better QoL for all subscales. 
Hospital Anxiety and Depression Scale (HADS). The HADS consists of 14 items 
scored on a 4-point Likert scale [16]. The summed total HADS scores range from 0 
to 42, and were used to reflect psychological distress in our sample of AYAs with 
cancer [17]. Higher total scores indicate more psychological distress.
Cancer Worry Scale (CWS). The CWS consists of eight items regarding concerns 
about cancer recurrence or progression of cancer. Items are scored on a 4-point 
Likert scale ranging from ‘never’ to ‘almost always’ [18]. Total CWS scores range 
from 8 to 32, and can be used to assess cancer worrying. Higher total scores 
indicate more fear of cancer recurrence or progression. Patients with a recent 
recurrence (n=5) or receiving treatment with palliative intent (n=7) did not 
complete the CWS because the item wording of this measure was irrelevant to 
them.
Statistical Analyses
To compare mean fatigue severity and the prevalence of severe fatigue in 
AYAs with cancer with population-based controls derived form the sample 
of CentERdata (n=1923), AYAs with cancer were matched on gender and age 
(within a range of 0 to 5 years) with 249 population-based controls. Given the 
relatively low proportion of CentERpanel members within the age range of 
our study sample, the highest possible ratio for matching AYAs with cancer to 
controls was 1:3. Precision matching was performed with STATA/SE. All other 
analyses were performed using SPSS Statistics (version 22.0). Descriptive 
statistics and frequencies concerning socio-demographic and clinical data were 
calculated. An independent samples t-test was used to compare fatigue severity 
scores between AYAs with cancer and matched population-based controls. We 
used a Chi-square test to compare the proportion of severely fatigued cases 
in AYAs with cancer and matched population-based controls. Pearson and 
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Point-Biserial correlations were calculated to examine associations between 
continuous variables or continuous and dichotomous variables, respectively. 
The significance level was set at .05. We did not adjust for multiple testing.
Results
In total, 309 letters requesting participation in the study were sent to 
AYAs with cancer visiting one of the members of the AYA team. The total 
sample of 89 participants comprised 57% of those who opted-in to the study 
(n=55) and 29% of all those solicited by mail (n=309). Six participants were 
excluded, four since they were diagnosed with cancer under the age of 18 
years and two because they were aged above 35 years at diagnosis. Table 1 
displays sociodemographic, disease and treatment-related characteristics 
of the final sample of 83 AYAs with cancer stratified by the presence of 
severe fatigue. Mean age at cancer diagnosis for the total sample was 
27.3 years (SD 4.4) and mean time since cancer diagnosis was 2.1 years 
(SD 2.6). The most common diagnosis was testicular cancer (34%) followed by 
sarcoma (19%). Disease stage at diagnosis was known and applicable in 67 
participants. Of those, 36 (54%) were diagnosed with early-stage disease 
(stages I-II) and 31 (46%) with late-stage disease (stages III-IV). The majority 
of participants had undergone surgery (n=70, 84%) and chemotherapy 
(n=72, 87%), but were not on active cancer treatment at the time of study 
participation (n=61, 73.5%). Mean duration of cancer treatment was 15.8 months 
(SD 20.6). For the subset of 61 patients not on active cancer treatment at the 
time of study participation, mean duration since completion of treatment was 
17.5 months (SD 30.6)
70
Chapter 4
Table 1. Characteristics of the study sample stratified by fatigue severity
Characteristics Total sample
(n=83)
Non-severely fatigued 
patients 
(n=43)
Severely fatigued 
patients 
(n=40)
Age at cancer diagnosis, 
mean (SD)
18-25 years
26-35 years
27.3 (4.4)
30 (36%)
53 (64%)
26.5 (4.6)
18 (42%)
25 (58%)
28.0 (4.1)
12 (30%)
28 (70%)
Age at participation, 
mean (SD)
18-25 years
26-35 years
> 35 years
29.4 (4.7)
19 (23%)
58 (70%)
6 (7%)
28.7 (5.0)
13 (30%)
27 (63%)
3 (7%)
30.2 (4.4)
6 (15%)
31 (77.5%)
3 (7.5%)
Gender
Male
Female
43 (52%)
40 (48%)
30 (70%)
13 (30%)
13 (32.5%)
27 (67.5%)
Partner a
Yes
No
58 (70%)
24 (29%)
32 (74%)
11 (26%)
26 (67%)
13 (33%)
Children a
Yes
No
27 (33%)
55 (66%)
30 (70%)
13 (30%)
25 (64%)
14 (36%)
Highest completed education a
Low
Intermediate
High
2 (2%)
36 (43%)
44 (53%)
0 (0%)
18 (42%)
25 (58%)
2 (5%)
18 (46%)
19 (49%)
Employed or studying a
Yes
No
Other
53 (64%)
26 (31%)
3 (4%)
37 (86%)
4 (9%)
2 (5%)
16 (40%)
22 (55%)
1 (2.5%)
Cancer diagnosis
Testicular cancer
Sarcoma 
Breast cancer
Haematological malignancy
Gynaecological cancer
Melanoma
Other b
28 (34%)
16 (19%)
10 (12%)
10 (12%)
9 (11%)
3 (4%)
7 (8%)
22 (51%)
5 (12%)
4 (9%)
2 (5%)
5 (12%)
2 (5%)
3 (7%)
6 (15%)
11 (27.5%)
6 (15%)
8 (20%)
4 (10%)
1 (2.5%)
4 (10%)
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Characteristics Total sample
(n=83)
Non-severely fatigued 
patients 
(n=43)
Severely fatigued 
patients 
(n=40)
Cancer stage at diagnosis
Not applicable
Stage I
Stage II
Stage III
Stage IV
Unknown
9 (11%)
11 (13%)
25 (30%)
13 (16%)
18 (22%)
7 (8%)
3 (7%)
6 (14%)
18 (42%)
3 (7%)
11 (26%)
2 (5%)
6 (15%)
5 (12.5%)
7 (17.5%)
10 (25%)
7 (17.5%)
5 (12.5%)
Time since cancer diagnosis, 
mean (SD) in years 2.1 (2.6) 2.0 (1.8) 2.2 (3.3)
Lifetime cancer treatment c 
Surgery
Chemotherapy
Radiotherapy
Immuno- or targeted therapy
Hormone therapy 
70 (84%)
72 (87%)
24 (29%)
13 (16%)
7 (8%)
38 (88%)
38 (88%)
10 (23%)
5 (12%)
4 (9%)
32 (80%)
34 (85%)
14 (35%)
8 (20%)
3 (7.5%)
Duration of cancer treatment,
mean (SD) in months 15.8 (20.6) 15.0 (22.1) 16.7 (19.2)
Intent of cancer treatment
Curative
Palliative
71 (85.5%)
12 (14.5%)
40 (93%)
3 (7%)
31 (77.5%)
9 (22.5%)
Treatment status at participation
No active treatment 
Active treatment
61 (73.5%)
22 (26.5%)
36 (83.7%)
7 (16.3%)
25 (62.5%)
15 (37.5%)
a Information was not available for n = 1 AYA with cancer
b  Including glioma (n=1), sigmoid carcinoma (n=1), oropharyngeal cancer (n=1), neuroendocrine 
tumor (n=1), lung cancer (n=1), salivary gland cancer (n=1), and adrenal gland cancer (n=1)
c Multiple answers possible. 
Prevalence of severe fatigue and impact on quality of life
AYAs with cancer reported a significantly higher fatigue severity score than 
matched population-based controls (31.5, SD 11.8 versus 24.9, SD 10.5, 
respectively, p < .001). The prevalence of severe fatigue in AYAs with cancer 
was significantly higher in comparison with matched population-based controls 
(48%, n=40/83 versus 20%, n=49/249, respectively, p < .001). Severely fatigued 
AYAs with cancer reported significantly lower scores on all four QoL subscales 
(i.e., physical, social, psychological, and spiritual well-being) and on total QoL, 
compared to their non-severely fatigued counterparts (p < .05, see Table 2).
Table 1. Continued
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Table 2. Impact of severe fatigue on quality of life of AYAs with cancer
QoL-CS Non-severely fatigued 
patients (n =43)
mean (SD)
Severely fatigued 
patients (n=40)
mean (SD)
Mean difference Sig.
Physical well-being 8.28 (± 1.21) 6.57 (±1.49) -1.71 .000**
Social well-being 5.41 (±1.33) 4.81 (±1.30) -0.60 .042*
Psychological well-being 6.27 (±1.29) 4.90 (±1.59) -1.37 .000**
Spiritual well-being 4.21 (±1.16) 3.29 (±1.36) -0.92 .001**
Total QoL 6.12 (±0.82) 4.95 (±1.13) -1.17 .000**
*Mean difference is significant at the 0.05 level. **Mean difference is significant at the 0.01 
level.
Table 3. Correlates of fatigue severity in AYAs with cancer
Correlates Correlation coefficients N Sig.
Sociodemographic variables
Age at cancer diagnosis
Age at participation
Gender (male/female)
Partner status (yes/no)
Children (yes/no)
Employed or studying (yes/no)
.194
.185
.336
.118
-.122
.394
83
83
83
82
82
79
.079
.093
.002**
.291
.273
.000**
Disease and treatment-related variables
Time since cancer diagnosis
Cancer stage at diagnosis (early/late)a
Duration of cancer treatment
Cancer treatment at participation (yes/no)
Time since completion of cancer treatment
Intent of cancer treatment (curative/palliative) 
Surgery (yes/no)
Chemotherapy (yes/no)
Radiotherapy (yes/no)
Immuno- or targeted therapy (yes/no)
Hormone therapy (yes/no)
.073
.322
.087
-.227
.060
.270
.178
.115
-.242
-.107
.064
83
67 
81
83
61
83
83
83
83
83
83
.513
.008*
.439
.039*
.646
.013*
.108
.302
.028*
.336
.563
Psychological variables
Psychological distress (HADS total)
Fear of recurrence or progression (CWS total)b
.553
.340
83
71 
.000**
.004**
*Correlation is significant at the 0.05 level. **Correlation is significant at the 0.01 level. 
a  Cancer stage was unknown for n=7 AYAs with cancer and not applicable for n=9 AYAs with 
cancer. 
b  CWS was not administered to n=12 AYAs with cancer, because they either had a recurrence 
(n=5) or received treatment with palliative intent (n=7).
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Sociodemographic, treatment-related, and psychosocial correlates 
of fatigue severity
Correlations are listed in Table 3. Higher psychological distress was strongly 
correlated to fatigue severity (R = .55; p < .001). Female gender, being unemployed 
(not having a job, sick leave or disablement insurance act), higher disease stage 
(III-IV) at diagnosis, and higher fear of recurrence or progression were moderate 
correlates (R‘s 0.30 to 0.50; p’s < .01). In addition, receiving active treatment at 
the time of study participation, palliative intent of treatment and having had 
radiotherapy were weakly associated with fatigue severity (R‘s 0.10 to 0.30; 
p’s < .05). No significant associations were observed between fatigue severity 
and the other sociodemographic, disease- and treatment related variables (see 
Table 3; p’s > .05). 
Discussion
In this study, severe fatigue affected almost half of the AYAs with cancer. 
The prevalence of severe fatigue in AYAs with cancer was more than twice as 
high in AYAs with cancer than in gender- and age-matched population-based 
controls (48% versus 20%). Severe fatigue as assessed with the CIS-fatigue is 
more prevalent amongst AYAs with cancer than adult disease-free breast cancer 
patients 3 years after diagnosis (38%) [19]. The prevalence amongst AYAs with 
cancer corresponds more closely with findings from a study performed in adult 
cancer patients during cancer treatment with palliative intent (47%) [13], which is 
remarkable given the major difference in prognosis between these two patient 
groups. In our sample, only a minority of the participants (n=12, 14.5%) were 
classified as being treated with palliative intent at the time of participation. 
Reasons for the high prevalence of severe fatigue in AYAs with cancer have not 
been studied. One might postulate that, in contrast to adult cancer patients, the 
higher prevalence of severe fatigue originates from the unique combination of 
being diagnosed and treated for cancer and the developmental milestones AYAs 
are confronted with during adolescence and young adulthood.
Alternatively, the higher prevalence of severe fatigue reported by participants 
in our study could be the result of selection bias. We recruited AYAs with cancer 
that consulted a multidisciplinary AYA team. The fact that patients consulted a 
specialized AYA team most likely indicates that these patients had additional 
disease and/or treatment-related questions or problems, although not all 
patients had a need for continued and specific care by the AYA team after the 
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first consultation. The percentage of patients having had chemotherapy as part 
of AYA cancer treatment was high (87%). This further supports the likelihood 
of selection bias in our sample and might overestimate disease severity of the 
entire AYA cancer patient population. Nonetheless, we can conclude that within 
the subset of AYAs with cancer consulting a multidisciplinary AYA team, the 
prevalence of severe fatigue is substantial. 
Significant differences were found in physical, social, psychological, spiritual, 
and total QoL for severely fatigued AYAs with cancer in comparison with 
non-severely fatigued patients, which echoes previous studies reporting on 
the detrimental effects of severe fatigue in adult cancer patients [6, 10]. More 
psychological distress was a strong correlate of fatigue severity in the present 
study. In addition, more cancer worrying, female gender, and being unemployed 
were moderately related to fatigue severity. Geue et al. (2014) studied gender-
specific differences in quality of life after AYA cancer and found lower QoL for 
women than men, including higher levels of fatigue [20]. The finding that more 
psychological distress and cancer worrying were associated with fatigue severity 
is in agreement with the impact of fatigue severity on QoL of AYAs with cancer 
in this study. However, given the cross-sectional design of our study we cannot 
draw conclusions on causality. This also limits interpreting the finding that being 
unemployed was linked to higher fatigue severity, although it may suggest that 
severely fatigued AYAs with cancer might not be able to find appropriate work. 
This emphasises the relevance of further research into this topic.
We only found weak or non-significant links between treatment-related variables 
and fatigue severity; receiving active treatment at the time of study participation, 
receiving treatment with palliative intent, and having had radiotherapy were 
significant but weakly related to fatigue severity. A moderate association was 
found between late-stage cancer at diagnosis and fatigue severity. In previous 
studies among adult cancer patients during and after treatment, fatigue appeared 
to be unrelated to disease-related variables, but the receipt of chemotherapy was 
associated with fatigue long after treatment [21]. A recently published review 
among breast cancer survivors after treatment also reported that survivors 
treated with chemotherapy were at higher risk for developing severe fatigue, as 
were those survivors with a higher disease stage at diagnosis [22]. As mentioned 
before, a noteworthy proportion of participants (87%) in our sample had been 
treated with chemotherapy.
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The present study has several limitations. The sample size of our study was 
relatively small and the low participation rate increases the probability of bias 
by non-response. Unfortunately, small sample sizes are also seen in other 
studies in which patients of AYA age are asked to participate [23, 24]. Recruitment 
for our study took place over a period of 4 years. Additional efforts to increase 
data collection, such as multiple mailings of questionnaires or follow-up phone 
calls, were only made in the latter part of the study. Our response rate might 
have been higher when these efforts were made throughout the entire duration 
of the study. However, in the AYA HOPE study fewer than half of the eligible 
AYAs with cancer responded to questionnaires despite extensive efforts such 
as multiple mailings, phone calls, and financial incentives [25]. One way to 
overcome the low response rate in AYA cancer research might be the use of in-
person contact and patient-preferred paper-pencil rather than online surveys as 
recently suggested by Rosenberg et al. [26]. Given the low incidence of cancer in 
AYAs between the ages of 18 to 35 years, recruitment from multiple institutions 
in an (inter)national AYA network could also aid the collection of larger samples. 
This would also increase the ability to generalize findings, which is limited in our 
study since we recruited patients at a single university medical center. While a 
broad range of potential correlates of fatigue severity was studied, we cannot 
rule out the involvement of other potentially relevant factors that have not been 
examined in this study. For example, sleep problems are strongly correlated 
with higher levels of fatigue in patients with cancer [27]. In addition, a low level 
of physical activity and pain are also correlated with cancer-related fatigue [28]. 
There is evidence that the effect of sleep problems on fatigue is mediated by 
pain [29]. Unfortunately, we did not include validated instruments to assess sleep 
problems, physical activity, and pain as potential correlates of fatigue severity in 
our sample, which is a significant limitation of the study. Notwithstanding these 
limitations, the present study is the first to apply a clinically relevant cut-off for 
severe fatigue in AYAs with cancer aged between 18 and 35 years at diagnosis.
In conclusion, given the high prevalence and significant impact of severe fatigue 
on quality of life of AYAs with cancer, health care providers should pay careful 
attention to this symptom. In particular, female AYAs with cancer, those with 
more advanced disease at diagnosis, higher levels of psychological distress, and 
more cancer worrying seem to experience higher levels of fatigue. The longer-
term survivorship rates of AYA cancer illustrate the potential longevity of AYAs 
with cancer. It is therefore important to investigate the course and persistence 
of severe fatigue in AYAs with cancer in longitudinal, population-based studies. 
Such studies would also aid the development of age-specific interventions 
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addressing persistent cancer-related fatigue in AYAs with cancer to enable 
full participation in society throughout survivorship. Although evidence-based 
interventions for the management of cancer-related fatigue in adult cancer 
survivors are available and recommended within guidelines issued by the 
American Society for Clinical Oncology [30], these interventions have not been 
tested extensively in AYAs with cancer. Researchers should investigate whether 
these interventions can also be successfully applied to alleviate persistent 
cancer-related fatigue, improve QoL, and facilitate participation in society for 
the understudied population of AYAs with cancer.
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Abstract
Purpose: To provide an overview of the literature on post-traumatic growth 
(PTG) and resilience among adolescent and young adult (AYA) cancer patients.
Methods: A literature search in Embase, PsychInfo, Pubmed, Web of Science, 
Cochrane Library, and Cinahl was carried out. Thirteen articles met the 
predefined inclusion criteria.
Results: Qualitative interview studies showed that AYA cancer patients report 
PTG and resilience: PTG is described by AYA cancer patients in terms of benefit 
finding including changing view of life and feeling stronger and more confident, 
whereas resilience is described as a balance of several factors including stress 
and coping, goals, optimism, finding meaning, connection and belonging. 
Quantitative studies showed that sociodemographic and clinical characteristics 
were not associated with PTG. Enduring stress was negatively, and social 
support positively, associated with PTG. Symptom distress and defensive coping 
were negatively and adaptive cognitive coping was positively associated with 
resilience. Both PTG and resilience were positively associated with satisfaction 
with life and health-related quality of life (HRQoL). Resilience was found to be a 
mediator in the relationship between symptom distress and HRQoL. 
Two interventions aiming to promote resilience, a stress management and 
a therapeutic music video-intervention, were not successful in significantly 
increasing overall resilience. 
Conclusion: Most AYA cancer patients report at least some PTG or resilience. 
Correlates of PTG and resilience, including symptom distress, stress, coping, 
social support and physical activity, provide further insight to improve the 
effectiveness of interventions aimed at promoting these positive outcomes and 
potentially buffer negative outcomes.
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Introduction
A common trend of incorporating data from adolescent and young adult (AYA) 
cancer patients into either childhood or older adult populations in research has 
created a gap in understanding the AYA cancer experience.1 Adolescence and 
young adulthood is a complex developmental phase in life defined not only 
by significant physical changes, but also by critical psychosocial challenges, 
including transitioning to independence from parents, establishing autonomy 
and self-identity (personal set of goals and values), engaging in interpersonal 
relationships (e.g. intimacy, marriage, family forming), along with educational 
and employment decisions and attainments.2 A cancer diagnosis during this 
unique phase of physical and psychosocial growth can disrupt the achievement 
of developmental milestones and have life-long repercussions. Research shows 
that AYA cancer patients demonstrate significantly worse health-related quality 
of life (HRQoL) and greater levels of psychological distress compared to healthy 
matched peers, due to these challenging circumstances.3 
 
Over the past decade, psychosocial research has broadened its scope from 
the negative aftermath of traumatic events,4, 5 such as a cancer diagnosis, to 
the identification of positive outcomes or positive ways in which people’s lives 
have changed as a result of a struggle with adversity.6, 7 Post-traumatic growth 
(PTG) is described as the positive psychological change that appears following 
significantly burdensome or traumatic life events. Specifically, people who 
have been exposed to trauma reported PTG in relationships, in their outlook 
on life, in their perception of themselves, in their spiritual beliefs and lastly in 
their appreciation of life.8 A vast body of research shows that the majority of 
people who have been exposed to a potentially traumatic event are resilient.9 
Resilience is the ability to cope with negative emotions that arise from a 
stressful experience, by identifying and developing resources to function.10 
Many studies on PTG have explicitly or implicitly equated PTG with resilience 
or have even gone a step further and considered PTG superior to resilient 
outcomes.11 For instance, Carver discriminated between PTG and resilience by 
defining resilience as a return to the prior level of functioning after difficulty and 
by relating PTG with not only returning to the prior level but exceeding it.12 This 
definition assumes that for PTG to occur, a person has to demonstrate resilience 
and return to a healthy functioning level before higher, even more efficient 
functioning levels can be reached. Tedeschi and Calhoun (1995) supported this 
assumption.13 They state that positive outcomes after traumatic life events 
depend on the coming together of several personal variables, resilience being 
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one of them. Hence, for PTG to develop, a person needs to not only be for example 
optimistic, hardy, and face life crises that represent irreversible changes, but they 
also need to be resilient in order for a new level of adaptation to be achieved. 
Westphal and Bonanno (2007) objected to the notion that resilience is often 
equated with PTG and suggest that PTG and resilience should be viewed as two 
independent constructs.14 They have even gone a step further and argued that it 
is very unlikely for resilient persons to perform the meaning making behaviours 
that are related to PTG since they do not struggle to the same extent as other, 
more traumatised persons would. Thus, survivors of trauma that are highly 
resilient will not engage in the cognitive processing that is essential for PTG to 
develop.14 Up to now there is little understanding of the relation between PTG 
and resilience and no empirical research thus far has tried to shed more light onto 
this association. Although PTG and resilience can both be seen as outcome as well 
as a process, the terms cannot be used interchangeably: PTG does not develop as 
a direct consequence of the traumatic experience but in the aftermath of it and 
in the struggle to find a new normal,15, 16 while resilience indicates the ability to 
cope with negative emotions that arise from a stressful experience and function at 
normal or close to normal capacity (maintain a stable equilibrium).17 Nevertheless, 
there is some evidence that both, PTG and resilience, can function as protective 
factors counterbalancing the stress-related adverse effects of cancer and thereby 
improving HRQoL of patients.18, 19 It may therefore be argued that interventions 
to improve psychological adaptation after cancer are not just about preventing, 
reducing, and/or treating psychological distress but also about increasing 
resilience and promoting PTG.20 Until now, there has been little examination of 
PTG and resilience outcomes in AYA cancer patients. This review study aims to 
provide an overview of the literature on PTG and resilience experiences, correlates 
and interventions among AYA cancer patients to inform future research.
Methods
Search strategy
A computerized search of the literature through Embase (1974 - present), 
PsychInfo (1806 - present), Pubmed (1946 - present), Web of Science (1945 - 
present), Cochrane Library, including Cochrane Central Register of Controlled 
Trials (CENTRAL) and Cinahl (1981-present, EBSCOhost) was carried out by two 
researchers (SG and OH) on November 30th 2016. The search strategy combined 
the terms (‘neoplasm’ or ‘cancer’) and (‘adolescent’ or ‘young adult’) with other 
key terms related to positive psychosocial outcomes including (‘posttraumatic 
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growth’ or ‘relating to others’ or ‘new possibilities’ or ‘spiritual change’ or ‘life 
appreciation’ or ‘personal strength’ or ‘empowerment’ or ‘emotional growth’ 
or ‘resilience’ or ‘benefit finding’ or ‘positive health’). The reference lists of 
all identified publications were examined to find relevant publications not 
identified via the search strategy. There were no limits with regard to the year 
of publication. The search yielded 264 unique hits.
 
Selection criteria
We used an inclusive approach with regard to the AYA cancer patient age definition. 
Several AYA age definitions are used globally, ranging from 12 years21 to 39 years,22 
based on physical and psychological developmental phase and accompanied care 
system (pediatric vs. adult oncology), aspects of tumor pathology or biology, or 
on health outcomes.23 All studies that presented results of patients who were 
within the age range of 12 to 39 years at time of cancer diagnosis were included. 
Furthermore, studies were included: (i) if PTG or resilience (according to the 
definition of the researchers) was assessed; (ii) if the publication was an original 
article published in English (no poster abstract, letter to the editor or systematic 
review paper). Studies were excluded if: (i) they focused solely on pediatric and/
or adult cancer patients; (ii) the study included patients of all ages but did not 
present the AYA patient data separately. The described inclusion and exclusion 
criteria were applied to the initial 264 hits. SG and OH screened all titles and 
abstracts, 38 articles met the criteria. After careful independent review by SG and 
OH, 13 articles meeting our selection criteria were included in our review. Figure 1 
presents the flow-chart of the selection procedure.
Quality assessment
The methodological quality of the 13 included studies was independently 
assessed by two reviewers (SG and OH) based on established criteria for 
systematic reviews (Table 1).24 The quality of a study can be described in 
terms of internal (methods) and external validity (representativeness and 
generalization). To cover both validity aspects the quality criteria were divided 
into 4 categories: assessment of outcomes, study population, study design and 
presentation of results. it was discussed in a meeting. For each quality criterion 
a study met, 1 point was assigned (highest possible score of 12 points). If a study 
did not meet our criteria or was described insufficiently or not at all, 0 points 
were assigned. Studies scoring 9 points or more were arbitrarily considered to 
be of ‘high quality’. Studies scoring between 6-8 points were rated as ‘adequate 
quality’. Studies scoring <6 points were rated as ‘low quality’.
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Figure 1: Prisma flow-chart of selection procedure
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Results
Study characteristics
In total, 13 studies were included, all published between February 2007 and 
February 2015. Qualitative (n=3), quantitative (cross-sectional cohort, n=8) 
as well as intervention studies (n=2) were present. The main findings are 
summarized in Table 2.
Methodological quality and issues
The quality scores ranged from 3 to 10.5 points (Table 1), and the mean quality 
score of all studies was 7.8 points. The Kappa inter rater agreement was 0.66 
(standard error of 0.16), indicating a good strength of agreement between the 
two independent reviewers.25 Three studies were of low, four of high and six 
of adequate quality. General limitations of the included studies were patient 
response rates under 75% (n=10), small patient sample sizes (n=7) and lack of 
longitudinally gathered data (n=8) or group comparisons (n=6). A complicating 
factor for data extraction was that PTG and/or resilience were often secondary 
outcomes in most of the quantitative studies, resulting in a limited presentation 
of the results for these outcomes. We will discuss the main results of the included 
studies according to their study design. 
Qualitative studies
Three qualitative semi-structured interview studies were included in this 
review.26-28 These studies showed that AYAs with cancer have the capacity to be 
resilient26 and almost all patients included in the studies reported some form of 
PTG.27, 28
AYAs with cancer described resilience as a balance of several factors including a) 
coping and stress; b) goals, purpose and planning; c) optimism; d) meaning and 
gratefulness; and e) connection and belonging.26 The balance of these factors 
could promoted by increasing specific skills (including benefit-finding, goal-
setting, stress management).26 For example, AYA cancer patients who were 
able to find meaning, stay positive, set goals, control stress, seemed to consider 
themselves resilient, but in periods of extreme anxiety or transition (for example 
when they did not know what to expect), they felt their resilience diminished. 
Similarly, AYA cancer patients who persisted in negative emotions or who could 
not built purpose or meaning perceived themselves little resilient. AYA cancer 
patients stated that levels of resilience shifted with specific experiences, moods 
and skills.
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5
The other two interview studies focused on PTG which was described more in 
terms of benefit finding.27, 28 Two recurrent themes emerged for the adolescent 
cancer experience: 1) loss of control, which resulted in anger or frustration and 
treatment non-adherence; and (2) benefit finding including improved bolstered 
relationships and improved personal attributes. All AYA cancer patients 
interviewed, except one, stated that they experienced at least one positive 
facet of being diagnosed with and treated for cancer.27 This was supported by 
the results of another study, showing that AYAs with cancer perceived that their 
view of life had been changed in a positive way.28 They felt stronger through 
having survived cancer. They felt this had weaponed them with the confidence 
and the faith that they could deal more effectively with other stressful situations.
Quantitative studies
Eight cohort studies, all with a cross-sectional design,18, 29-35 and two intervention 
studies were included in this review.36, 37
Measures
Different questionnaires were used to assess PTG and resilience. Most of the 
questionnaires were not specifically developed for AYAs with cancer, however in 
most cases the reported psychometric properties were good.
Four of the five studies focusing on PTG used the Posttraumatic Growth Inventory 
(PTGI)29-31 or its short form.32 The PTGI is a well-validated 21-item questionnaire 
including factors of New Possibilities, Relating to Others, Personal Strength, 
Spiritual Change, and Appreciation of Life.38 The questionnaire measures how 
successful individuals, coping with the aftermath of trauma, are in rebuilding 
or strengthening their perceptions of their self and others, and the meaning 
of events. A recent study showed that the PTGI was clear, appropriate, and 
relevant for AYAs with cancer.39 One study used the personal growth scale of 
the Psychological Well Being Scale (PWBS). A theoretical model shows that 
psychological well-being consists of six specific dimensions of health: Autonomy, 
Environmental Mastery, Personal Growth, Positive Relations With Others, 
Purpose in Life, Self-Acceptance.40 The personal growth scale is not validated 
among AYAs with cancer and it is limited by only measuring one aspect of PTG. 
Two of the five studies focusing on resilience used the Haase Adolescent 
Resilience in Illness Scale (HARS), 30,33 which measures how adolescents with an 
illness think or feel about managing their health after diagnosis of the disease.10 
The Ego-Resiliency Scale was used in one study34 and is based on the concept of 
ego-resiliency or the ability to adapt one’s level of emotional control up or down 
94
Chapter 5
appropriate to the conditions.41 Another study assessed resilience with the 
Resilience Scale (RS),18 which had the best psychometric properties to measure 
resilience among adolescent populations.42 The RS focuses on psychological 
qualities rather than deficits (e.g. personal competence and acceptance of self 
and life).43 The last study used the Connor-Davidson Resilience Scale (CD-RISC),29 
measuring five dimensions of resilience: (1) personal competence; (2) trust in 
one’s intuition, tolerance of negative emotions, and strengthening effects of 
stress; (3) secure relationships and positive acceptance of change; (4) control; 
(5) spiritual effects.44
PTG/resilience levels of AYAs with cancer compared to healthy controls
Mean PTG and resilience levels of AYAs with cancer are described per study in 
Table 2. Two studies compared the levels of PTG of AYAs with cancer with those 
of healthy controls.32, 35 In the first study, the in-treatment group of AYA cancer 
patients scored significantly lower compared to age-matched healthy controls 
and off-treatment AYA cancer patients on PTG as measured by the personal 
growth subscale of the psychological well-being scale (PWBS).35 In the other 
study, PTG levels as measured by the Posttraumatic Growth Inventory (PTGI) 
of AYA cancer patients did not differ from healthy controls matched on age, 
gender, educational level and partnership status.32 
With respect to resilience, one study found that AYA cancer patients had a 
significantly lower resilience score compared to gender- and age-matched 
healthy controls on the Ego Resilience scale.34
Correlates of PTG/resilience
Six studies examined the correlates of PTG or resilience.18,29,30,33-35 Socio-
demographic and clinical characteristics were not associated with PTG. PTG 
scores did not vary by age, gender, stage/severity of the disease,29, 30 race, 
relationship status, and treatment status, except for the PTGI subscale of 
‘New Possibilities’, of which the score was slightly lower in Caucasian patients 
compared to non-white patients.30 In another study, personal growth scores 
of the PWBS were compared between the in- and off-treatment AYA cancer 
patient age groups 15-20, 21-29 and 30-39 years, but no significant differences 
were found.35 
Some evidence was found for an association between psychosocial factors and 
PTG. Stress (negative) and social support (positive) were significantly associated 
with PTG.29 A significant interaction was found between physical activity and 
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social support, indicating a strong positive association between social support 
and PTG in inactive persons and a weaker association for active persons. 
There is a lack of studies examining the clinical and sociodemographic 
correlates of resilience among AYAs with cancer. Only one study showed 
that age, time since diagnosis and school grade were not correlated with 
resilience.33 This same study found that usage of a cognitive coping strategy 
to be associated with higher levels of resilience and usage of a defensive 
coping strategy to be associated with lower levels of resilience. However, no 
significant association between coping style and resilience was found in another 
study.34 In this study a significant negative association between expectations 
of the future and resilience, and significant positive associations between 
resilience and openness to experience and impulse control was found. In 
addition, cancer symptom distress was negatively associated with resilience.18 
Association PTG/resilience with other outcomes
Three studies examined the association between PTG or resilience and other 
outcome measures.18, 30, 31 No significant relationship between PTG and overall 
post-traumatic stress (PTS) severity was observed.30 However, curvilinear 
relationships between re-experiencing (a PTS symptom) and two of five PTG 
indicators (New Possibilities, Personal Strengths) were found, indicating some 
degree of distress related to the cancer experience was needed to develop PTG.30 
Another study found that PTG was positively associated with both general and 
health-related life satisfaction.31 
Resilience was found to be a mediator in the relation between HRQoL and 
cancer symptom distress, indicating that resilience might play a role in limiting 
the adverse effects of cancer symptoms on HRQoL.18 
Intervention studies
Two intervention studies were included.36, 37 The Promoting Resilience in 
Stress Management (PRISM) intervention consisted of two long or four short 
skill-based modules focused on managing stress (stress management/coping 
and goal setting) and building resilience (cognitive restructuring and benefit-
finding).36 Although a small effect size was found, the scores before and after 
intervention did not differ significantly. The second intervention, a Therapeutic 
Music Video (TMV) aimed to (a) increase protective factors like hope-derived 
meaning, courageous coping, spiritual feelings, family environment and social 
integration; (b) diminish risk factors like defensive coping and illness-related 
distress; and (c) increase levels of resilience and self-transcendence.37 AYAs with 
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cancer were randomly allocated to either the TMV-intervention or a low dose 
audio book control group, both under supervision of a therapist, and completed 
six sessions over three weeks. Overall resilience did not differ significantly 
between the two groups directly post-intervention, nor 100 days later. However, 
positive coping, social integration, and family environment were improved after 
the TMV intervention.
Discussion
This study aimed to provide an overview of the studies conducted on PTG and 
resilience in AYA cancer patients. The included qualitative studies, showed that 
most AYA cancer patients have the capacity to be resilient or showed some form 
of PTG. Cross-sectional cohort studies found no significant differences in PTG 
and resilience between AYA cancer patients and healthy controls, except for 
two studies showing that (on-treatment) patients had lower levels compared 
to healthy controls. Sociodemographic and clinical characteristics were not 
associated with PTG or resilience, except for race. Social support was positively 
and enduring distress negatively correlated with PTG. Symptom distress and 
defensive coping were negatively and adaptive cognitive coping was positively 
associated with resilience. PTG and resilience were found to be of significant 
influence on general and health-related life satisfaction and HRQoL of AYA 
cancer patients. The two resilience interventions did not result in significant 
improvements in overall resilience levels of AYA cancer patients. 
Prevalence of PTG and resilience: theoretical considerations
Overall, the results of the qualitative and quantitative studies suggest that AYAs 
with cancer experience at least some degree of PTG and resilience. This is in line 
with a study showing that almost 85% of childhood cancer survivors report at 
least one positive aspect of their cancer journey,45 and another study showing 
that up to 87% of the adult cancer survivors report PTG.46 The studies included 
in our review found no or only small differences in PTG and resilience scores 
between AYA cancer patients and healthy controls. However, prevalence rates 
of PTG or resilience are difficult to determine because of the heterogeneity of 
the study samples. The interpretation of these results is further complicated 
by the fact that for both, PTG and resilience, different definitions, theoretical 
frameworks and assessment tools were used.47, 48 Most researchers adopted the 
model of Tedeschi and Calhoun38 for analyzing PTG in the aftermath of cancer 
and relied on the associated PTGI assessment tool. However, this tool was 
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derived from research on war, natural disasters or other types trauma and not 
cancer.48 The extent of PTG experienced might be affected by the nature of the 
trauma.49 Cancer is different compared to other traumas in terms of the internal 
nature of the crisis, the multiple stressors, and future-focused fears.50 Cancer 
often has a nuanced onset (routine screening examinations), continues through 
cancer diagnosis and treatments, and it goes on for many years with the fear of 
future recurrences or disease progression. The PTGI does not assess the specific 
nature of the cancer experience. AYA cancer patients and healthy controls may 
have different reference points and are therefore not easily comparable. 
With regard to resilience three general ways have been used to describe it: as 
a baseline characteristic, as an outcome itself or as a mechanism to improve 
(positive) outcomes.51 Among AYAs with cancer, resilience is described as the 
process of finding or developing resources to manage stressors and reach positive 
outcomes,10 and the two most commonly used frameworks are the Resilience in 
Illness Model52 and its adolescent version.10 This framework comprises of health-
protective (e.g. social integration and courageous coping) and risk factors (e.g. 
illness related distress and defensive coping) and outcomes. Future research 
should explore the best framework for studying resilience and an assessment 
tool should be developed that assesses all components of resilience. 
In addition, future research should focus on examining the relation between 
PTG and resilience, because this could have important implications for both 
preventive interventions as well as trauma counseling. 
Correlates of PTG and resilience
PTG and resilience may not occur in all AYA cancer patients, identification of 
correlates creates opportunities to improve these outcomes. Sociodemographic 
and clinical factors were not associated with both outcomes. However, one of 
the included studies in our review found a difference between in-treatment AYA 
cancer patients who had lower PTG scores compared to both off-treatment AYA 
cancer patients and healthy controls,35 which is congruent with studies among 
adult cancer survivors.20 According to the Tedeschi and Calhoun definition, PTG 
needs time to appear in the aftermath of a traumatic event. It implies that 
moving beyond the daily demands of cancer and threat to one’s health or life 
provides room for greater processing of growth. Other cancer and treatment 
characteristics show contradictory associations with PTG and resilience among 
pediatric and adult cancer survivors.6, 7, 20, 53, 54 In case of PTG this is not unexpected, 
98
Chapter 5
as the PTGI, the most commonly used PTG assessment tool, does not explicitly 
refer to the medical nature of trauma and may therefore not be completely 
adequate to capture the full spectrum of positive reactions in cancer.48 With 
regard to the sociodemographic variables, most studies showed no relationship 
between gender and positive outcomes in adults with cancer, although there 
is also evidence that women report higher levels of PTG.20, 55, 56 There is some 
evidence indicating that racial or ethnic minority groups tend to report higher 
levels of PTG.20 Several studies observed higher socioeconomic status (income 
and educational level) was associated with higher PTG or resilience,57-60 however 
other studies found no relationship.20 The choice of one or another questionnaire 
may have conditioned the emergence of specific variables that better fitted 
with the tool itself, resulting in a relevant risk of outcome bias.48 More studies, 
using an appropriate definition, theoretical framework and assessment tool, 
must be conducted to identify sociodemographic and clinical correlates of PTG 
and resilience.
Psychosocial factors were more often found to be correlates of PTG and 
resilience. An adaptive coping strategy (cognitive or problem-oriented coping) 
was associated with higher levels of resilience among AYA cancer patients. This 
coping mechanism is used for protection of self in new dangerous situations, 
till sufficient resources are available for developing context-specific adaptive 
coping skills. Adaptive coping strategies such as acceptance, religious coping, 
and positive reinterpretation were also positively associated with PTG in adult 
cancer patient studies.53, 54, 61, 62 Nonadaptive ways of coping (e.g. defensive 
coping) can be changed into adaptive coping if the AYA cancer patient has 
enough time to mobilize or create other protective factors to diminish the 
impact of cancer and its treatment. In their relatively short lives, most AYA 
cancer patients may not have experienced many major life events. As such, their 
coping skills to handle new traumatic situations may not have been optimally 
developed yet, which makes AYAs in more need of some support with coping. 
Social support was positively correlated with PTG. Social support including 
acceptance and empathic conversations may strengthen AYA cancer patients 
to process their trauma, facilitate coping and increase adjustment.63, 64 Ongoing 
support encourages AYA cancer patients to communicate openly about and 
cognitively process their cancer through self-disclosure.8 Nevertheless, AYA 
cancer patients often indicate problems with maintaining normal, pre-cancer 
relationships with family and friends, informing others about their disease, 
maintaining school and/or work and other activities, and dealing with feeling 
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different.10 Studies have shown that support received from other AYA cancer 
patients is incredibly important for this age group.63 Ways to enhance social 
support should be explored, although (online) peer support groups and age-
specific information portals for AYA cancer patients have been shown to 
significantly reduce feelings of social isolation, improve knowledge, self-
efficacy, problem-solving skills and effective interpersonal interactions.65 
Stress was negatively associated with PTG,29 indicating that low levels of 
distress experienced after cancer treatment has ended can stimulate processing 
of the cancer experience, allowing growth. This finding, however, is incongruent 
with the PTG theory of Tedeschi and Calhoun38 suggesting that traumatic 
events may serve as promotors for the development of PTG because stress 
facilitates peoples’ cognitive process for rebuilding their views of themselves, 
their environment and their future.8 A study among childhood cancer survivors 
indeed found a positive correlation between post-traumatic stress and PTG.45 
Another study included in this review found a curvilinear relationship between 
post-traumatic stress (re-experiencing) and PTG (new possibilities and personal 
strengths),30 suggesting that there may be an optimal level of (post-traumatic) 
stress that strengthens PTG. When the post-traumatic stress levels increase 
beyond that point, a person may be overwhelmed by the stress, and adaptation 
and PTG may be negatively affected.66 The results of this study indicate that 
re-experiencing may help to adapt psychologically. More research is needed to 
determine the threshold by which stress levels become too high to allow PTG to 
take place.
Interventions
Searching for potential ways to enhance PTG or resilience among AYA cancer 
patients is important, as the results of this review show that both are associated 
with better HRQoL and higher levels of satisfaction with life. Based on the 
correlates of PTG and resilience found in this review, coping mechanisms and/
or social support are potential targets for intervention. Until now there are no 
interventions that are convincingly successful in promoting PTG or resilience 
among AYA cancer patients. However, both described resilience interventions 
were underpowered and participants were not screened for low resilience 
levels before the start of the intervention. Furthermore, both interventions 
were brief in nature which may be insufficient to learn and incorporate new 
skills. The PRISM intervention seems promising as the intervention is based 
on important correlates of positive outcomes: stress management and coping 
skills. Future studies with sufficient power should further explore the efficacy of 
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this intervention, whereby social support also should also be considered as an 
important element. 
Implications for practice and future research
As a result of the lack of one standard definition, theoretical framework, and 
assessment tool, for both PTG and resilience, research is still inconclusive in 
identifying correlates and mediators of PTG and resilience. 
Development of future interventions should be informed by the specific needs 
and capacities of AYAs with cancer. Future studies should investigate whether 
PTG and resilience can simply be encouraged by prompting AYA cancer patients 
to describe positive experiences that have resulted from cancer. An intervention 
among adult breast cancer survivors where survivors were asked to write about 
positive experiences (feelings and thoughts) related to their cancer, showed that 
those who wrote down positive feelings reported less health care professional 
visits and lower levels of distress than survivors who wrote down facts of their 
experience.67 The correlates of PTG and resilience may inform researchers and 
health care professionals on key elements to target in future interventions. For 
example, health care professionals may be able to recognize protective (social 
support) or risk factors (stress) and enable coping by supporting adaptive coping 
strategies. Health care professionals can also assist with problem solving, giving 
information in small amounts, listening, and showing empathy.68 Among adult 
cancer patients, two cognitive-behavioral interventions, including elements of 
relaxation exercises, conflict resolution and emotional expression, and coping 
skills training had positive effects on PTG.69, 70 
Limitations
This review has several limitations which should be mentioned. First, the small 
number of included studies and the heterogeneity of study samples and designs, 
makes it impossible to draw definitive conclusions about prevalence rates and 
correlates of both outcomes. In addition, different instruments were used to 
assess PTG or resilience, which could have resulted in contradictory study 
findings. There is a lack of a unifying description and therefore subsequent 
operationalization and measurement of both constructs. Researchers should 
explore the best ways to measure PTG and resilience and determine cut-off 
values for these instruments, making it easier to distinguish those who adjust 
well from those who could probably benefit from a PTG or resilience promoting 
intervention. The quality of the included studies was moderate to high (except 
for the qualitative studies). However, three shortcomings that need attention 
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for future studies are the patient response rates under 75%, the small patient 
sample sizes and cross-sectional study designs. 
To conclude, most AYA cancer patients report some degree of resilience or PTG. 
The factors associated with PTG and resilience found in this review, including 
stress, coping and social support, provide tentative insight to improve the 
effectiveness of interventions aimed at promoting these positive outcomes and 
potentially buffer more negative outcomes.
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Abstract 
Background: The difficulties adolescents and young adults (AYAs) encounter 
during a cancer experience may result in a reduction or absence of empowerment. 
The aims of the current study were to assess levels of empowerment and 
associated (demographic, clinical or psychological) factors and examine the 
association between empowerment and health- related quality of life (HRQoL) 
among AYA patients with cancer
 
Methods: Patients aged 18 to 35 years at time of cancer diagnosis and who were 
seen by one of the members of the specialized multidisciplinary AYA team of 
the Radboud university medical center, were invited to complete questionnaires 
regarding empowerment, HRQoL, and sociodemographic, clinical and 
psychological characteristics (autonomy, coping, unmet social support needs 
and psychological distress).
Results: A total of 83 AYA patients completed the questionnaires. The mean 
age of participants at a diagnosis was 27.5 years. The vast majority had been 
treated with chemotherapy (86%), had more advanced stage of disease and had 
completed treatment at the time of participation (74%). The mean empowerment 
level was 154.1 (standard deviation, 17.8) with a range of 114 to 200. Multivariate 
analysis demonstratrd that the autonomy subscales of self awareness (β = .35), 
capacity for managing new situations (β = .19) and social support (β = .35) 
were found to be positively associated with empowerment. Coping difficulties 
(β = -.19) were found to be negatively associated with empowerment. 
Empowerment was independently associated with physical (β = .31), 
psychological (β = .50), social (β = .39), religious (β = .33) and total HRQoL 
(β= .52; all P<.01). 
Conclusions: Low levels of empowerment were associated with low levels of 
autonomy and social support, female sex and coping difficulties among AYA 
patients with cancer. Recognizing these patients as candidates for empowerment 
interventions ultimately could help to improve HRQoL in late adolescence and 
young adulthood.
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Introduction
Adolescents and young adults (AYAs), diagnosed with cancer at the age of 
18 to 35 years, form a distinct group between pediatric and adult oncology[1]. 
Our definition of AYA (those aged 18-35 years) is based on the organization of 
the health care system in the Netherlands, in which there is a clear distinction 
between pediatric (ages birth-18 years) versus medical oncology. According to 
Barr and colleagues “there is broad agreement but less than unanimity that 
adolescence ranges from 15 to 19 years of age, resulting in young adulthood 
beginning at age 20 years”. Therefore the age range of 18 to 35 years used herein 
appears to indicate late adolescence and young adulthood[2]. In the Netherlands 
approximately 2700 AYA patients are diagnosed with cancer annually - which 
is approximately 5 times the number of cases diagnosed in children a birth 
to 17 years[3]. In addition to differences in tumor biology, limited progress in 
survival, lower clinical trial participation rates, and insufficient awareness of 
cancer symptoms among patients and professionals, this group has distinctive 
psychosocial and supportive care needs compared with their younger and older 
counterparts[1]. Late adolescence and young adulthood is a period of complex 
development; for example, it is during this period that one creates one’s 
own identity and body image, and establishes autonomy, responsibility and 
independence. A cancer diagnosis poses existential questions to AYA patients 
regarding their future, encompassing premature confrontation with mortality; 
changes in physical appearance; increased dependence on parents; potential 
loss of reproductive capacity; and disruptions in social life, education and 
employment due to treatment. These factors may have a negative impact on 
health-related quality of life (HRQoL)[4].
Empowerment is a factor that may be associated with HRQoL and has 
become a topical issue in cancer survivorship over recent years[5-10]. With its 
roots in community psychology, empowerment was originally defined as “the 
mechanism by which people, organizations, and communities gain mastery over 
their lives”[11]. The topical nature and the extensive (mis)use of empowerment 
in health care has led to a lack of clarity in regard to its definition and 
measurement[12]. For example, empowerment can be viewed as a process versus 
an outcome, and on an individual versus collective level[12-14]. For this current 
study, we used the construct of psychological empowerment of Zimmerman[15] 
that views empowerment as an outcome measure on the level of the individual 
patient: “psychological empowerment is a feeling of control, a critical 
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awareness of one’s environment and active engagement in it”. In accordance 
with a recent review on measuring and defining empowerment in patients with 
cancer[16], Zimmerman states that empowerment reflects a broad construct 
and comprehends intrapersonal, interactional, and behavioral components[15]. 
The intrapersonal component refers to how people think about themselves and 
includes perceived control, self-efficacy, perceived competence and mastery. 
The interactional component refers to how people think about and relate to their 
social environment, and the behavioral component of empowerment relates to 
concrete behaviors of a person to change his or her situation (e.g. active coping, 
and participation in decision making) [14, 15].
Empowered AYA patients with cancer may be more likely to understand and 
participate in their own care by mobilizing resources and taking actions that 
can reduce distress, enhance strategies for dealing with cancer and improve 
HRQoL[5, 6]. In view of this knowledge, it is important to evaluate which 
sociodemographic (eg, sex), clinical (eg, treatment intent) and psychological 
(eg, loss of autonomy, coping difficulties, high levels of psychological distress, 
and unmet social support needs) factors are associated with low levels of 
empowerment among AYA patients with cancer. This also may help us to identify 
those patients who might benefit from additional support or interventions.
In summary, the objectives of the current study were to assess the: 1) levels and 
associated factors (demographic, clinical and psychological) of empowerment; 
2) association between empowerment and HRQoL among AYA patients.
Methods 
Participants
Patients aged 18 to 35 years at the time of cancer diagnosis, and who had been 
seen by at least 1 of the members of the AYA team of the Radboud University 
Medical Center in The Netherlands, were invited to participate in this study. 
The AYA team is a dedicated multidisciplinary team including a medical 
oncologist, clinical nurse specialist, medical psychologist, and social worker. 
Patients consulting the AYA team receive regular medical care from their own 
treating medical specialist in the Radboud University Medical Center (medical 
oncologist, hematologist, surgeon, gynecologist etc.) and visit the AYA team for 
age-specific questions and care needs. In general, patients visiting the AYA team 
represent a group of patients with high disease severity, who are diagnosed with 
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a relatively advanced stage of disease and undergoing intensive treatments, 
and who are reporting more difficulties with coping. Patients with lower stage 
disease (eg, cervical cancer, melanoma) who are treated solely by surgery, are 
not often seen by the AYA team.
For the current study, AYA patients with cancer were included independently 
of the status of treatment (during or after treatment), the type of treatment 
(surgery, chemotherapy, radiotherapy, immunotherapy/targeted therapy and 
hormonal therapy or a combination), or the number of AYA team visits (some 
patients only had one introduction talk with 1 of the members of the team and 
did not receive specific care thereafter) to depict the real-life heterogeneous 
sample of AYA patients with cancer visiting the AYA team. Inclusion commenced 
January 2012 and ended March 2016.
Procedure
Potential study participants were recruited via letters describing the study 
and inviting patients to participate in the study. Patients who were willing to 
participate had to actively opt-in to the study by providing written informed 
consent by email to a member of the AYA team. Participants were then sent a 
single set of questionnaires by email that could be completed online. The study 
was deemed exempt from full review and approval by a research ethics comittee 
(CMO Regio Arnhem - Nijmegen).
Measures
Empowerment
The Cancer Empowerment Questionnaire (CEQ) is based on Zimmerman’s 
theory of psychological empowerment and to the best of our knowledge 
is one of first empowerment questionnaires validated in patients with 
cancer[8, 15, 16]. Validation in survivors of breast cancer provided a 4-factor 
structure representing the intrapersonal and interpersonal strengths of patients 
with cancer [8]. The CEQ consists of 40 items with 4 subscales: Personal Strength 
(19 items, range 19-95, α = .90), Social Support (9 items, range 9-45, α = .76), 
Community (6 items, range 6-30, α = .81) and Health Care (6 items, range 6-30, 
α = .78). Personal Strength encompasses intrapersonal aspects of empowerment 
regarding self-efficacy, self-esteem, optimism and personal competence. 
The remaining 3 subscales represent the interpersonal aspects of empowerment 
with items of perceived support from individuals close to the patient (Social 
Support), feelings of acceptance and support from the social community 
(Community), and the perception of good and collaborative relationships with 
112
Chapter 6
health care professionals (Health Care). Examples of questions regarding each 
subscale are: “I think I am worthwhile” (Personal Strength), “The people around 
me accept me” (Social Support), “The society respects my rights as a citizen” 
(Community), and “My health care professionals are there when I need them” 
(Health Care). The 40 items are rated on a 5-point Likert scale ranging from 1 
(strongly disagree) to 5 (strongly agree). Total scores (scale) can rfeaenlgineg 
fsr oomf e4m0 pto w20e0rm. Setnrto nagree ri ndicated by higher scores [8]. 
Baseline internal consistency was good (Cronbach’s α, .93).
Health-related Quality of life
The Quality of Life for Cancer Survivors (QoL-CS) questionnaire measures 
the HRQoL of patients with cancer. It consists of 41 items on the physical, 
psychological, social and religious impact of cancer on the life of the patient. 
Respondents rate themselves along an interval rating scale ranging from 0 to 10 
for each item. For subscale scoring purposes, all items were ordered, so that 0 
indicated the lowest or worst possible HRQoL, and 10 indicated the highest or 
best possible HRQoL outcome. An overall QoL score was computed by averaging 
all 41 items[17].
Associated factors
Sociodemographic and clinical characteristics
Demographic data, including age, sex, partnership, having children, living 
situation, educational level, and employment status were gathered by self-
report. Medical data, including tumor type, disease stage, type(s) of treatment(s) 
received, treatment status (on/off treatment) and time since initial diagnosis 
were extracted from the patients’ medical records by 2 of the researchers 
[SK,SvD].
Autonomy-connectedness
The Autonomy Connectedness Scale (ACS-30) questionnaire measures 
individual differences in autonomy-connectedness (ie, the capacity for self-
governance, including in social relationships). It consists of 30 items divided into 
3 subscales: Self-Awareness (7 items, [eg, “I often do not know what my opinion 
is”]), Sensitivity to Others (17 items [eg, “I often wonder what other people think 
of me”]), and Capacity for Managing New Situations (6 items [eg, “I quickly feel 
at ease in new situations”]). All items are measured with 5-point scales, ranging 
from disagree to agree[18, 19]. Internal consistency in this study was good with α 
values of .81, .82 and .80, respectively.
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Psychological distress
Psychological distress was assessed with the Hospital Anxiety and Depression 
Scale (HADS), with 7 items each for assessing symptoms of anxiety and 
depression. All items were scored on a 0-point to 3-point scale, with higher 
scores indicating more symptoms. A total score was calculated, with higher 
scores indicating more distress[20].
Social support and coping
Two items (amount of social support and coping difficulties) were added as 
separate correlates for empowerment. They were selected from the QoL-CS 
questionnaire[17]. The question regarding the amount of social support was: 
“Was the amount of support you received from others sufficient?” For coping 
difficulties the question was: “How difficult is it for you nowadays to cope with 
the effects of disease and treatment?”. Respondents rate themselves along 
an interval rating scale ranging from 0 to 10 for each item. For social support 
a higher score indicates sufficient social support, whereas a higher score on 
coping indicates more coping difficulties.
Statistical analysis
Analyses were performed using Statistical Package for the Social Sciences 
version 22 (SPSS), Chicago, IL, USA and 2-sided P values <.05 were considered 
statistically significant. Descriptive statistics and frequencies concerning 
socio-demographic, clinical data, levels of empowerment and correlates 
were calculated. Pearson and Phi correlations were calculated to examine 
associations between 2 continuous variables and continuous and dichotomous 
variables, respectively. This first was performed for correlates of levels of 
empowerment and thereafter this was performed for correlates of HRQoL. To 
determine independent effects of covariates on levels of empowerment and 
HRQoL respectively, multivariate linear regression analyses were performed 
including only those covariates that were significant at the bivariate level.
Results 
Sociodemographic and clinical patient characteristics
In total, 309 letters requesting participation in the study were sent to AYA 
patients with cancer visiting 1 of the members of the AYA team. A total of 89 
patients, comprising 57% who opted to take part in the study (155 patients) 
and 29% of those invited (309 patients), completed the online questionnaire. 
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Six patients were excluded due to age criteria: 4 diagnosed with cancer at age 
<18 years and 2 were aged >35 years at the time of diagnosis. Table 1 shows 
sociodemographic, disease and treatmentrelated characteristics of the final 
sample (83 patients). The mean age at diagnosis was 27.5 years (standard 
deviation [SD], 4.6 years) with a range of 18 to 35 years and a median age at 
diagnosis of 27 years. Three patients (3.6%) were aged 18 and 19 years. The 
average time since diagnosis was 2.1 years (SD, 2.6 years) and 86% received 
curative treatment. Of the participants 52% were male. The most commonly 
diagnosed cancers were testicular cancer (34%) and sarcoma (19%).
Table 1: Characteristics of the AYA patient study sample
Total N=83(%)
Gender
Male
Female
43(52%)
40(48%)
Age at diagnosis M(SD), y 27.5(4.6)
Age at survey M(SD), y 29.6(4.8)
Time since cancer diagnosis M(SD), y 2.1(2.6)
Cancer diagnosis
Testicular cancer
Sarcoma
Breast cancer
Lymphoma/Leukemia
Gynecological cancer
Melanoma
Other*
28(34%)
16(19%)
10(12%)
10(12%)
9(11%)
3(4%)
7(8%)
AJCC TNM Staging system stage of disease
NA
Stage I
Stage II
Stage III
Stage IV
Unknown
9(11%)
11(13%)
25(30%)
13(16%)
18(22%)
7(8%)
Treatment intention 
Curative
Palliative
71(86%)
12(14%)
Treatment status
Active 
Completed
22 (26%)
61 (74%)
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Treatment type(yes)
Surgery
Chemotherapy
Radiotherapy
Immunotherapy/targeted therapy
Hormonal therapy
Systemic therapy other
70(84%)
72(87%)
24(29%)
13(16%)
7(8%)
13(16%)
Partner
Yes 
No
58(70%)
24(29%)
Children
Yes
No
27(33%)
55(66%)
Living situation
With parents
On own
With partner
14(17%)
24(29%)
44(53%)
Highest completed educationa
Low/ Intermediate 
High
38(46%)
44(53%)
Employed/studying
Yes
No
68(82%)
15(18%)
Received social support meeting needs mean (SD)b 8.1(1.8)
Coping with effects of cancer and its treatment mean (SD)c 4.1(2.6)
Psychological distress mean (SD)d 11.0(6.6)
Autonomy connectedness mean (SD)
Self-awarenesse
Sensitivity to othersf
Handle new situationsg
25.9(6.1)
57.2(10)
19.2(5.5)
Abbreviations: AYA, adolescents and young adults; NA, not applicable; SD, standard deviation.
Not all numbers add up to 83 because of missing data
* brain tumor in 1 patient, sigmoid carcinoma in 1 patient, orofaryngeal cancer in 1 patient, 
neuroendocrine tumor in 1 patiënt, salivary gland in 1 patiënt, adrenal carcinoma in 1 patiënt, 
and lung cancer in 1 patient.
a  0 indicates low/intermediate vocational education or less and 1 indicates high-level vocational 
education/university.
b Score ranges from 0 to 10, with a higher score indicating more social support.
c Score ranges from 0 to 10, with a higher score indicating more coping difficulties.
d Score ranges from 0 to 42, with a higher score indicating more distress.
e Score ranges from 7 to 35,with a higher score indicating more self-awareness.
f Score ranges from 17 to 85, with a higher score indicatng more sensitivity to others.
g Score ranges from 6 to 30, with a higher score indicating easiness to handle new situations.
Table 1: Continued
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Levels of empowerment
Mean empowerment level was 154.1(SD, 17.8), with a range of 114 to 200. The 
mean scores for each domain were 74(SD, 9.8) for Personal Strength, 36.5 (SD, 
4.1) for Social Support, 19.7 (SD, 4.6) for Community, and 23.9 (SD, 3.4) for 
Health Care.
Associated factors of empowerment
Factors associated with total empowerment and the 4 empowerment subscales are 
presented in Table 2. Female sex was found to be negatively associated with total 
empowerment and all empowerment subscales except Social Support. Employment 
and education were found to be positively associated with the empowerment subscale 
Personal Strength. Higher disease stage was positively associated with the subscale 
Social Support. Palliative treatment intent was found to be negatively associated 
with Personal Strength. With regard to autonomy, self-awareness and capacity to 
handle new situations were positively associated with total empowerment and all 
subscales except self-awareness and the empowerment Community subscale. On 
the autonomy subscale, sensitivity to others was found to be negatively associated 
with total empowerment and the empowerment Community subscale. Perception 
of social support showed a strong positive association with total empowerment 
and all empowerment subscales. Coping difficulties and psychological distress were 
negatively associated with total empowerment and all subscales except for the 
empowerment Community subscale.
In multivariate linear analysis, using total empowerment as outcome, and including 
univariate significant correlates (except for psychological distress which was highly 
correlated with coping [correlation coefficient of >0.8]), the results remained 
significant for self-awareness (β = .35; P<.01), new situations (β = .19; P=.05), coping 
difficulties (β =-.19; P=.04), and social support (β =.35; P<.01), but not sex (β =-.14; 
P=.11) or sensitivity to others (β =.08; P=.38).
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Table 2: Associated factors of empowerment
Personal strength Social support Community Health care Total
Sociodemographic and clinical 
Age diagnosis, y -0.05 -0.10 -0.01 -0.16 -0.08
Gender: 0 for male and 1 for female -0.26* -0.21 -0.28* -0.31** -0.32**
Partner: 0 for yes and 1 for no -0.21 -0.12 -0.13 -0.06 -0.19
Educational levela 0.20 0.09 -0.04 0.05 0.13
Living statusb -0.05 -0.03 -0.08 -0.09 -0.07
Work/school 0 for no and 1 for yes 0.22* -0.03 -0.13 -0.02 0.07
Children 0 for no and 1 for yes 0.04 -0.01 -0.03 -0.09 -0.01
Time since diagnosis, y 0.07 -0.03 -0.18 0.03 -0.01
Disease stage c -0.12 0.26* 0.11 0.17 0.01
Treatment statusd 0.03 -0.12 -0.09 0.06 -0.02
Treatment intente -0.23* -0.10 0.01 -0.08 -0.16
Chemotherapy 0 for no and 1 for yes 0.13 0.09 0.03 0.09 0.12
Autonony connectedness
Self-awareness 0.55** 0.47** 0.19 0.27* 0.51*
Sensitivity to others -0.21 -0.14 -0.24* -0.07 -0.22*
Capacity new situations 0.51** 0.42** 0.23* 0.27* 0.48**
Other
Amount social support meeting needs 0.34** 0.46** 0.39** 0.46** 0.48**
Coping difficulties -0.47** -0.23* -0.11 -0.25* -0.38**
Psychological distress -0.66** -0.48** -0.16 -0.37** -0.58**
*p<0.05;**p<0.01
a  0=indicates low/intermediate vocational education or less and 1 indicates highlevelvocational 
education / university.
b  0= indicates with parent and 1 indicates independent/together with partner(children) or 
friends.
c 0 indicates stages I and II, and 1 indicates stage III and IV.
d 0 indicates receiving treatment and 1 indicates completed treatment.
e 0 indicates curative and 1 indicates palliative.
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Table 3: Correlations between empowerment, other covariates and health related quality of 
life (HRQoL)
Physical Psychological Social Religious Total HRQoL
Empowerment
Personal strength 0.45** 0.63** 0.42** 0.29** 0.65**
Social support 0.26* 0.43** 0.40** 0.22* 0.46**
Community 0.21 0.21 0.22* 0.24* 0.28*
Health care 0.41** 0.42** 0.45** 0.27* 0.52**
Total 0.44** 0.58** 0.47** 0.32** 0.63**
Sociodemographic and clinical
Age diagnosis, y -0.18 -0.11 0.01 -0.05 -0.12
Age survey, y -0.13 -0.05 0.10 -0.05 -0.05
Sex: 0 for male and 1 for female -0.35** -0.39** -0.35** -0.16 -0.43**
Partner: 0 for yes and 1 for no -0.11 -0.09 0.05 -0.15 -0.09
Educational levela 0.15 0.01 -0.18 0.15 0.03
Living statusb -0.01 -0.07 0.02 0.01 -0.03
Work/school: 0 for no and 1 for yes 0.22* 0.17 -0.09 0.37** 0.20
Children: 0 for no and 1 for yes 0.11 -0.04 0.04 -0.01 0.02
Time since diagnosis, y 0.04 0.03 0.11 0.02 0.06
Disease stagec -0.11 -0.17 -0.04 -0.23 -0.19
Treatment statusd 0.27* 0.16 0.04 0.10 0.18
Treatment intente -0.27* -0.31** -0.13 -0.30** -0.35**
Chemotherapy: 0 for no and 1 for yes 0.14 0.18 0.10 -0.05 0.16
Autonomy-connectedness
Self-awareness 0.14 0.20 0.25* 0.12 0.25*
Sensitivity to others -0.01 -0.31** -0.32** 0.07 -0.24*
Capacity new situations 0.31** 0.36** 0.25* 0.20 0.40**
*p<0.05;**p<0.01
a  0 indicates low/intermediate vocational education or less and 1 indicates high-level 
vocational education/university
b  0 indicates with parent and 1 indicates independent/together with partner (children) or 
friends.
c 0 indicates stages I and II and 1 indicates stage III ansd IV.
d 0 indicates receiving treatment and 1 indicates completed treatment.
e 0 indicates curative and 1 indicates palliative.
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Associations between empowerment and HRQoL among AYA 
patients
Bivariate correlations demostrated that all empowerment subscales were positively 
associated with HRQoL, except for the Community subscale which was not 
associated with physical and psychological HRQoL. Several sociodemographic, 
clinical and personal factors were also found to be significantly associated with 
HRQoL(Table 3). 
Female sex was negatively associated with all HRQoL subscales except for the 
religious subscale. Having work or attending school was positively associated with 
the religious HRQoL subscale. Completion of cancer treatment was positively 
associated with the physical HRQoL subscale. Palliative treatment intent was 
negatively associated with all HRQoL scales except the social subscale. The 
autonomy subscale of Self- Awareness was found to be positively associated with 
total and social HRQoL. The autonomy subscale demonstrated that sensitivity to 
others was negatively associated with psychological, social and total HRQoL. In 
addition, the autonomy subscale capacity to handle new situations had a strong 
positive association with all HRQoL scales except the religious subscale. To assess 
the independent association of empowerment with the 5 HRQoL scales, multivariate 
linear regression analyses were conducted with HRQoL scales as outcomes, total 
empowerment score as an independent variable, and including all significant 
correlates in univariate analyses. Empowerment remained significant for physical 
(β = 0.31; P<.01), psychological (β = .50; P<.01), social (β = .39; P<.01), religious 
(β = .33; P<.01) and total HRQoL (β = .52; P<.01). 
Sensitivity analysis demonstrated that the empowerment scales were only 
significantly associated with HRQoL for those patients treated with curative intent 
and not for those treated with palliative intent.
Discussion
This resultsofthecurrentstudy indicate that AYA patientswithcancerwho were 
treated in a specialized care center had relatively high levels of empowerment. 
There was a wide range of levels of empowerment, indicating room for 
improvement. Empowerment levels in the current study were comparable to 
those in a previous study in patients with breast cancer; however, this study 
only included female patients who were older than patients in the current study 
sample[21]. The results of the current study demonstrated that the most important 
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factors associated with empowerment in AYA patients were autonomy, sex, social 
support and coping. This provides beneficial insight into groups that may benefit 
from support interventions that aim to empower AYA patients. AYA patients 
with higher levels of empowerment were more likely to be male, have higher 
autonomy scores and receive more social support. These patients also reported 
fewer difficulties in coping and lower levels of psychological distress. The current 
study data have demonstrated the importance of high levels of empowerment 
because this was found to be was positively associated with HRQoL.
Autonomy was strongly associated with empowerment. Self-awareness and 
the capacity to handle new situations were independently associated with total 
empowerment. Developing autonomy is generally experienced as young people 
mature[22]. Although many AYA patients have developed decisionmaking skills 
regarding their own health or life goals[22], others will still look to others to help 
them with decision-making and indeed they may return to a state of dependency 
when faced with cancer[23]. Health related information should be delivered in a 
manner which is appropriate to the age of the patient because this is critical in 
helping AYA individuals learn to cope with their disease and navigate the health 
care system[24]. The capacity to handle new situations is closely related to the 
concept of coping. In their relatively short lives, most AYA patients have not 
encountered many major life events. AYA patients may require more support as 
they have not had the opportunity to develop skills that enable them to cope with 
new and challenging situations. We found that being female had a significant, 
negative correlation with empowerment. This may be explained by the findings 
of a study that demonstrated that women tend to use less effective, emotion-
focused coping strategies, whereas men use more effective problem-focused or 
instrumental methods of handling stressful experiences[25]. Additional support for 
female AYA patients may be warranted; however, we should not assume that all 
male AYA patients will require less social support.
Although AYA patients often feel isolated, perceived social support from family 
and friends contributes to high levels of empowerment[7]. A cancer diagnosis 
and its treatment lead to increased dependency on parents and/ or partners 
and sets AYA patients apart from their healthy peers. AYA autonomy and the 
development of identity in general depends largely on peer acceptance and 
relationships[26]. Not unexpectedly, studies have shown that support from other 
AYA cancer patients is incredibly important for this age group in helping them 
to cope with their disease[27]. In addition, AYA patients want to provide support 
to their own family and friends to create a sense of self-worth, however this 
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contribution is not always possible during their disease trajectory due to the 
effects of cancer and its treatment[28]. Those with high levels of sensitivity 
towards others, more commonly women, have greater difficulty accepting this 
realization and therefore feel less empowered[25]. As the results of the current 
study demonstrate, return into society, through employment or education, 
contributes further to empowerment by creating a sense of selfworth/ 
confidence and perceiving oneself as being useful. A perceived lack of social 
support, absence of self-worth and appropriate coping skills may all have a 
negative effect on psychological distress, which itself was a strong negative 
correlate of empowerment. Last, the results of the current study demonstrate 
that treatment intent (curative vs. palliative) also contributes to the levels of 
personal strength. The needs of AYA patients with advanced cancer intensify as 
they near the end of their lives[29]. The physical changes associated with advanced 
disease result in loss of capacity to manage activities of daily living and aspects 
of medical regimens[5]. In addition, the stress of living with an enduring sense 
of loss brings new challenges, such as when to hand responsibilities to others 
and whether to discuss emotional or spiritual concerns and end-of life decisions. 
Providing appropriate support to allow patients to maintain a level of autonomy 
is very important in this phase[5].
Given the strong correlation between empowerment and HRQoL found in the 
current study and others[30] and relatively high levels of empowerment measured 
in this AYA sample, strategies to reinforce empowerment in AYA patients should 
be explored. Interventions could focus on 1 or all 4 domains of empowerment. 
First, the sense of personal strength can be positively influenced by self-
management (ie, the comprehensive engagement of the AYA patient in problem-
solving, decision-making, and daily health-related behaviors in partnership 
with health care professionals and community)[31]. Self-management will help 
patients to manage the medical aspects of cancer, by managing life roles 
(including changes in roles brought by cancer), and managing the psychosocial 
consequences of cancer[32]. Such a selfmanagement intervention might include 
cognitive behavioral therapy components such as psychoeducation, cognitive 
reframing, goal planning and process evaluation[33]. Second, social support 
can be enhanced by offering reallife and digital platforms for AYA patients 
in which they can virtually meet and share information and feelings with 
peers[34]. For example, online peer support groups and age-specific information 
portals for AYA patients have been shown to significantly reduce feelings of 
social isolation, improve knowledge, selfefficacy, problem-solving skills and 
effective interpersonal interactions[35]. With regard to the third empowerment 
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dimension, community, attention should be paid to reframing the perception 
of AYA patients as a burden to society. The fourth empowerment dimension, 
health care, can be improved by creating inpatient and outpatient dedicated 
multifunctional spaces to suit the needs of AYA patients, training AYAdedicated 
professional caregivers and establishing educational programs for healthcare 
professionals. For example, additional medical training in fertility preservation 
or AYA survivorship care could be provided at the (under)graduate level, in 
primary care residencies, and adult oncology fellowships. Future research should 
explore the best ways to increase levels of empowerment among AYA patients.
The current study has several limitations. First, all participants were treated in 
a single center and received multidisciplinary care by a dedicated AYA team. 
Therefore, it could be that the empowerment levels of the current sample are 
higher than those of AYA patients treated in other centers in The Netherlands 
without age-specific care. However, the patients in the current study sample 
were diagnosed with a relatively advanced stage of disease and were treated 
intensively, mostly with > 1 treatment modality. This might be an overestimation 
in disease severity of the entire AYA cancer population, in which lower stage 
disease (cervical cancer, melanoma, thyroid cancer, and brain tumor) treated 
solely by surgery is more common. Both factors limit the generalizability of 
the results of the current study. A second limitation of the current study is 
the low response rate, which is not unusual in studies in young patients with 
cancer but was even lower than in previous questionnaire studies[36, 37] among 
AYA patients (29% response rate in the current study sample vs 43% and 52% 
in previous studies). Unfortunately, we do not have information regarding the 
reasons for no participation. Because demographic data were not collected of 
the nonresponders, we could not rule out selection bias. Third, empowerment 
is rarely formally assessed as outcome and to our knowledge a few validated 
questionnaires exist, particularly for the cancer setting[6], therefore making 
it difficult to compare the results of the current study with those from other 
groups of cancer patients. Fourth, the cross-sectional design of the current 
study limits the determination of causal associations between the study 
variables. Longitudinal research is needed to assess changes in empowerment 
levels over time to determine the best time to intervene for those patients 
with low levels. Fifth, the question remains whether the higher levels of 
empowerment are caused by the fact that all AYA patients consulted at least 1 
member of the multidisciplinary AYA team, or by the psychometric properties 
of the empowerment questionnaire. Although the CEQ has demonstrated 
good psychometric properties, to the best of our knowledge the sensitivity and 
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specificity of this instrument have not been tested and there is no validated 
cutoff point in the cancer setting.
Empowerment is an important factor related to HRQoL in late adolescence and 
young adulthood. Empowerment levels as measured in the current study were 
quite high in AYA patients with cancer who were treated in a specialized care 
center. Low levels of empowerment were associated with low levels of autonomy 
and social support, female sex, and coping difficulties. Future research should 
explore the best ways to increase empowerment in identified risk groups. 
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Abstract
Purpose: Peer support is an important unmet need among adolescent and 
young adult (AYA) cancer patients. The aim of this study is to describe the use 
and evaluation of a Dutch secure online support community for AYA diagnosed 
with cancer between 18 and 35 years. 
Methods: User statistics were collected with Google analytics. Community 
members were asked to complete questionnaires on the usefulness of the 
community. A content analysis using Linguistic Inquiry and Word Count was 
performed.
Results: Between 2010 and 2017, 433 AYA became a member of the community 
(71% female; mean age at diagnosis 25.7 years; 52 Dutch hospitals represented). 
The mean time since diagnosis when subscribing to the community was 2.7 years 
(SD 4.4). Questionnaire data among 30 AYA community members indicated that 
the use of the community resulted in acknowledgement and advice regarding 
problems (56%) and the feeling of being supported (63%). Almost half of the 
respondents felt less lonely, 78% experienced recognition in stories of other 
AYA. Anonymized content analysis (n=14) showed that the majority of the online 
discussions encompassed emotional and cognitive expressions, and emotional 
support.
Conclusion: The secure Dutch online AYA community can help AYA cancer 
patients to express feelings, exchange information, address peer support and has 
been found helpful in coping with cancer. As AYA cancer patients often lack the 
option to meet each other in person the AYA community is helpful in establishing 
peer support. Its use would benefit from promotion by health care professionals.  
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Introduction
Adolescence and young adulthood are crucial phases regarding social, 
professional, physical and psychological development. Having cancer seriously 
disrupts this development and can have a negative impact on issues regarding 
control over life, body image, finances, education, work plans, relationships and 
plans for having children.1 The Dutch definition of AYA (diagnosed with cancer 
between 18 and 35 years) is based on the organization of the health care system 
in the Netherlands, in which pediatric oncology, for patients between 0 and 18 
years at diagnosis is centralized, and adult oncology is only centralized for rare 
or complex cancer types. AYA cancer patients can not  profit from integrated 
care provided by pediatric oncology centers. 
AYA cancer patients frequently (40-50%) report unmet (supportive) needs 
including contact with peers, access to age-appropriate information, treatment 
facilities, emotional support services and fertility services,2-4 thus underlining 
the fact that supportive care for this age group is not optimal to address all age-
specific needs.5 In response, in the Netherlands and other European countries 
initiatives to improve AYA cancer care have started recently.6,7  
E-Health interventions are increasingly being used in cancer care, e.g. to support 
patients in managing problems in daily life and gaining knowledge.8 E-Health can 
be defined as “information and communication technology, especially the Internet, 
to improve or enable health and health care”.9 According to the behavior change 
model of Ritterband, internet interventions can lead to symptom improvement 
through a combination of personal and environmental factors on the one hand 
(e.g. knowledge, motivation and beliefs) and specific website characteristics on 
the other hand (e.g. appearance, content, delivery).10 The internet can be used 
by patients to find (medical) information and share stories on weblogs, forums, 
and online social networks (Facebook, Twitter) and online communities.11 Online 
communities are platforms where individuals meet and exchange experience and 
information.12 Previous studies showed that participating in an online community 
can have an empowering and therapeutic effect: patients find informational and 
emotional support,13,14 recognition,12,15 emotional expression, and insight.16 As 
a technical- and electronics-savvy generation, AYAs are primed to benefit from 
supportive care delivered through e-Health, alongside usual care.17,18 Currently 
there are six AYA communities/websites with different features to exchange 
informational, emotional and social support as described in Table 1. However, 
none of them provides a secure environment. 
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Because AYA with cancer express age-specific peer support as an important unmet 
need and exchange of information can be rather privacy-sensitive, a secure, 
closed online community could be an asset addressing this need.18-20  In 2010 an 
online community named AYA4 (All Information You’ve Asked for) was developed 
by and for Dutch AYA cancer patients treated at the Radboud university medical 
center (Radboudumc). This online community became available for all AYA 
cancer patients in the Netherlands in 2014. The aim of this article is to describe 
how the Dutch online AYA community is currently being used and to evaluate in 
particular (1) user statistics (2) usefulness and (3) content analysis addressing the 
psychological processes expressed in the messages on the forum. 
Methods
Development of an online AYA community
The online community for AYA cancer patients was developed in close 
collaboration between the department of medical oncology, REshape & 
Innovation Center and AYA cancer patients of the Radboudumc. The community 
works as follows. At first access a community manager verifies age and disease 
specific information in the treating hospital. A disclaimer explains details of the 
community, for example that members have to sign a digital will to define what 
has to be done with their community content after one’s death. The content 
of the community is only accessible for AYA patients with login details. The 
only person who has access and is able to communicate with all users is the 
community manager, a non-health care professional, trained in communication, 
who is online for about four hours daily (with a stand-in in case of absence). 
When patients log in for the first time, they are welcomed by the community 
manager and they are being notified that she can facilitate forum discussions. 
She will not share personal information of AYA community members with health 
care professionals, unless the AYA patients gives explicit permission to do so. 
Procedure
The Ethics Committee of the Radboudumc judged that no detailed review was 
warranted given the non-intrusive character of this study (#2016-2872).
Study 1: User statistics
When signing up to the community, patients have to fill out the following 
information: first name, surname, gender, date of birth, telephone number, 
email address, treating hospital, patient identification number, treating 
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physician, nurse specialist, type of cancer diagnosis, age at and date of cancer 
diagnosis, date of start treatment and what to do with the account in case of 
death. Logging data (assessed 11 April 2017) about activity and duration of 
logging in were analyzed using Google Analytics, a web analytics service offered 
by Google, that tracks and records website traffic. Login data of the community 
manager were excluded from this analysis. 
Study 2: Evaluation 
The evaluation study of the online AYA community was part of a larger as yet 
unpublished study aimed to gain insight into the supportive care needs of AYA 
cancer patients in the Netherlands. Patients aged between 18 and 35 years at time 
of cancer diagnosis were invited to participate and were recruited via a website 
of patients advocates (www.kanker.nl and www.aya4net.nl). Participants (n=66) 
were asked whether they were familiar with AYA care and if they were aware of 
the existence of the online AYA community. 59% (n=39) indicated to know the 
community. Nine of them were not a member of the community and were asked 
for their reasons of not being a member. Those patients who indicated to be a 
member of the community (n=30) were asked to answer questions about the 
usefulness of the community.
Study 3: Content analysis
The content of the forum (discussions between AYA patients) contains privacy-
sensitive personal information: names, diagnoses, and shared experiences. This 
type of information cannot be used for research purposes without the explicit 
consent of the authors, in this case the AYA patients.21 Therefore, we asked 
the members permission to use the content of their forum messages through 
an opt-in procedure: we published a message on the forum in the first half of 
April 2016 in which we explained the aim of our study and asked the users to 
give consent for using their data in anonymized form. The data of patients 
who gave informed consent were anonymized according to recommendations 
of King.22 An independent research assistant went through all messages in our 
sample manually and replaced all mentions of person names (except for names 
of caregivers) by the string ‘****’. All anonymized messages by users who 
gave consent were brought together in a sample that we will refer to as the 
anonymized sample. 
A commonly used and well-studied methodology for investigating the 
psychological processes through language use is the Linguistic Inquiry and Word 
count (LIWC).23 LIWC analyzes texts for indicators of psychological processes 
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that are important for psychologically processing of difficult experiences.24,25 
The developers of the LIWC defined a set of linguistic and psychological 
categories that can be recognized by words in the text. For each category, they 
defined a set of words that are indicators for that category. For example, the 
word me is an indicator of the linguistic category ‘1st person singular’, and the 
word good is an indicator of the psychological category ‘positive emotions’. 
We used the Dutch version of the LIWC consisting of 66 categories.26 There 
are five types of categories: (1) standard linguistic dimensions (e.g. personal 
pronouns, 1st person singular, past tense verbs); (2) psychological processes (e.g. 
positive emotions, anxiety, humans); (3) relativity (time and space); (4) personal 
concerns (e.g. work, money, religion); (5) experimental dimensions (swearing). 
The categories are organized hierarchically. For example, the main category 
‘cognitive processes’ under ‘psychological processes’ has several subcategories, 
among which ‘insight’, ‘inclusive’, and ‘exclusive’. Due to this hierarchy, a word 
can belong to more than one category. For example, the word ik (‘I’) occurs in 
the category ‘pronoun’ as well as the category ‘1st person singular’.
The LIWC has been used before to distill these psychological processes from the 
content of online support communities.27,28 In this study, we did not analyze the 
language use of individual authors on the forum, but quantified the presence 
of LIWC categories in the anonymized sample as a whole. We implemented the 
LIWC using the word lists published for the Dutch version of the LIWC.26 Our 
LIWC script takes as input the complete text of our anonymized sample, and a 
dictionary of LIWC categories with the indicator words per category. The script 
splits the text in words, then looks up each word in the LIWC dictionary, and adds 
a count for the corresponding LIWC category. For example, each occurrence of 
the word me in the forum leads to a count for the category ‘1st person singular’ 
and each occurrence of the word good in the forum leads to a count for the 
category ‘positive emotions’ The output of the script is a count of indicator words 
occurring for each LIWC category. We sorted the categories by their frequencies 
of occurrence in order to analyze which linguistic and psychological categories 
are the most frequent in the forum. Results are depicted as relative word counts 
per  category, which is the sum of the numbers of occurrences of all the words in 
the category divided by the total number of words in the sample.
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Results
User statistics
As of November 2017 the community has 433 registered members with a mean 
age at diagnosis of 25.7 years (SD 4.9) of which 71% is female. Of these members 
18% were diagnosed with breast cancer, 17% with lymphoma, 10% with sarcoma, 
7% with leukemia and 7% with testicular cancer and 41 % with other cancer types. 
The mean time since diagnosis when subscribing to the online AYA community 
was 2.7 years (SD 4.4) with a median time of 1 year. Members were from 52 
out of 91 hospitals in the Netherlands. In 2016 the online AYA community was 
visited 35,327 times. A visit is defined as a single online activity of a person at a 
certain time point by means of an electronic device. On average a visitor was 
online for 1 minute and 23 seconds and looked at 2.47 pages per visit. The most 
frequently visited part of the community is the introduction page where AYA 
cancer patients introduce themselves by giving background information about 
their diagnosis, treatment trajectory and daily life problems because of cancer. 
Evaluation 
Sixty-six patients answered AYA questionnaires of whom 39 (59%) responded 
to have been informed about the AYA community. Thirty of them (77%) became 
member of the AYA community and used the community on a regular basis. 
The nine patients who were not a member indicated that they had no interest 
(3 patients), thought it was not useful for them (1 patient), indicated that the 
community was not available at the time they were diagnosed (2 patients), 
or were too fearful to hear the stories of other patients (3 patients). Of the 
30 community members, 25 (83%) were female. Of this group, mean age at 
diagnosis was 25.6 years (SD 6.4, range 18-35) and mean age of questionnaire 
completion was 29.8 years (SD 5.3, range 22-39). Most frequent cancer 
diagnoses were breast cancer (20%), lymphoma (17%) and brain tumor (10%). 
Nine (30%) members rated the community as a little bit useful and 18 (60%) 
rated the community as highly useful, 3 (10%) patients had no opinion. Use 
of the community resulted in acknowledgement of their problems (56%) and 
the feeling of being supported and having valuable contacts with peers (63%). 
Almost half of the users felt less lonely, 78% experienced recognition in the 
cancer stories of other AYAs. In an open question AYA patients indicated the 
strong willingness to do something for other patients as a main reason to be an 
active member of the community (Table 2).
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Table 2: Answers to the evaluation questionnaire about usefulness of the online AYA community 
among 30 members
Answers given about usefulness community AYA community members (%)
I feel listened to 9 (33%)
I get recognition/acknowledgement 15 (56%)
I find recognition in the stories of peers 21 (78%)
I don’t feel lonely any more 13 (48%)
I have good contact with peers 17 (63%)
My questions are being answered 9 (33%)
I feel more self-confident 7 (26%)
I get advice about coping with problems 12 (44%)
I make new friends 12 (44%)
I feel reassured 4 (15%)
I feel safe 7 (26%)
I feel supported 17 (63%)
Other -  It gives me the opportunity to share knowledge and to help 
others. It appears valuable to do something in a hopeless 
situation
- I can support others
- It is good to notice that I am not the only person with problems
Content analysis using LIWC
Only 14 members of the online community provided consent for use of their 
message in our content analysis. Together, these 14 members have posted 1896 
messages on 293 topics between February 2014 (date online AYA community 
became available as national service) and June 2016. This is 44% (total amount 
of messages was 4332) of the total number of messages posted in this period, 
indicating that these 14 members are among the most active members of the 
forum. The mean number of messages posted by the included users is 135 (SD 
103, range 5-386). We analyzed the 1896 messages in our sample using the LIWC 
categories. The total number of words in the sample is 108,881; the number of 
distinct words is 11,622. Of these, 1,981 occur in one or more LIWC categories. 
Figure 1 shows the 20 most frequent LIWC categories in the sample, with their 
relative word counts. The most frequent LIWC category is ‘present tense’. There 
are 13,888 occurrences of words from that category in our sample (e.g. ‘is’, 
‘have’, ‘be’, ‘am’). This gives a relative word count of 0.128  (13,888/108,888) for 
the category ‘present tense’. 
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Figure 1: The 20 most frequent LIWC categories in the online AYA community sample, with 
their relative word counts
LIWC: Linguistic Inquiry and Word Count
AYA: Adolescent and Young Adult
Discussion
This study reports about the use, evaluation and content analysis of the online 
community for Dutch AYA cancer patients. To our knowledge, this is one of the 
first secure, closed communities for AYA cancer patients in Europe. Our online 
community is only accessible for AYA patients and survivors which is in contrast 
with the large USA community where family, friends and professionals also 
have access.19,29-32 The Australian community is also accessible for siblings and 
offspring of family members with cancer.33 In the United Kingdom and Australia, 
digital platforms focus on younger age groups (16-25 years34 and 12-24 years33 
respectively) in comparison to the USA online support forum who serves AYA 
cancer patients between 15 and 39 years. All online communities have in 
common that members provide and receive informational, emotional and/or 
social support to some degree. 
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User statistics of AYA communities were never reported. The user statistics 
of our study showed that the most common tumor types were breast cancer 
and lymphoma and that members were most often women. This is in line 
with previous research where most members were female.34,35 It could be that 
men have less need for peer support and are therefore less likely to become a 
member, or prefer other kinds of peer support e.g. face-to-face or via sporting 
activities.36 The short mean duration of online community visits may indicate 
that members use the community not as an extensive chat service but more as 
a forum to gain knowledge, express emotions and get recognition. However, 
it might also be an indication of the fact that AYA patients got scared of all 
that is written or that they did not like the online community and thought it 
was something else. In this way the results of the current study are hypothesis 
generating and further in depth research about the reasons for the short online 
duration time is recommended.
More than half of the  members participating in our study rated the community 
as highly useful especially with regard to acknowledgement of feeling supported 
and establishment of valuable contacts with peers. This is in line with the results 
of the content analysis showing that members of the online AYA community 
indeed find emotional and cognitive expression, and emotional support. Given 
the theory of Ritterband, it could be hypothesized that higher levels of emotional 
and cognitive expression and emotional support may lead to better symptom 
control as this theory stated that internet interventions can lead to symptom 
improvement through mechanisms like social support, transferring knowledge 
and feelings of recognition.10  
The interpretation of the LIWC categories displays that the first three 
categories in Figure 1 are standard linguistic dimensions. Personal pronouns and 
especially references to self (I, me, mine) are very common in discussion forum 
messages, indicating that the authors share narratives about themselves.37 The 
most interesting categories in Figure 1 are the cognitive processes, the social 
processes and the affective processes. The category cognitive processes includes 
the subcategories ‘inclusive’, ‘exclusive’, ‘discrepancy’, ‘insight’ and ‘tentative’. 
Examples of words that belong to the category ‘inclusive’ are: also, with and 
completely, while example words of the category ‘exclusive’ are: without, outside 
and except. The category discrepancy covers words such as should, hope, must 
and want, indicating a reality that is different than expected or wished for. 
The category ‘insight’ contains words such as find, see, and know, indicating 
insightful disclosure, a construct of empowerment that has been reported 
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before for peer-directed patient support groups.28 The category ‘tentative’ 
contains words such as maybe, hope, and sometimes, indicating uncertainty. 
The category social processes covers words that describe interactions such as 
ask, people and welcome, The category affective processes includes feelings 
and responses. In the online AYA community sample, positive emotions are the 
most prominent, with words such as good, success, nice, happy, and better. The 
high frequency of words indicating cognitive, social and affective processes 
may indicate that members of the online community find emotional support, 
emotional expression and insight on the discussion forum. 
In 2012, Love et al. reported about content analysis of messages in an open 
online AYA cancer support forum in the USA. They found that AYAs exchange 
emotional and informational support, cope with difficult emotions, use 
particular language to describe experiences, enact identity, and communicate 
membership on this online cancer support forum.19 Although we used another 
method to explore content, our results are largely in line with Love et al. In 
our study we also found that the majority of online discussions encompassed 
emotional support and emotional expression. Moreover, our results show that 
the community members gained more insight, expressed by words related to 
thinking, knowing and considering. A difference between both studies, is that 
our content analysis was based on larger amount of messages than in the study 
of Love et al. 
The main limitation of our study was the low participation rate of AYA 
community members which may limit the generalizability of our results. This 
may be explained by several factors. First, although in the Netherlands every 
year approximately 2,700 patients between the age of 18-35 years are diagnosed 
with cancer, currently the AYA community has only 433 members. This might be 
attributable to the fact that patients and/or health care professionals are not 
familiar with AYA care and that the online AYA community only recently became 
available on a national level. Second, only a small part of the community 
members is active in discussions. This is in line with previous literature showing 
that only 10% of community members are active posters, the remaining 90% can 
be classified as ‘lurkers’.38 Third, as the online AYA community was developed 
eight years ago and patients grow older, some early members may now have 
less need for peer support.  Fourth, interviews with AYA cancer patients also 
revealed that the online AYA community was used to establish a first contact 
with peers and afterwards other faster social media like WhatsApp were used 
to intensify the contact. Fifth, we cannot rule out selection bias, as patients 
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recruited in the evaluation and the content analysis study might be the ones 
that are highly in need of peer support (‘superusers’) due to multiple health 
problems or are the patients who act as patient advocates.
The online AYA community is an example of an e-Health intervention, that is 
highly valued by some users. E-Health has high confidentiality experience 
among cancer patients39 and has the potential to be cost-effective and to 
improve patient empowerment40, psychological well-being,39,41 and health-
related quality of life.41 Future studies should aim at in-depth knowledge about 
the use of the community in terms of not becoming a member of the community, 
reasons for stop using, reasons men visit the community less often and whether 
additional elements should be added in particular to make it more attractive 
for men. It is also worth exploring whether psychological interventions like 
cognitive-behavioral therapy could be safe  and effectively delivered online to 
AYA cancer patients.42 We expect that the AYA community will expand in terms 
of members and reputation in the future, since it only recently expanded from 
the regional to the national level.
In conclusion, the Dutch online AYA community facilitates peer support in a 
secure digital environment and, in particular, leads to expressing feelings, 
exchanging information and better coping with cancer. Health care professionals 
should play an active role in drawing attention to the existence and the possible 
benefits of the online AYA community.  
141
Online support community for AYA
7
References
1. Bellizzi KM, Smith A, Schmidt S, et al: Positive and negative psychosocial impact of being diagnosed 
with cancer as an adolescent or young adult. Cancer 2012:118:5155-62
2. Bibby H, White V, Thompson K, et al: What Are the Unmet Needs and Care Experiences of Adolescents 
and Young Adults with Cancer? A Systematic Review. J Adolesc Young Adult Oncol 2016;6(1):6-30
3. D’Agostino NM, Penney A, Zebrack B: Providing developmentally appropriate psychosocial care to 
adolescent and young adult cancer survivors. Cancer 2011;117:2329-34
4. Galan S, de la Vega R, Miro J: Needs of adolescents and young adults after cancer treatment: a 
systematic review. Eur J Cancer Care (Engl) 2016 Aug 10. doi: 10.1111/ecc.12558. [Epub ahead of print]
5. Zebrack B: Information and service needs for young adult cancer patients. Support Care Cancer 
2008;16:1353-60
6. Stark D, Bielack S, Brugieres L, et al: Teenagers and young adults with cancer in Europe: from national 
programmes to a European integrated coordinated project. Eur J Cancer Care (Engl) 2016;25:419-27
7. Ferrari A, Thomas D, Franklin AR, et al: Starting an adolescent and young adult program: some 
success stories and some obstacles to overcome. J Clin Oncol 2010;28:4850-4857
8. Slev VN, Mistiaen P, Pasman HR, et al: Effects of eHealth for patients and informal caregivers 
confronted with cancer: A meta-review. Int J Med Inform 2016;87:54-67
9. Bright MA, Fleisher L, Thomsen C, et al: Exploring e-Health usage and interest among cancer 
information service users: the need for personalized interactions and multiple channels remains. J 
Health Commun 2005; 10 Suppl 1:35-52
10. Ritterband LM, Thorndike FP, Cox DJ, et al: A behavior change model for internet interventions. Ann 
Behav Med 2009;38:18-27
11. Schiffman JD, Csongradi E, Suzuki LK: Internet use among adolescent and young adults (AYA) with 
cancer. Pediatr Blood Cancer 2008;51:410-415
12. van Uden-Kraan CF, Drossaert CH, Taal E, et al: Participation in online patient support groups 
endorses patients’ empowerment. Patient Educ Couns 2009;74:61-69
13. Fernsler JI, Manchester LJ: Evaluation of a computer-based cancer support network. Cancer Pract 
1997;5:46-51
14. Mo PK, Coulson NS: Exploring the communication of social support within virtual communities: a 
content analysis of messages posted to an online HIV/AIDS support group. Cyberpsychol Behav 
2008;11:371-374
15. van Uden-Kraan CF, Drossaert CH, Taal E, et al: Empowering processes and outcomes of participation 
in online support groups for patients with breast cancer, arthritis, or fibromyalgia. Qual Health Res 
2008;18:405-417
16. Setoyama Y, Nakayama K, Yamazaki Y: Peer support from online community on the internet among 
patients with breast cancer in Japan. Stud Health Technol Inform 2009;146:886
17. Piper LE: Generation Y in healthcare: leading millennials in an era of reform. Front Health Serv Manage 
2012;29:16-28
18. Abrol E, Groszmann M, Pitman A, et al: Exploring the digital technology preferences of teenagers 
and young adults (TYA) with cancer and survivors: a cross-sectional service evaluation questionnaire. 
J Cancer Surviv 2017;11(6):670-682
19. Love B, Crook B, Thompson CM, et al: Exploring psychosocial support online: a content analysis 
of messages in an adolescent and young adult cancer community. Cyberpsychol Behav Soc Netw 
2012;15:555-559
20. Frost J, Vermeulen IE, Beekers N: Anonymity versus privacy: selective information sharing in online 
cancer communities. J Med Internet Res 2014;16:e126
21. Wilkinson D, Thelwall M: Researching personal information on the public web: Methods and 
ethics. Social Science Computer Review 2011.29(4):387-401
142
Chapter 7
22. King SA: Researching Internet communities: Proposed ethical guidelines for the reporting of results. The 
Information Society 1996;12:119-128
23. available at http://liwc.wpengine.com 
24. Pennebaker JW, Francis, M. E., & Booth, R. J. : Linguistic inquiry and word count: LIWC 2001, Mahway: 
Lawrence Erlbaum Associates, 2001 
25. Tausczik YR, Pennebaker JW: The psychological meaning of words: LIWC and computerized text analysis 
methods. Journal of Language and Social Psychology 2010;29(1):24-54
26. Zijlstra H, van Meerveld T, van Middendorp H, et al: Dutch version of the Linguistic Inquiry and Word 
Count (LIWC), a computerized text analysis program. Gedrag & Gezondheid: Tijdschrift voor Psychologie 
en Gezondheid 2004;32(4):271-281
27. Owen JE, Klapow JC, Roth DL, et al: Randomized pilot of a self-guided internet coping group for women 
with early-stage breast cancer. Ann Behav Med 2005;30:54-64
28. Lieberman M: The role of insightful disclosure in outcomes for women in peer-directed breast cancer 
groups: a replication study. Psychooncology 2007;16:961-964
29. Crook B, Love B: Examining the Light and Dark of an Online Young Adult Cancer Support Community. 
Qual Health Res 2017;27:938-948
30. Thompson CM, Crook B, Love B, et al: Understanding how adolescents and young adults with 
cancer talk about needs in online and face-to-face support groups. J Health Psychol 2015 Apr 27. pii: 
1359105315581515. [Epub ahead of print]
31. Pounders K, Stowers K, Wilcox G, et al: Exploring gender and identity issues among female adolescent 
and young adults who connect in an anonymous platform. J Health Psychol 2017;22:548-560
32. Donovan EE LL, Tardif S et al. : Patterns of social support communicated in response to expressions of 
uncertainty in an online community of young adults with cancer. J Appl Comm Res 2014;42(4):432-455
33. Patterson P, McDonald FE, Orchard P: A new Australian online and phone mental health support service 
for young people living with cancer. Australas Psychiatry 2014;22:165-169
34. Griffiths C, Panteli N, Brunton D, et al: Designing and evaluating the acceptability of Realshare: An online 
support community for teenagers and young adults with cancer. J Health Psychol 2015;20:1589-1601
35. Fasciano KM, Souza PM, Braun I, et al: An Innovative Website in the United States for Meeting the 
Emotional and Supportive Care Needs of Young Adults with Cancer. J Adolesc Young Adult Oncol 
2015;4:44-49
36. Sawyer SM, McNeil R, McCarthy M, et al: Unmet need for healthcare services in adolescents and young 
adults with cancer and their parent carers. Support Care Cancer 2017;25(7):2229-2239
37. Morrow PR: Telling about problems and giving advice in an Internet discussion forum: Some discourse 
features. Discourse studies 2006;8:531-548
38. Zhang S, O’Carroll Bantum E, Owen J, et al: Online cancer communities as informatics intervention for 
social support: conceptualization, characterization, and impact. J Am Med Inform Assoc, 2017;24(2):451-
459
39. Leykin Y, Thekdi SM, Shumay DM, et al: Internet interventions for improving psychological well-being in 
psycho-oncology: review and recommendations. Psychooncology 2012;21:1016-1025
40. Kuijpers W, Groen WG, Aaronson NK, et al: A systematic review of web-based interventions for patient 
empowerment and physical activity in chronic diseases: Relevance for cancer survivors. Journal of Medical 
Internet Research 2013 Feb 20;15(2):e37
41. Hong Y, Pena-Purcell NC, Ory MG: Outcomes of online support and resources for cancer survivors: a 
systematic literature review. Patient Educ Couns 2012;86:288-96
42. McGill BC, Sansom-Daly UM, Wakefield CE, et al: Therapeutic Alliance and Group Cohesion in an Online 
Support Program for Adolescent and Young Adult Cancer Survivors: Lessons from “Recapture Life”. J 
Adolesc Young Adult Oncol 2017;6:568-572
43. available at http://sunzi.lib.hku.hk/ER/detail/hku/3840056 
44. Elwell L, Grogan S, Coulson N: Adolescents living with cancer: the role of computer-mediated support 
groups. J Health Psychol 2011;16:236-248
143
Online support community for AYA
7
 
144
145
Chapter 8
Experiences of parents and general practitioners with 
end of life care in adolescents and young adults (AYAs) 
with cancer
Suzanne EJ Kaal, Noortje MJ Kuijken, Constant AHHVM Verhagen, Rosemarie 
Jansen, Petra Servaes, Winette TA van der Graaf
Journal of Adolescent and Young Adult Oncology 2016; 5: 64-68
8
146
Chapter 8
Abstract
This study aims to analyse the experiences of Dutch bereaved parents and 
general practitioners (GPs) with palliative care of AYAs (18-35 years) in the 
terminal stage. Fifteen parents and nine GPs involved with nine deceased AYAs 
filled out questionnaires and were interviewed by telephone, respectively. In 
general, the parents were satisfied with the emotional care they themselves 
received and the medical care that their child received. The GPs were very 
satisfied with the cooperation with the palliative team. Gaps are present in the 
areas of symptom control, communication between hospital professionals and 
parents, aftercare and transition between hospital and GP. 
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Introduction 
Adolescents and young adults (AYAs) aged 18 to 35 years and diagnosed with 
cancer, have a 5-year survival rate of 77% and approximately one quarter of 
them dies of cancer.1,2 Compared to palliative care for children, the care of AYAs 
has an extra dimension. Namely, it should take into account the normal physical 
and psychological changes associated with this life phase, including attainment 
of independence and social skills, peer acceptance, and self-image building.3 
The terminal stage of AYAs is not only characterized by specific problems for 
patients, but also for parents. Parents are conflicted with trying to balance 
between taking care of their child on the one hand, and respecting his/her 
autonomy on the other hand. Parents may feel helpless and sometimes even 
feel excluded by the health care system.4,5 Furthermore, physical pain and lack of 
medical and emotional care at the moment of death of their child are important 
issues that should be addressed to reduce long-term distress in bereaved 
parents.6 Sharing the emotional burden with others, professionally and socially, 
and good aftercare appear to benefit this process of bereavement.7,8 However, 
many parents report the contact with health care professionals after their 
child’s death to be insufficient.4 Previous research has also shown that informal 
caregivers (i.e. family or friends) would like to receive more information about 
the patient’s prognosis and process of dying, and more support in increasing 
their knowledge and skills concerning pain and symptom control.9-13 
In general, little is known about the experiences of parents who have lost a child 
at AYA age. Furthermore, general practitioners (GPs) are rarely confronted with 
a terminally ill AYA. In 2013 only 227 patients aged 15 to 34 years died of cancer in 
the Netherlands.14 Information on the GPs’ experiences with providing palliative 
care to this group of patients and their families is also lacking. In order to gain 
insight into the experiences and needs of bereaved parents and GPs concerned 
with palliative care of AYAs in the terminal stage this study aims to answer 
the following research questions: 1) How do bereaved parents experience the 
palliative care for their child and (after)care for themselves? 2) What are parents’ 
experiences with social support around the loss of their child? 3) What is the 
impact of the loss of a child on parents’ psychological wellbeing? and 4) How 
do GPs experience the palliative care of a terminally ill AYA and his/her family? 
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Methods
Participants
Fifteen parents (eight mothers, seven fathers) of nine deceased AYAs participated 
in this study. The AYAs, aged 18 to 35 years, had died of cancer in the past two 
years and had been treated by the Department of Medical Oncology of the 
Radboud University Medical Center. During the last three months of their lives, 
the AYAs had lived with their parents and had been cared for by them. A total of 
nine GPs involved with the care for eight AYAs also participated in the study (one 
AYA had two GPs). Ethical approval for the study was obtained from the local 
certified Medical Ethics Committee. 
Procedure
The parents of ten AYAs were approached by their child’s former Medical 
Oncologist to participate in this study. Fifteen parents of nine different AYAs 
agreed to participate and filled out four questionnaires. Nine of the ten approached 
GPs agreed to participate and were interviewed by telephone (tape-recorded). 
The interview questions for the GPs were formulated by NK and SK (table 1). 
At home, the parents filled out the following questionnaires:
To measure parents experience with palliative care for their child and (after)
care for themselves, a general, non-validated questionnaire was used. It 
was derived from a previous questionnaire developed by the research team, 
measuring experiences in partners from deceased patients. It consisted of 51 
items on: demographic characteristics (marital status, level of education); 
the period during which the child was terminally ill and the period thereafter; 
the relationship with the child and their partner; emotional, practical and 
professional support; and communication with GP and hospital. 
To measure parents’ experiences with social support around the loss of their 
child, the Dutch Inventory for Social Reliance (ISR) was used. It assesses 
qualitative aspects of social support and contains 11 items on a 4-point scale. 
Three factors are distinguished: potentially present (but not necessarily given) 
emotional confidentiality (the perceived possibility to share joy and sorrow with 
each other, five items, range 5-20), actual confidentiality (actual sharing joy and 
sorrow with other people, three items, range 3-12) and mutual visiting (visiting 
family and friends reciprocally, two items, range 2-8).15,16. Parents completed 
the ISR twice; once to measure current social support (ISR-now) and once to 
measure the social support received during the child’s illness (ISR-then).
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Table 1: Questions asked to GPs’ in the telephonic interviews about the period delivering end 
of life AYA care
1. How did you perceive the cooperation between intramural physician/team and yourself?
2. Did you perceive enough support (emotional, practical) from the hospital team?
3. How would you describe the relationship with the AYA and the parents in the terminal phase?
4. Did you feel capable enough to deliver AYA end of life care?
5. Would extra training be helpful in delivering better AYA end of life care?
6. Have you experienced any differences in comparison to delivering adult palliative care?
7.  Do you have the impression that the parents currently have problems concerning the loss of their child 
(depression, anxiety, complicated mourning)?
8. Have you been involved in aftercare for the parents after their child passed away?
9. Do you have any suggestions/recommendations to improve end of life AYA care regarding cooperation, communication?
GP: General Practitioner
Table 2: Symptoms During the Last Three Months Before Death According to the Parents
Symptom Parents of AYA Total %
1 1 2 2 3 3 4 5 5 6 7 7 8 9 9
Pain x x x x x x x x* x* x x x x x x 15 100
Fatigue x x x x x x x x x x x x x x 14 93.3
Nausea x x x* x x x* x x x x x* x x 13 86.7
Anxiety x x x x* x x x* x x x 10 66.7
Somnolence x x x x x x x x 8 53.3
Constipation x* x* x x x x x 7 46.7
Insomnia x x x x 4 26.7
Anorexia x x x 3 20.0
Dyspnoea x 1 6.7
Depression x 1 6.7
In assessing psychological wellbeing of the parents, two questionnaires were 
used. The validated Dutch translation of the Inventory of Traumatic Grief (ITG) 
measures the intensity of mourning and differentiates between normal and 
‘potentially problematic’ mourning.17 It consists of 29 items rating on a 5-point 
scale, with a range from 0 to 116. A score above 39 indicates complicated 
mourning, and a score above 87 indicates severe complicated mourning for 
which specialized treatment should be strongly advised. The validated Dutch 
translation of the Hospital Anxiety and Depression Scale (HADS) measures anxiety 
(7 items) and depression (7 items) during the past week. Per item a score between 
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0 and 3 is assigned, leading to a score range of 0-21 for anxiety and depression 
trait, respectively. A total score of 12 or above or a score of 8 or above on one of 
the subscales indicates the need for involvement of a specialized caregiver.18,19 
Analysis
For the analysis of the results of the questionnaires, descriptive statistics were 
calculated. The interviews with the GPs were analyzed qualitatively and answers 
were clustered in different themes. 
Results
Results of the general questionnaire
Demographics of the parents
Fifteen parents (of which six couples, eight mothers, seven fathers) of nine AYAs 
filled out the questionnaires. The parents of one AYA were divorced. At the time 
of participation, the median age of the mothers was 51.5 years (range 48-59 
years) and of the fathers 55.0 years (range 51-66 years). The majority of the 
participants (60%, three fathers, six mothers) had an intermediate educational 
level. The time between the death of the AYA and participation in the study 
ranged from 3 months to 2 years. At the moment of death, the AYAs had a 
median age of 21.0 years (range 18-28 years).
  
Summary of parents’ experiences
Table 2 represents parental report of the symptoms that the AYAs had suffered 
from during the last three months before death. The most frequently mentioned 
symptoms were pain, fatigue, nausea, anxiety, somnolence and constipation. 
Of these, constipation, nausea, anxiety and pain were not adequately palliated. 
Five parents (33%) experienced problems in communication with hospital-
based healthcare workers and two parents reported communication problems 
regarding the role and accessibility of the GP. The majority of the parents 
indicated that their relationship with their child before he or she got ill was very 
good. Five parents stated that they felt emotionally more connected with their 
child. The majority of the parents experienced sleeping problems (80%). Six 
parents (40%) had mental complaints (depression or anxiety) after their child 
had passed away. Eight of the fifteen parents (53%) reported using professional 
bereavement counseling after their child’s death, with which the majority was 
satisfied. Almost three-quarters of parents reported their expectations of the 
GP and the hospital in terms of guidance, medical care, responsibility and 
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accessibility were fulfilled. One parent reported a perceived lack of empathy 
on behalf of the GP, two felt insufficiently supported and one reported a lack 
of acknowledgement concerning mistakes made by the GP. One parent missed 
having contact with the hospital after her child’s death.
Results of the ISR, ITG and HADS
Table 3 shows the results of the ISR-now and ISR-then. The mean scores on the 
three factors were comparable at both moments for mothers as well as fathers. 
Strikingly, the mean scores on potential confidentiality were higher during their 
child’s illness than at the time of participation in this study. The mean scores on 
actual confidentiality and mutual visiting of the fathers were also higher during 
their child’s illness than at the time of participation. The results of the ITG show 
that five mothers (63%) and four fathers (57%), (60% of all participants) scored 
above 39, which is indicative for complicated mourning. The results of the HADS 
(Table 4) show that four parents (27%) scored 8 or above on the anxiety scale 
and nine parents (60%) scored high on the depression scale. Ten of the fifteen 
(67%) parents scored above cut off point on the total HADS scale.
Results of the interviews with GPs
In general, the GPs were positive about the collaboration with the intramural 
physician. One GP reported that his role had been ancillary because of the very 
close bond between patient and oncologist. Three of the nine GPs were dissatisfied 
about the collaboration with the intramural physician. This was due to problems in 
communication, which was based mainly on letters. Regular telephonic feedback, 
according to the GPs, would create an open atmosphere in which mutual support 
and teamwork could prevail. Four GPs reported that the collaboration with the 
palliative team was found to be very instrumental (well accessible, good advice and 
support). Seven of the nine GPs experienced the palliative care for an AYA as more 
difficult because of the age of the patient. They reported an emotional feeling of 
“unfairness” and a greater empathy for the family. Another complicating factor 
of this care was the uncommunicative character of the AYA (reporting symptoms 
very late, not willing to talk about dying).
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Table 3: Results of the Inventory for Social Reliance-Now and Inventory for Social Reliance-
Then
Couple Female (n = 8) Male (n = 7)
Potential 
confidentiality
Actual 
confidentiality
Mutual visiting Potential 
confidentiality
Actual 
confidentiality
Mutual visiting
Now Then Now Then Now Then Now Then Now Then Now Then
A 17 20 11 10 7 7 13 13 6 7 5 6
B 14 16 7 7 6 5 14 16 9 7 6 7
C 13 12 7 7 6 6 12 13 6 6 5 4
D 13 19 6 7 6 7 11 14 4 6 6 7
E 17 20 7 7 6 5 20 20 6 7 3 4
F 8 7 6 6 4 5 5 11 4 5 5 5
No couple 19 19 6 7 5 4
No couple 9 12 7 8 3 5
No couple 16 18 8 7 7 5
Mean 13.38 15.50 7.38 7.37 5.63 5.63 13.43 15.14 5.86 6.43 5.00 5.29
(SD) (3.42) (4.72) (1.60) (1.19) (1.41) (0.92) (5.06) (3.34) (1.68) (0.79) (1.00) (1.38)
* Symptom not adequately palliated according to parent AYA, adolescent and young adult
Table 4: Results of the Hospital Anxiety and Depression Scale
Couple Female Male
Anxiety Depression Anxiety Depression
A 4 5 1 3
B 4 6 4 3
C 7 8 5 9
D 5 2 13 11
E 15 14 5 7
F 0 15 7 19
No couple 8 13
No couple 10 13
No couple 7 12
Mean (SD) 6.50 (4.50) 9.37 (4.78) 6.14 (3.76) 9.29 (5.71)
Discussion
This study consists of an analysis of the experiences of parents and GPs with end 
of life care aspects of deceased AYA cancer patients. The majority of the parents 
were satisfied with the emotional support they received and the medical care 
their child received by the hospital and GP during the terminal stage. However, 
we found that more than half of the parents noticed their child was suffering 
and these symptoms were not always well controlled.
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In accordance with previous studies, it was found that some improvements 
are needed in the communication between hospital team and GP.8,12,13,20,21 The 
transition period from hospital to GP-guided care proved to be a risky period 
with regard to exchange of contextual and disease related issues. Also, parents 
reported communication problems with hospital-based healthcare workers and 
regarding the role and accessibility of the GP . The input of the palliative team 
was highly appreciated by GPs, underlining the fact that integrated care, with 
close collaboration between hospital and other health care workers directly 
involved AYA care, is optimal.13,22 
Psychological distress in bereaved parents is illustrated by the fact that 60% 
of them had scores indicative of complicated mourning which is slightly higher 
compared to parents who experienced grief related separation distress after 
losing a child (median age of death 8.3 years) 23. However, we found substantially 
higher scores on depression and anxiety compared to parents who lost a child 
at a younger age. 23,24 Almost half of the parents did not receive any aftercare 
and reported missing this kind of support. It has been confirmed in literature, 
suggesting that offering aftercare is an important part of standard professional 
support.11 
Strengths of this study include that the results are based on the perspective 
of both the care receivers as well as the care providers. Moreover, it is the 
first analysis of this kind in the Dutch health care setting. Limitations are the 
retrospective study nature with a different length of time between the death of 
the AYA and the participation in this study (recall bias, normal grief regresses 
over time), as well as the small number of participants. Disease severity and 
length of time under palliative care have also not been addressed. Nevertheless, 
the results of our study are valuable and can form the basis for further research 
on and improvement of end of life AYA care. 
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This thesis focused on aspects of health-related quality of life (HRQoL), 
psychosocial outcomes and adaptations and supportive and palliative care issues 
among adolescent and young adult (AYA) cancer patients. In this final chapter, 
the previous chapters are summarized and discussed. Practical implications 
along with recommendations for future research are formulated. 
Part I: Health-related quality of life, psychosocial 
outcomes and adaptations
HRQoL is one of the most widely used patient reported outcomes (PRO). 
Measuring HRQoL provides insight in the effect of cancer and its treatment on 
physical, psychological and social functioning. Chapter 2 describes the top ten 
HRQoL priorities relevant to AYA cancer patients (stratified by gender, cancer 
type, treatment intention, partner status and having children) and whether there 
is a discrepancy between items prioritized by AYA cancer patients and oncology 
health care professionals (HCP). Patients (n=83) scored significantly lower on 
negatively formulated HRQoL issues (e.g. fatigue, coping difficulties, feeling 
isolated) and significantly higher on positive formulated issues (e.g. support 
from others, overall physical health, happiness) compared to HCP (n=34). The 
most important issues for AYA cancer patients were: perceived support from 
others, distress about initial cancer diagnosis, distress for family, overall quality 
of life and happiness. HCP perceived distress about initial cancer diagnosis, 
distress for family, cancer treatment distress, interference of illness with 
employment/study and fatigue as most important for AYA. The top ten priorities 
of patients versus perceptions of HCP overlapped for five out of ten items. It 
was concluded that AYA cancer patients perceived most negative HRQoL items 
as less problematic compared to HCP. The discrepancy between patients and 
HCP illustrates the importance of patient participation, i.e. involving patients 
in organizing and prioritizing their own (psychosocial) care, and broadening 
the problem-focused perspective of HCP to positive outcomes in delivering 
supportive care. 
In Chapter 3 we report on prevalence and correlates of fear of cancer recurrence 
(FCR) which is a frequently reported problem among cancer patients in general. 
Previous research has shown that younger age is associated with higher levels of 
FCR. However, little attention has been given to date about how FCR manifests 
itself among AYA cancer patients. High FCR was experienced in 62% of the AYA 
cancer patients, which was higher than reported in previous studies among 
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mixed adult cancer patient samples. High FCR was significantly associated 
with lower levels of social and psychological functioning and overall HRQoL 
and higher levels of psychological distress. These results illustrate that FCR 
is a significant problem among AYA cancer patients. HCP should pay specific 
attention to this problem, for instance with a screening instrument for FCR, and 
the provision of appropriate psychosocial care when needed.
Chapter 4 focused on the prevalence, impact, and correlates of severe fatigue in 
AYA cancer patients. Severe fatigue, based on a validated cut-off score, occurred 
in 48% of participating AYA cancer patients visiting the AYA outpatient clinic. 
This proportion is significantly higher compared to the proportion of severely 
fatigued gender and age matched population-based controls, in which only 20% 
scored above the cut -off. We demonstrated that severely fatigued AYA cancer 
patients reported significantly lower HRQoL in the physical, psychological, social 
and spiritual domain. Fatigue severity was associated with female sex, being 
unemployed (or not studying), late stage cancer at diagnosis, receiving active 
treatment at the time of study participation, palliative intent of treatment, 
and having had radiotherapy as part of cancer treatment. In addition, FCR and 
higher psychological distress were associated with higher cancer-related fatigue 
scores. The findings of this study emphasize the importance of careful attention 
for fatigue in this population. Screening for the presence of severe fatigue at 
regular intervals as well as the identification of treatable contributing factors 
(e.g. anaemia, hypothyroidism, psychological distress, and sleep disorders) 
is warranted not only during cancer treatment but also after completion of 
treatment. 
Chapter 5 entails an overview of the literature on post-traumatic growth 
(PTG) and resilience among AYA cancer patients. Qualitative interview studies 
showed that AYA cancer patients report PTG and resilience: PTG is described 
by AYA cancer patients in terms of benefit finding, including changing views of 
life and feeling stronger and more confident, whereas resilience is described 
as a balance of several factors, including stress and coping, goals, optimism, 
finding meaning, connection and belonging. Quantitative studies showed that 
sociodemographic and clinical characteristics were not associated with PTG. 
Enduring stress was negatively, and social support positively associated with 
PTG. Symptom distress and defensive coping were negatively and adaptive 
cognitive coping was positively associated with resilience. Both PTG and 
resilience were positively associated with satisfaction with life and HRQoL. 
Resilience was found to be a mediator in the relationship between symptom 
160
Chapter 9
distress and HRQoL. Two interventions aiming to promote resilience, a stress 
management and a therapeutic music video-intervention, were not successful 
in significantly increasing overall resilience. Most AYA cancer patients reported 
at least some PTG or resilience. Correlates of PTG and resilience, including 
symptom distress, stress, coping, social support, and physical activity, provide 
further insight to improve the effectiveness of interventions aimed at promoting 
these positive outcomes and potentially buffer negative outcomes.
One of the hypothesized mechanisms behind resilience and PTG is 
empowerment. The difficulties AYAs encounter during a cancer experience 
may result in a reduction or absence of empowerment. The aims of Chapter 6 
were to assess levels of empowerment and associated (demographic, clinical, or 
psychological) factors and examine the association between empowerment and 
HRQoL among AYA cancer patients. Multivariate analysis demonstrated that 
autonomy (self-awareness, capacity for managing new situations) and social 
support were positively associated with empowerment. Coping difficulties 
were found to be negatively associated with empowerment. Empowerment 
was independently associated with physical, psychological, social, religious and 
overall HRQoL. Recognizing these patients as candidates for empowerment 
interventions could help to improve HRQoL in AYAs. 
Part II: Supportive and palliative care 
It is of utmost importance to provide the best supportive care to each AYA 
cancer patient and its caregivers. In Chapter 7 the user statistics, evaluation and 
content analysis of a Dutch secure online support community for AYA cancer 
patients was described. Since the start in 2010 the community has grown to 433 
members (71% female; mean age at diagnosis 25.7 years) from 52 out 91 hospitals 
in the Netherlands in 2017. A national questionnaire survey among 66 AYA 
cancer patients showed that 30 of them used the community on a regular basis. 
They indicated that the use of the community resulted in acknowledgement 
and advice regarding problems (56%) and the feeling of being supported (63%). 
Almost half of the respondents felt less lonely and 78% experienced recognition 
in other AYAs cancer stories. Anonymized content analysis showed that the 
majority of the online discussions encompassed emotional and cognitive 
expressions, and emotional support. It was concluded that AYA cancer patients 
often lack the option to meet each other in person. The secure Dutch online 
AYA community can help AYA cancer patients to express feelings, exchange 
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information, address peer support and is found helpful in coping with cancer. 
Its use would benefit from promotion by health care professionals. Of note, only 
few AYA patients (n=14) gave informed consent for content analysis, in spite of 
their knowledge that their data would be analysed in an anonymous form.    
In Chapter 8 the experiences of Dutch bereaved parents and general practitioners 
(GPs) with palliative care of AYAs in the terminal stage were analyzed. Fifteen 
parents and nine GPs involved with nine deceased AYAs filled out questionnaires 
and were interviewed by telephone, respectively. In general, the parents were 
satisfied with the emotional care they themselves received and the medical 
care that their child received. The GPs were very satisfied with the cooperation 
with the palliative team. Gaps were identified in the areas of symptom control, 
communication between hospital professionals and parents, aftercare, and 
transition between hospital and GP.
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General discussion
Part I: Health-related quality of life, psychosocial 
outcomes and adaptations
Adolescent and young adult (AYA) cancer patients: an understudied 
population with regard to psychosocial outcomes and its correlates
Historically, children with cancer have gained a lot of attention, partly because 
successes in treatment have led to an increasing number of survivors reaching 
adulthood, in which long-term and late effects of treatment, so-called 
survivorship issues, affect HRQoL, even decades after end of treatment1-3. 
Surprisingly, AYA cancer survivors have not had this attention while they 
outnumber paediatric cancer cases, still have cancer at a very young and 
unusual age, and -as total group- have a 80% chance to survive, with also the 
risk of survivorship issues4. The good news is that over the last two decades the 
attention for AYAs with cancer has grown substantially, e.g. reflected by the 
development of AYA oncology guidelines5 and the annually recurring global AYA 
oncology conference. Stuck between paediatric and adult oncology patients, 
this age group has specific issues and accompanying unmet informational 
and supportive care needs6. AYA age-specific care can only be delivered after 
examination of the HRQoL problems AYA report and after a method or procedure 
has been developed to assess which AYA patients will face more issues and 
may develop impaired physical, psychological or social functioning. Given the 
lack of systematic identification of AYA patient subgroups that might be more 
susceptible to poor health outcomes (e.g. impaired HRQoL, more symptoms, 
low empowerment) there is a high demand for relevant and structured 
research. The role of sociodemographic and treatment-associated risks and/
or psychosocial factors (social support, coping, autonomy) for impaired health 
outcomes, remains largely unknown. With the aim of developing an optimal AYA 
supportive care program with age-adjusted guidelines we thus require insight 
not only who is more at risk, but also when and why they are at risk. Therefore, 
the first part of this thesis addressed the HRQoL issues of importance to AYA 
with cancer and its correlates. 
Negative outcomes
It was shown that AYA cancer patients rated negative HRQoL issues (e.g. financial 
issues, concentration/memory problems) as less important compared to health 
care professionals (HCP). However, some specific problems like cancer-related 
fatigue and fear of cancer recurrence (FCR) were highly prevalent among AYAs, 
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which indicates that screening on these symptoms might be warranted as they 
highly affect HRQoL. Successful interventions that target FCR are developed 
for adult cancer patients including mind-body interventions (utilizing the mind’s 
capacity to affect the body and its physiological responses e.g. mindfulness), 
interventions aimed at more effective patient-provider communication, and 
handling stress through counseling7,8. Future research should examine if these 
interventions are feasible and effective for AYAs. 
Severe cancer-related fatigue was found to be more prevalent in AYAs than 
in healthy peers. A recent study showed similar results but also reported that 
AYA cancer patients had higher levels of fatigue than older cancer patients9. 
Interventions aimed at diminishing fatigue among adult cancer patients in 
general have been examined previously. Exercise (i.e. aerobic, anaerobic or both), 
psychological (i.e. cognitive behavioural or psycho-educational therapies), and 
exercise plus psychological interventions improved cancer-related fatigue during 
and after primary cancer treatment, whereas pharmacological interventions did 
not10. Whether AYA suffering from severe fatigue equally benefit from these 
interventions is subject for further research. It may well be that the requests 
posed by society on people of this young age make AYA cancer patients more 
vulnerable for (cancer-related) fatigue.
Although AYA cancer patients rated several HRQoL issues as less important 
compared to HCP, the overall HRQoL of the AYA cancer population described 
in the literature is worse compared with normative populations11,12. Some 
interventions that aim to promote HRQoL of AYA are described in the 
literature13-15. A recent systematic literature review on health promotion and 
psychological interventions concluded that interventions delivered face-to-face 
and those that facilitate peer-to-peer support are promising. Harnessing social 
media and technology to deliver interventions is likely to increase and these 
modes of delivery require further investigations13. Very recently a Smartphone 
application, consisting of a symptom and activity diary, a communication 
network and forum and an information bank, has been developed aiming to 
improve HRQoL in AYA cancer patients14. A prospective, non-randomized study 
showed that offering a fitbit (a digital activity tracker that measures physical 
activity) or other wearable technology at time of cancer diagnosis improves 
HRQoL in AYAs over time, probably through mechanisms as reducing fatigue, 
enhancing physical activity and prevention of social isolation15.
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Positive outcomes
This thesis showed that post-traumatic growth (PTG) and resilience are 
relevant positive psychosocial health outcomes in AYA cancer patients. AYA 
rated negative HRQoL issues less high compared to HCP, showing that most 
AYA perceive themselves as resilient and are able to overcome the negative 
consequences of having cancer. Notably, this may also illustrate the fact that 
young people not have a reference frame and do not always oversee already 
the consequences of cancer and its treatments they may experience later in life, 
which is in contrast to the perception of (experienced) health care professionals. 
A longitudinal cohort study among AYA identified more benefits than burdens 
throughout cancer treatment. The most prevalent benefit was a positive 
changed sense-of-self. Over time participants tended to focus more on personal 
strengths and life purpose16.  Much of today’s psychosocial oncology research is 
derived from Selye’s theoretical stress and coping models, in which an emotional 
response to traumatic events or conditions may be experienced as “distress” 
(negative) or “eustress” (positive)17. When applying the stress coping theory to 
investigations of patients’ psychosocial adaptation to cancer, it suggests that it 
is theoretically possible to experience both positive and negative responses to 
cancer simultaneously. In previous literature positive adaptation to traumatic 
life events, including serious illness, as PTG has been conceptualized 18,19. 
Positive changes reported by cancer survivors have included a greater sense 
of closeness to others, higher appreciation of everyday life, recognition of new 
possibilities in life, a sense of personal strength, and deeper spirituality20. In 
a semi-structured interview study of AYAs with cancer21, two recurrent topics 
emerged: (1) loss of control resulting in a sense of frustration and anger; and 
(2) benefit finding such as improved personal attributes and strengthened 
relationships. Recently it was shown that PTG has a direct positive predictive 
effect on mental HRQoL but not on physical HRQoL among AYA with cancer22. 
One potential implication of the findings of this thesis is that helping AYAs with 
cancer who experience low or decreasing levels of PTG to find meaning and 
benefits in the cancer experience, may help improve their mental adjustment. 
This may be accomplished by encouraging the reappraisal of the situation 
(positive reframing)  or the emotional disclosure of inner feelings and fears23. 
A written emotional disclosure intervention, whereby adult breast cancer 
survivors were randomized to write about positive thoughts and feelings related 
to their cancer, showed that those who wrote down positive feelings reported 
less physician visits for medical comorbidities and distress than survivors who 
wrote down facts of their experience 23. In addition, two cognitive-behavioural 
interventions for adult cancer patients, that included elements of coping skills 
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training, relaxation exercises, conflict resolution and emotional expression, had 
beneficial effects on PTG 24,25. Another way to enhance PTG, may be regular 
physical activity. The physiological benefit of physical activity may be stress 
reduction. Physical activity may also increase levels of social support for AYA 
cancer patients and serve as an active coping strategy to decrease levels of 
distress26. In addition, physical activity can improve AYA cancer patients’ self-
efficacy levels, whereby the experience of positive feelings may be enhanced. 
As PTG predicts mental well-being, interventions focused on improving PTG are 
likely beneficial in the early post-treatment period.
This thesis also showed that empowerment was independently associated 
with physical, psychological, social, religious and total HRQoL. Identification 
of correlates of empowerment (e.g. autonomy, social support, female sex 
and coping difficulties) will help us to develop interventions to reinforce 
empowerment. For example, interventions with cognitive behavioural therapy 
elements through eHealth have proven to be effective (e.g. BREATH study)27.  A 
recent study showed that the majority of lymphoma patients reported that they 
would like to receive feedback on their questionnaires answers, comparison of 
their own complaints with those of other patients or their own score over time28. 
In response to this need, the LIVE trial has been developed to examine whether 
feedback to patients on their patiënt reported outcomes (PROs) and access to 
a web-based, self-management intervention will increase self-management 
skills and satisfaction with information, and reduce psychological distress in 
lymphoma patients29. Such a PRO and self-management intervention focusing 
on age-specific aspects could also be an option for AYA to increase their self-
management skills and increasing empowerment. 
Part II: Supportive and palliative care 
The organisation of oncology health care in the Netherlands, with a clear 
separation between paediatric and adult oncology, was not ideally suitable for 
AYA cancer patients with their age-specific HRQoL issues. Traditionally, when 
reaching adulthood, patients of 18 years or older are treated in adult treatment 
centres. These centres often deliver care through disease-focused models in 
which high patient volumes and limited infrastructure challenge the ability to 
address the specific care needs of AYAs with cancer. In addition, AYA patients 
represent a small percentage of adult patients with cancer and thus health care 
teams have less experience and expertise with this population. 
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AYA oncology in the Netherlands
During the realisation of this thesis, there has been considerable development of 
AYA cancer care worldwide and also in the Netherlands. In 2009, the Department 
of Medical Oncology in collaboration with the Department of Medical Psychology 
of the Radboud university medical center (Radboudumc)  launched the AYA 
Expertise Platform, a close collaboration of AYA cancer patients and health care 
professionals. The main goal of the Platform is to improve the care for and the 
quality of life of AYA cancer patients by developing structural, standardized, 
comprehensive and patient-centered guidelines for AYA cancer care. An AYA 
outpatient clinic was launched where AYA cancer patients, regardless of their 
treatment status, type and intent of treatment, could address their age-specific 
questions to a dedicated multidisciplinary AYA team (expert nurse, medical 
oncologist, psychologist, social worker and a clinical physician occupational 
health in oncology). The AYA outpatient clinic turned out to be an easy accessible 
service for AYA cancer patients. In 2010, an online community named AYA4 (All 
Information You’ve Asked for) was developed by and for AYA cancer patients 
treated at the Radboudumc. The AYA4 online community became available for 
all AYA cancer patients in the Netherlands in 2014. One of the aims of this thesis 
was to examine how these new initiatives were rated by AYA cancer patients.
Online initiatives: the road ahead 
Since AYA are digital natives and have grown up with internet, social media and 
other digital technologies, it seems reasonable to develop online supportive 
care interventions. By doing so, it is of the utmost importance to develop these 
interventions in co-creation and co-participation with AYA cancer patients. 
Before the development of the AYA online community, AYA cancer patients 
were interviewed about their needs and problems during and after the cancer 
journey. Based on their input, the AYA online community was developed. 
This thesis showed that the online community can help AYA cancer patients 
to express feelings, exchange information, address peer support and is found 
helpful in coping with cancer. Whether the AYA online community has to be 
expanded over the next years, for whom and in which form is subject of further 
research. In the forthcoming years we should focus on which patients have most 
advantage of using the AYA online community and whether elements should 
be added to make it more attractive. For example, it might be interesting to 
explore if psychological interventions like cognitive-behavioral therapy or self-
management interventions could be delivered safely and effectively online to 
AYA cancer patients in need of such intervention. In addition, it is worth exploring 
if the community can be used for direct face-to-face digital interaction between 
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AYA patients and health care professionals for example to educate about and 
discuss age-specific topics (figure 1). At the start of the community in 2010 other 
social media like what’s app were not available and nowadays are being used 
by 70% of the worldwide population. Moreover, it is interesting to examine if 
the positive effect of the AYA online community differs between so-called 
‘lurkers’  (members of an online application who read content, but not actively 
post content or discuss with other members, in general the vast majority) and 
active members (in general a small minority). In its current form the AYA online 
community is not attractive for users with handheld electronic devices. The 
process of co-creation and co-participation has developed strongly over the last 
years. Recently a co-creative smartphone app for AYA with cancer was developed 
in Denmark. Based on the input of patients the app has now three primary 
features: a symptom and activity diary; a supportive communication network 
between app users; and a “one-stop-shop” information bank with practical 
information as well as links to patient organizations and other resources14. It 
might be interesting to integrate this type of app to the online community in 
order to offer this information more easily to users with handheld electronic 
devices (smartphone). In The Netherlands we recently created the MATCH app 
which aims to (re-)connect AYA with their peers and stimulate communication 
and compassion30. This app was an answer to the desire of AYA, their family and 
friends who indicated a need to stay in contact after a cancer diagnosis. The 
usefulness of the MATCH app is currently being studied. 
One of the major challenges in this modern digital era with rapid evolvement of 
online interventions is to examine whether these interventions are truly helpful 
for users. The classical randomized controlled trial is a solid but time-consuming 
method to determine the usefulness of a new digital application. When results 
are awaited, sometimes over several years, patients do not have access to this 
potentially helpful intervention and seek help for their problems for example 
by consulting a physician, psychologist or social worker. Meanwhile, new 
applications are being developed even before the previous ones had proven 
to be effective (or not). There is a tendency to develop, test the effectiveness 
and implement new applications during the use by the target population31. If 
we want to study whether an online intervention is effective, we first have to 
adjust our expectations about the feasibility of such research project. Then, we 
have to predefine clinically relevant end points which are realistic and robust. 
For example, when testing an online application in AYA, we can focus on end 
points such as less health care consumption for psychosocial problems or faster 
return to work. We have to look for quicker evaluation methods which can give 
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an acceptable degree of evidence. Also, from the very start of any intervention 
we should monitor engagement and early markers of possible effectiveness or 
for signs that the intervention is not working. Lastly, whether this continuous 
process of renewal and improvement of digital interventions is cost-effective 
will be a subject of debate and an important topic for future research. 
Palliative and end-of-life care
As one in five AYA patients dies of cancer, it is important to deliver palliative and 
end-of-life care adjusted to the needs of this age group. This thesis showed that 
general practitioners (GP) involved in AYA end-of-life care were very satisfied with 
the cooperation with the palliative team, but improvements have to be made 
concerning symptom control, communication between hospital professionals 
and parents, aftercare, and transition of care between hospital and GP. Previous 
research showed that AYAs reported anticipatory grief over their lives that have 
not yet been lived and that they may be reluctant to face the irreversibility and 
progression of their disease. This may lead to delays in the start of palliative and 
end-of-life care32. It was also shown that AYAs who die in the hospital tend to use 
palliative care services very late in the course of their cancer and often undergo 
aggressive treatment until death is near33. Therefore, it should be encouraged to 
introduce palliative care in an early stage into standard supportive clinical care 
Figure 1: Age-specific topics in the AYA cancer patient population
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for AYA, meaning from the time of diagnosis until the time of death or cure. The 
palliative care should be provided by a multidisciplinary team with expertise in 
understanding the psychosocial, emotional, developmental, and financial issues 
that are unique for AYAs5. With regard to end-of-life care, a recent study showed 
that end-of-life care preferences for AYA may differ from those of the adult 
population34. AYA patients more frequently died at home compared to older 
adults and received more frequently chemotherapy in the last month of their life. 
Discussions about end-of-life preferences should begin at the time of starting 
(palliative) treatment, but details should be individualised according to the 
preferences of the AYA patient and family. Exploring individual preferences 
for end-of-life care  and providing interventions that are specific to the needs 
of the AYA cancer patient population could significantly improve end-of-life 
care35. Physicians with expertise in end-of-life care should facilitate discussion 
of difficult issues such as nutrition/hydration, sedation, treatment cessation and 
place of death36. This thesis illustrates that timely involvement of the GP, good 
communication between hospital health care professionals and GPs regarding 
disease-related and contextual issues, are essential elements in delivering 
age-appropriate end-of-life care in AYA. Many AYA cancer patients indicate 
a preference for dying at home, yet most die in the hospital37-39. An advanced 
care planning document incorporating a discussion regarding goals of care, 
preferred location of care, preference for place of death, and consent to future 
intervention, including cardiopulmonary resuscitation could assist in pursuing 
this objective34,35. In the context of AYA end-of-life care it is worth mentioning 
that since 2009 there is a unique AYA hospice in the centre of The Netherlands 
(Leiden), a place where exclusively patients at AYA age with any form of incurable 
disease can spend the last phase of their life if dying at home is not preferred.
Limitations and future strategies
There are a few limitations of the studies in this thesis that are worth mentioning. 
First, the AYA patient study sample of chapter 2,3,4, and 6 was derived from 
a single center university hospital, the Radboudumc and therefore the study 
sample is limited. Since the Radboudumc is an expert center for bone sarcoma 
and testicular cancer, types of cancer that require intensive chemotherapeutic 
treatment, there might be an overestimation of disease severity of the entire 
AYA cancer population in which lower stage disease treated solely by surgery 
is more common. Future studies should undertake in a more mixed and larger 
population of AYA treated at hospitals (university and non-university) across the 
Netherlands. Second, although not uncommon in AYA research, the response 
rate among AYA patients was rather low (29%) as described in our chapters 
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concerning HRQoL issues, fatigue, fear of cancer recurrence and empowerment. 
Previous psychosocial studies in AYA cancer patient populations also showed 
low response rates of 31%40, 43%41 en 52%42, partially reflecting the difficulty in 
locating and recruiting a geographically mobile young adult population that in 
most cases are many years beyond therapy and no longer live with their parents. 
To improve the response rates, it would be beneficial to use in-person contact 
and, remarkably, patient-preferred paper-pencil rather than online surveys as 
suggested by Rosenberg et al, who examined the best method to recruit AYA 
patients (14-25 years)43. This might be different in AYA patient of older age. 
Other reasons for AYAs not participating in research could be that they are not 
interested in filling out questionnaires as they want to forget their cancer and 
just feeling ‘normal’ or that they are not aware of the importance of research or 
do not see themselves as an (AYA ex-) cancer patient, but just as a cancer patient. 
Future research in the AYA population will be more successful if we are better 
informed about the reasons for non-participation. To increase response rate, 
we could also ask their proxies to complete questionnaires. This adds valuable 
information for researchers and implicates that filling out questionnaires is ‘just 
normal’. Third, we did not make use of AYA-specific HRQoL questionnaires, as 
they were not in place yet when we started with this research. In the meantime, 
a few AYA specific questionnaires have been developed. For example, adult and 
paediatric measures have been adapted to the specific issues relevant to AYAs 
and have AYA versions (PedsQL)44 and there are measures which have been 
developed with and designed specifically for AYAs (CNQ-YP)45. In response to the 
need for AYA specific questionnaires the EORTC Quality of Life Group developed 
the EORTC-QLQ-AYA module with AYA specific issues (for example impact on 
family, dependency on others, interrupted education, workability) to measure 
HRQoL46. The first phase of the questionnaire development showed that AYAs 
with cancer have to deal with disrupted life plans and difficulty establishing 
romantic relationships which are likely to be more common to AYAs with cancer 
and might not be captured by existing HRQoL measures46. The Impact Of Cancer 
AYA (IOC-AYA) questionnaire has shown good psychometric properties to 
measure positive and negative HRQoL aspects in the AYA population40 and could 
therefore also be an asset in future research using AYA-specific questionnaires.
Clinical implications and recommendations
Currently, AYA cancer care, research and education in the Netherlands is 
governed by the Dutch AYA ‘Young and Cancer’ Platform, which was founded in 
2016. There are six regional comprehensive AYA networks, where an AYA expert 
university hospital with inpatient and outpatient facilities is connected with the 
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surrounding regional hospitals. AYA care is delivered by means of an echelon 
system. Standard age-specific and psychosocial care for AYAs can be delivered 
nearby the patient coordinated from the nearest treating hospital. When an AYA 
needs more complex multidisciplinary care, this is covered by one of six regional 
expert centers across the country. The echelon system is currently implemented 
across the country. After enrolment it is essential to evaluate the AYA care 
program in terms of improvements in patient satisfaction, HRQoL, survival, and 
clinical outcomes (eg trial participation). Future studies need to provide objective 
evidence, with newly defined robust and predefined endpoints (for example less 
health care consumption for psychosocial problems or faster return to work), 
demonstrating the efficacy of critical components of the AYA care programs in 
order to create evidence-based guidelines, referral pathways, and education32. 
These predefined endpoints have to be established by a multidisciplinary team 
including AYA cancer patients, proxies, health care professionals, researchers 
and other stakeholders. 
Although a recent paper showed that the distress thermometer is feasible and 
applicable in Asian AYA cancer patients to evaluate distress47, one could argue if 
measuring distress is the best way. Based on the findings in chapter 5 and 6 we 
would make a plea to investigate whether it would be more suitable to measure 
empowerment by means of a ‘(em)power(ment) thermometer’. Focussing on 
measuring power or resilience, which has a more positive connotation, instead 
of problems or distress might be a more appealing and more informative way to 
assess positive HRQoL issues among AYA cancer patients. 
Future research
The aims of future research should be to collect more data in a larger AYA patient 
population in the Netherlands. These data should focus on the most important 
HRQoL issues and correlates in a mixed AYA population with regard to age, sex, 
tumour type, disease stage, type of treatment and treatment intent (curative/
palliative). The infrastructure of the Dutch AYA ‘Young and Cancer’ Platform 
enables us to perform research on a larger scale. In depth focus should be paid to 
developing (online) interventions to increase personal strength, reduce cancer-
related fatigue and diminish fear of cancer recurrence.  Future research should 
examine which AYA cancer patients will benefit most (or not) of the use of the 
AYA online community and to determine if the community has to be adapted 
or extended to the needs of the users. We should integrate existing online tools 
or applications aiming to support AYA into one larger online platform, where 
in the end AYA cancer patients can choose their type of online support or 
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informational tool aiming to empower them. Also, we should focus on the user-
generated content analysis available on the renewed AYA community available 
for AYAs, because this gives relevant patient-reported information. With 
regard to palliative and end-of-life care in AYA, the focus should be on a better 
transition from hospital-based care to home-based care and improvement of 
interprofessional communication. It is worth exploring if digital communication 
between patient, general practitioner and hospital health care provider, within 
the boundaries set by privacy regulations, can help in achieving these goals. 
As chapter 2 illustrates the discrepancy between top 10 HRQoL issues between 
AYA and health care professionals, efforts should be undertaken to educate 
health care professionals on cancer at AYA age and to show them the pathways 
in delivering age-appropriate care across The Netherlands. It could be very 
helpful for health care professionals to visit the annual SPACE4AYA conference 
where state of the art information will be discussed on AYA care, education and 
research and interaction between AYA patients and health care professionals 
is stimulated48. Because cancer at AYA age is a rare disease, international 
cooperation in AYA research would increase the amount of data, accentuates 
intercultural differences and would facilitate the development of and enrolment 
in clinical trials for AYA. In addition, the AYA oncology agenda should be 
moved beyond high-income countries to support those in less-privileged 
circumstances49. 
Concluding remarks
AYA cancer patients have been recognised as a distinct population with unique 
medical and psychosocial needs. Health care professionals should be able to 
identify issues specific to the AYA population and recommend appropriate 
interventions with the aim of improving outcomes. AYA patients should have 
access to age-specific supportive care as well as medical subspecialty services 
accompanying their cancer diagnosis. Over the past years age-specific care for 
AYA in the Netherlands has made an impressive development, albeit with a 
continuously perceived pressure due to the lack of structured financial support. 
National governance of AYA care, research and education is covered by the 
Dutch AYA ‘Young and Cancer’ Platform. Now it is time to demonstrate the 
added value of this national program, which was once started based on vision 
and good will, but has evolved to a professional organisation, and we need to 
lobby for its financial sustainability. At the same time, we need to scale our 
research to a nationwide infrastructure for comprehensive health outcomes 
and intervention research. In this way we will be able to work towards more 
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tailored care with the ultimate goal to generate better medical and psychosocial 
outcomes of AYA cancer patients. 
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Kanker bij jongvolwassenen
Dit proefschrift gaat over AYA’s, jongvolwassenen die in de leeftijd tussen 18 
en 35 jaar kanker krijgen. De term AYA is afkomstig uit het Engels en staat 
voor Adolescent and Young Adult. Jaarlijks wordt in Nederland bij ongeveer 
2700 nieuwe patiënten in de leeftijd van 18 tot 35 jaar de diagnose kanker 
gesteld. De soorten kanker bij AYA’s kunnen in drie groepen verdeeld worden 
namelijk de staart van de kindertumoren ((zoals acute lymfatische leukemie of 
kinderhersentumoren), typische AYA-tumoren (zoals zaadbalkanker, Hodgkin 
lymfoom, melanoom, schildklierkanker) en het begin van de volwassen 
tumoren (zoals borstkanker, dikke darmkanker). Vanuit historisch perspectief is 
er veel aandacht uitgegaan naar kinderen (0-18 jaar) met kanker. Door betere 
behandelingen is de overleving van kinderen met kanker over de tijd verbeterd, 
maar de prijs van deze intensieve behandelingen is onder andere het ontstaan 
van late effecten. Opvallend genoeg is deze aandacht er niet geweest voor de 
AYA-leeftijdsgroep, terwijl de frequentie van nieuwe tumoren 5x zo hoog ligt 
als op kinderleeftijd, 80% van hen geneest en ook zij nog een lang leven voor 
zich hebben waardoor ook bij hen de impact van late effecten van kanker groot 
kan zijn. In de leeftijdsfase van adolescentie en jongvolwassenheid staat het 
behalen van ontwikkelingsmijlpalen centraal zoals het afronden van school of 
studie, een eigen identiteit vormen, relaties aangaan, een eerste baan krijgen, 
financieel onafhankelijk worden en een gezin stichten. Het krijgen van kanker 
op AYA-leeftijd kan ervoor zorgen dat de ontwikkeling stagneert en dat de 
AYA moeite heeft met functioneren op persoonlijk, sociaal en maatschappelijk 
vlak. AYA’s kunnen vragen of problemen rapporteren zoals bijvoorbeeld op het 
gebied van relaties, vruchtbaarheid, studie, werk, verzekeringen of hypotheken. 
Deze zogenaamde leeftijdsspecifieke aspecten staan weergegeven in figuur 1. 
Ontwikkeling van AYA-oncologie in Nederland
De laatste jaren is er aanzienlijke vooruitgang geboekt in de opzet van zorg 
voor AYA’s wereldwijd alsook in Nederland. In 2009 werd het regionaal AYA 
Kenniscentrum Radboudumc opgericht door de afdelingen Medische Oncologie 
en Medische Psychologie van het Radboudumc in Nijmegen. Dit is een 
samenwerkingsverband tussen patiënten op AYA-leeftijd en zorgprofessionals 
betrokken bij de dagelijkse zorg voor AYA’s met als doel de zorg voor en de 
kwaliteit van leven van AYA’s te verbeteren. In 2009 werd de 1e AYA-poli geopend 
in het Radboudumc. Dit is een laagdrempelig loket waar AYA’s, ongeacht soort 
kanker en type behandeling, terecht kunnen met hun leeftijdsspecifieke vragen 
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(zie figuur 1). De essentiële vraag van de zorgprofessionals bij elke AYA die de 
AYA-poli bezoekt is: wie ben jij en wat heb jij nodig? De patiënten die de AYA-
poli bezoeken worden besproken in het multidisciplinaire team bestaande uit 
een verpleegkundig specialist, medisch psycholoog, maatschappelijk werker, 
klinisch arbeidsgeneeskundige oncologie en een internist-oncoloog, allen 
met specifieke kennis op het gebied van kanker op AYA-leeftijd. In 2010 werd 
de online AYA community opgericht met de naam AYA4 wat staat voor All 
Information You’ve Asked for. Deze digitale ontmoetingsplek was aanvankelijk 
alleen beschikbaar voor AYA’s van het Radboudumc, maar werd in 2014 
toegankelijk voor alle AYA’s in Nederland. 
Op dit moment wordt AYA-zorg, onderzoek en onderwijs in Nederland 
gecoördineerd door de Stichting Nationaal AYA ‘Jong & Kanker’ Platform 
(www.aya4net.nl). Deze stichting is in 2016 opgericht en heeft een eigen 
bestuur. Thans zijn er zes regionale AYA kennisnetwerken verdeeld over 
Nederland waar de zorg geëchelonneerd wordt aangeboden. Dat wil zeggen 
dat standaard leeftijdsspecifieke en psychosociale zorg wordt aangeboden door 
zorgprofessionals van het behandelend naburig ziekenhuis. Indien er echter 
een indicatie bestaat voor complexe multidisciplinaire AYA-zorg, kan de AYA 
verwezen worden naar een regionaal AYA kenniscentrum. De leeftijdsspecifieke 
zorg volgt de medisch-technische zorg. Daarnaast kunnen zorgprofessionals uit 
heel Nederland de AYA Kenniscentra consulteren. 
Doel van dit proefschrift
De onderzoeken beschreven in dit proefschrift zijn grotendeels uitgevoerd 
onder AYA-patiënten die het AYA-poli zorgteam van het regionaal AYA 
kenniscentrum Radboudumc in Nijmegen hebben bezocht en onder AYA’s uit 
heel Nederland die gebruik maken van de online AYA community. Het doel van 
dit proefschrift is om beter inzicht te krijgen in de AYA-doelgroep om de zorg 
voor hen te verbeteren. Door subgroepen te identificeren die meer risico lopen 
op bijvoorbeeld psychosociale problemen tijdens en na behandeling, kunnen 
we de zorg voor deze doelgroep pro-actiever en meer op maat leveren en 
optimaliseren. Dit proefschrift is onderverdeeld in twee delen. Deel I gaat in op 
kwaliteit van leven en psychosociale aspecten van kanker op AYA-leeftijd. Deel 
II gaat in ondersteunende en palliatieve zorg voor AYA’s. 
Hieronder volgt een overzicht van de belangrijkste resultaten van dit proefschrift. 
Nadien wordt afgesloten met aanbevelingen voor toekomstig onderzoek en 
adviezen over hoe de zorg voor AYA’s verder verbeterd kan worden. 
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Deel I: Kwaliteit van leven en psychosociale aspecten 
bij AYA’s
Het meten van kwaliteit van leven vanuit het perspectief van de AYA geeft 
inzicht in het effect van kanker en de behandeling ervan op fysiek, psychisch en 
sociaal functioneren.  
In Hoofdstuk 2 wordt beschreven welke 10 kwaliteit van leven onderwerpen 
door AYA’s als belangrijkste worden ervaren. Deze top 10 wordt vergeleken met 
de top 10 die zorgprofessionals, betrokken bij AYA-zorg, aangeven als in hun 
ogen het meest relevant voor AYA’s. Er deden 83 AYA’s en 34 zorgprofessionals 
mee aan dit onderzoek. De belangrijkste onderwerpen voor AYA‘s met kanker 
waren ontvangen steun van anderen, angst voor de initiële diagnose van 
kanker, angst voor de impact op het gezin, de algehele kwaliteit van leven 
en geluk. Zorgprofessionals gaven aan dat zij angst voor de initiële diagnose 
van kanker, angst voor de impact op het gezin, vermoeidheid, angst voor de 
kankerbehandeling, het interfereren van kanker en de behandeling op werk of 
studie de belangrijkste onderwerpen voor AYA’s vonden die hun kwaliteit van 
leven konden beïnvloeden. De top 10 onderwerpen van AYA’s versus die van de 
zorgprofessionals overlappen elkaar op vijf van de tien items. AYA’s scoorden 
significant lager op negatief geformuleerde kwaliteit van leven items zoals 
vermoeidheid, problemen met omgaan met kanker en zich geïsoleerd voelen. 
Zij scoorden significant hoger op positief geformuleerde onderwerpen zoals 
steun van anderen, algemene fysieke gezondheid en geluk in vergelijking met 
de zorgprofessionals.  Geconcludeerd werd dat AYA’s de kwaliteit van leven 
onderwerpen die het meest negatief geformuleerd waren minder problematisch 
ervoeren dan zorgprofessionals meenden dat AYA’s dat zouden ervaren. De 
discrepantie in de prioritering van kwaliteit van leven onderwerpen door AYA-
patiënten en zorgprofessionals illustreert het belang van patiëntenparticipatie 
bij de inhoud en de organisatie van AYA specifieke zorg. Het perspectief van 
de zorgprofessional, dat voornamelijk probleemgericht is, kan worden vergroot 
door het meenemen van het patiëntenperspectief, wat de leeftijdsspecifieke 
zorg, en uiteindelijk de kwaliteit van leven van de AYA’s, ten goede kan komen.
 
Hoofdstuk 3 richt zich op het vaststellen van de prevalentie van angst voor 
terugkeer van kanker bij AYA’s en factoren die daarmee geassocieerd zijn zoals 
kwaliteit van leven, angst en distress. Angst voor terugkeer van kanker is een 
veel voorkomend probleem bij patiënten met kanker. Eerder onderzoek heeft 
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aangetoond dat een jongere leeftijd geassocieerd is met meer angst voor 
terugkeer van kanker. Tot op heden was er weinig bekend over hoe angst voor 
terugkeer zich manifesteert bij AYA’s. Door 73 AYA’s die het multidisciplinaire 
AYA-poli zorgteam van het Radboudumc consulteerden, werden vragenlijsten 
ingevuld over onder andere angst voor terugkeer van kanker, kwaliteit van 
leven, angst en depressie. Bij 62 % van hen was sprake van een hoge mate van 
angst voor terugkeer van kanker. Dit was hoger dan gerapporteerd in studies 
bij volwassen patiënten met kanker. Een hoge mate van angst voor terugkeer 
van kanker was geassocieerd met lagere niveaus van sociaal en psychisch 
functioneren en kwaliteit van leven en met meer psychische distress. Deze 
resultaten illustreren dat angst voor terugkeer van de kanker een belangrijk 
probleem is bij AYA’s. Als aanbeveling wordt meegegeven dat de zorgverlener 
specifieke aandacht zou moeten besteden aan de mate aan angst voor terugkeer 
van kanker bijvoorbeeld door systematisch hierop te screenen. Dit kan helpen 
om de psychosociale zorg daarop gericht aan te passen.  
Hoofdstuk 4 beschrijft de prevalentie van ernstige vermoeidheid bij AYA’s, de 
impact die ernstige vermoeidheid heeft en welke factoren hieraan bijdragen. 
Ernstige vermoeidheid op basis van een gevalideerde afkapwaarde in een 
vragenlijst kwam voor bij 48% (n=40/83) van de AYA’s die de AYA-polikliniek 
bezochten. Dit percentage is aanzienlijk hoger dan in de algemene populatie waar 
slechts 20% van de op leeftijd en geslacht gematchte groep ernstig vermoeid is. 
Dit onderzoek toonde aan dat ernstig vermoeide AYA’s een significant lagere 
kwaliteit van leven rapporteerden op zowel het fysieke, psychologische, sociale 
als spirituele domein. Ernstige vermoeidheid was geassocieerd met vrouwelijk 
geslacht, werkloosheid (of niet studerend), vergevorderde kanker bij diagnose, 
actieve behandeling ten tijde van het invullen van de vragenlijst, palliatieve 
intentie van de behandeling en eerdere bestraling. Daarnaast lieten de 
resultaten zien dat hogere vermoeidheidscores geassocieerd waren met angst 
voor terugkeer van kanker en met psychische distress. De bevindingen van deze 
studie benadrukken het belang van zorgvuldige aandacht voor vermoeidheid 
bij AYA’s. Op grond van de resultaten is het aan te bevelen met regelmaat te 
screenen op de aanwezigheid van ernstige vermoeidheid en om behandelbare 
factoren te identificeren (bijvoorbeeld psychische klachten en slaapstoornissen). 
Dit geldt voor zowel tijdens als na afloop van de behandeling voor kanker. 
Hoofdstuk 5 bevat een literatuuroverzicht over post-traumatische groei 
en veerkracht bij AYA’s met kanker. Kwalitatieve interviewstudies toonden 
aan dat post-traumatische groei door AYA’s beschreven werd in termen van 
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voordelen, waaronder een veranderde kijk op het leven en het zich sterker 
en zelfverzekerder voelen. Veerkracht werd beschreven als een evenwicht 
tussen verschillende factoren, waaronder stress en omgaan met kanker, doelen 
stellen, optimisme, betekenis en zingeving, verbinding maken met anderen en 
ergens bij horen. Kwantitatief onderzoek toonde aan dat sociodemografische 
en klinische kenmerken niet geassocieerd waren met post-traumatische groei. 
Langdurige stress was negatief en sociale steun positief geassocieerd met post-
traumatische groei. Angst voor ziekte- en behandelingsgerelateerde symptomen, 
en een defensieve coping strategie waren negatief geassocieerd met veerkracht. 
Als er daarentegen sprake was van meer bewust omgaan met ervaringen, de 
zogenaamde adaptieve cognitieve coping, dan was dit positief geassocieerd 
met veerkracht. Zowel post-traumatische groei als veerkracht waren positief 
geassocieerd met tevredenheid met het leven en met kwaliteit van leven. Hoe 
ten gevolge van ziekte- en behandelingsgerelateerde distress de ervaren kwaliteit 
van leven bepaald wordt, heeft o.a. te maken met veerkracht. In het review 
worden twee interventies beschreven die onder andere gericht waren op het 
bevorderen van veerkracht, namelijk een stress-management interventie en een 
therapeutische videoclip-interventie. Het bleek dat deze er niet in slaagden de 
algehele veerkracht te vergroten onder deelnemende AYA’s. De meeste AYA’s 
ervoeren slechts een beetje post-traumatische groei of veerkracht. Onderzoek 
naar factoren die geassocieerd zijn met post-traumatische groei en veerkracht, 
zoals distress ten gevolge van ziekte en behandelingsgerelateerde symptomen, 
stress, omgaan met kanker, sociale steun en fysieke activiteit kan bijdragen aan 
inzicht in welke interventies zinvol en effectief zijn ter verbetering van post-
traumatische groei en veerkracht en het uiteindelijk verminderen van negatieve 
uitkomsten. 
Een van de veronderstelde mechanismen om post-traumatische groei en 
veerkracht te bereiken is empowerment. Empowerment is het vermogen van 
een persoon zichzelf te versterken om controle te verwerven of behouden 
over zijn eigen leven. De vragen en problemen die AYA’s tegenkomen tijdens 
en na kanker, kunnen van invloed zijn op de mate van empowerment die zij 
ervaren. De doelstelling van hoofdstuk 6 was om de mate van empowerment en 
daarmee geassocieerde (demografische, klinische of psychologische) factoren 
te onderzoeken en om het verband tussen empowerment en kwaliteit van leven 
bij AYA’s te onderzoeken. De vragenlijsten werden door 83 AYA’s ingevuld. 
Van hen was 83% behandeld met (onder andere) chemotherapie en had 74% 
de behandeling voor kanker afgerond. De multivariate analyse toonde aan dat 
onderdelen van autonomie (zelfbewustzijn, het vermogen om nieuwe situaties 
183
9
te overzien) en sociale steun positief geassocieerd waren met empowerment. 
Vrouwelijke AYA’s scoorden lager op empowerment in vergelijking met 
mannelijke AYA’s. Coping problematiek, oftewel moeite hebben met het 
omgaan met de ziekte, bleek negatief geassocieerd te zijn met empowerment. 
Empowerment was onafhankelijk geassocieerd met fysieke, psychologische, 
sociale, religieus en algemene ervaren kwaliteit van leven. Het herkennen 
van AYA-patiënten die baat zouden kunnen hebben bij interventies die het 
doel hebben om de empowerment te vergroten, zou kunnen bijdragen aan de 
verbetering van hun kwaliteit van leven.
Deel II: ondersteunende en palliatieve zorg 
Om te kunnen omgaan met kanker en de gevolgen van de behandeling is het van 
essentieel belang om de juiste leeftijdsspecifieke zorg op het juiste moment en de 
juiste plek te kunnen bieden aan elke AYA en diens naaste. In Hoofdstuk 7 worden 
het gebruik en de evaluatie beschreven van de online AYA community, een digitale 
‘hangplek’ voor Nederlandse AYA’s.  De community heet AYA4 en is de afkorting 
van ‘All Information You’ve Asked for’. Deze community was door AYA’s gewenst 
omdat AYA’s aangaven dat het lastig was andere AYA’s te ontmoeten. In 2010 
werd de community op basis van de wensen van AYA’s ontwikkeld en in gebruik 
genomen. De AYA community werd op uitdrukkelijk verzoek van AYA’s alleen 
toegankelijk gemaakt voor henzelf. Sinds de start van de AYA community in 2010 
is het ledental in 2017 uitgegroeid naar 433 waarvan 71% vrouw is. De gemiddelde 
leeftijd bij diagnose kanker was 25,7 jaar. De leden zijn afkomstig van 52 van de 91 
ziekenhuizen in Nederland. Uit een nationaal vragenlijstonderzoek onder 66 AYA’s 
bleek dat 30 van hen de AYA community regelmatig gebruikten. Zij gaven aan 
dat de community bijdroeg aan het gevoel van erkenning en herkenning (78%), 
door de verhalen van andere AYA’s. Zesenvijftig % gaf aan in de community bij 
andere AYA’s terecht te kunnen voor advies met betrekking tot problemen, 63% 
ervoer ondersteund te worden door andere leden van de community. Bijna de 
helft van de respondenten voelde zich minder eenzaam. Slechts 14 AYA’s gaven 
toestemming om hun bijdragen (teksten, discussies) aan de community voor 
een wetenschappelijke studie anoniem te analyseren. De analyse van de inhoud 
liet zien dat de meerderheid van de online discussies gingen over het delen van 
informatie en emotie en het ondersteunen van elkaar daarbij. AYA’s missen, 
gezien de zeldzaamheid van kanker op de AYA leeftijd, vaak de mogelijkheid om 
elkaar persoonlijk te ontmoeten. De resultaten van de beveiligde Nederlandse 
online AYA community laten zien dat de community bijdraagt aan de mogelijkheid 
om met elkaar in contact te komen. AYA’s gaven aan dat contact met andere 
AYA’s hen helpt om gevoelens te uiten, om informatie uit te wisselen, om hulp te 
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vragen en te krijgen bij het omgaan met kanker en de gevolgen ervan. Het strekt 
tot aanbeveling dat zorgprofessionals AYA’s attenderen op het bestaan en de 
voordelen van de community. 
Omdat 1 op de 5 AYA’s met kanker overlijdt aan de ziekte is het belangrijk om 
de palliatieve zorg, waarvan terminale zorg een onderdeel is, goed in te richten. 
In Hoofdstuk 8 worden de ervaringen van nabestaanden en huisartsen in 
Nederland met palliatieve zorg voor AYA’s in de terminale fase geanalyseerd. 
Vijftien ouders en negen huisartsen betrokken bij negen overleden AYA’s 
vulden vragenlijsten in en werden respectievelijk telefonisch geïnterviewd. 
Over het algemeen waren de ouders tevreden met de emotionele zorg die ze 
zelf ontvingen en de medische zorg die hun kind ontving. De huisartsen waren 
zeer tevreden over de samenwerking met het palliatieve team. Hiaten werden 
geïdentificeerd op het gebied van symptoombeheersing, communicatie tussen 
ziekenhuisprofessionals en ouders, nazorg en de overgang tussen ziekenhuis en 
huisarts. Dit onderzoek geeft aan dat de zorg, met name in de transitiefase van 
ziekenhuis naar huisarts verbeterd kan worden en dat er specifieke punten voor 
verbetering liggen.
In Hoofdstuk 9 worden de praktische implicaties van de bevindingen beschreven 
en aanbevelingen voor toekomstig onderzoek voorgesteld. Dit proefschrift heeft 
belangrijke inzichten opgeleverd omtrent kwaliteit van leven van AYA’s. Het 
heeft de 10 meest belangrijke kwaliteit van leven items getoond onder AYA’s die 
belangrijk verschilden van de top 10 die zorgprofessionals voor hen in gedachten 
hadden. Moeheid en angst voor terugkeer van kanker zijn belangrijke elementen 
die de kwaliteit van leven van AYA’s kunnen beïnvloeden. Gelukkig bestaan er 
ook positieve uitkomsten van patiënten die op AYA-leeftijd kanker krijgen zoals 
post-traumatische groei en veerkracht. Deze positieve uitkomsten hangen samen 
met  empowerment, een gevoel van controle hebben over het eigen leven. Omdat 
empowerment geassocieerd is met kwaliteit van leven, is het zaak om interventies 
te ontwikkelen om empowerment te vergroten. Tevens heeft dit proefschrift 
laten zien dat de online AYA community een nuttige digitale tool is waar AYA’s 
met elkaar in contact kunnen komen om informatie, emoties en ervaringen uit te 
wisselen. Toekomstig onderzoek dient zich te richten op de vraag welke AYA’s het 
meeste voordeel hebben van het gebruik van de community, hoe de community 
uitgebreid dient te worden en de toegevoegde waarde van de inhoudsanalyse van 
de community. Met betrekking tot terminale zorg voor AYA’s is er nog verbetering 
wenselijk op het gebied van de transitie en communicatie van ziekenhuis naar 
thuissituatie en symptoomcontrole.
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In de nabije toekomst zullen we ons verder richten op het verzamelen van 
meer data in een grotere AYA-populatie afkomstig uit meer ziekenhuizen in 
Nederland. De infrastructuur van het Nationaal AYA ‘Jong & Kanker’ Platform 
maakt grootschalig onderzoek en educatie van zorgprofessionals gemakkelijker. 
Daarnaast is het zinvol om (online) interventies te ontwikkelen voor AYA’s om 
enerzijds persoonlijke kracht te vergroten en anderzijds vermoeidheid en angst 
voor terugkeer van kanker te verminderen. Het is van belang dat AYA-zorg in 
de toekomst wordt geëvalueerd in termen van patiënttevredenheid, kwaliteit 
van leven, overleving en deelname aan klinische studies. Daarbij kunnen 
nieuwe, robuuste eindpunten, zoals bijvoorbeeld minder zorgconsumptie voor 
psychosociale problemen en een snellere terugkeer naar werk, behulpzaam zijn 
om de effectiviteit van AYA-zorg aan te tonen. 
Figuur 1: Leeftijdsspecifieke aspecten bij AYA’s met kanker
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Concluderend
AYA’s met kanker vormen een aparte groep met unieke medische en 
psychosociale zorgbehoeften. Zorgprofessionals dienen meer zicht te krijgen in 
factoren die specifiek zijn voor de AYA-populatie om zowel de leeftijdsspecifieke 
ondersteunende zorg als de medische zorg te verbeteren. Het is van groot 
belang om te bepalen welke AYA-patiënten meer risico hebben op psychosociale 
problemen en dus baat kunnen hebben bij (online) interventies. De laatste jaren 
is er grote vooruitgang geboekt op het gebied van AYA zorg, onderzoek en 
onderwijs, onder andere door de oprichting van de Stichting Nationaal AYA ‘Jong 
& Kanker’ Platform. Helaas bestaat er nog geen structurele financiering voor 
deze zorg. De Stichting Oncologische Samenwerking (SONCOS), het platform 
voor interdisciplinair overleg en professionele samenwerking in de oncologische 
zorg tussen beroepsverenigingen, heeft het belang van leeftijdsspecifieke AYA-
zorg onderkend. Omdat AYA-zorg inmiddels is opgenomen in het SONCOS 
normeringsrapport, wordt deze zorg minder vrijblijvend en kan er in de 
toekomst ook op getoetst worden. Dit proefschrift is een aanzet om te komen 
tot proactieve psychosociale  AYA-zorg op maat waarbij verder onderzoek zal 
uitwijzen of dit leidt tot betere uitkomsten in de kwaliteit van leven van AYA’s. 
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Dankwoord
Mijn boekje is af! Maar mijn werk in ‘AYA-land’ is nog niet klaar. Toch sluit ik, 
met gepaste trots, een belangrijke periode af. Een periode van leren, groeien, 
doorzetten, groot worden en soms (een beetje) worstelen. Het overkoepelende 
werkwoord voor dit alles is promoveren. Onderstaande personen hebben op 
enigerlei wijze bijgedragen aan de totstandkoming van dit proefschrift en wil ik 
daarom graag bedanken. 
AYA-patiënten van het Radboudumc. Ik stond aan de zijlijn van de paden die 
jullie vaak noodgedwongen moesten bewandelen. Paden die gekenmerkt 
werden door hoop en vrees, vallen en opstaan, een lach en een traan. Ik heb 
gepoogd jullie op je pad te steunen en te helpen waar nodig. Het is een voorrecht 
om dat te mogen doen. Jullie wisten mij steeds te motiveren om door te gaan 
en de passie in mijn werk te blijven ervaren. Dank jullie wel. Speciale dank aan 
alle AYA’s die hebben deelgenomen aan mijn onderzoek en hebben meegedacht 
over de opzet en uitrol van AYA-zorg. Samen gaat het beter!
Prof. dr. Winette van der Graaf, beste Winette, door jou ben ik destijds 
geënthousiasmeerd geraakt voor AYA-zorg en AYA-onderzoek. In jouw oratie 
sprak je over rolmodellen, jij bent een rolmodel voor mij. Jij weet als geen 
ander de context van de spreekkamer te vertalen in nieuwe onderzoeksvragen 
en daarmee uiteindelijk het verschil te maken op het gebied van onderzoek en 
patiëntenzorg. Ik heb veel van je geleerd en met je gedeeld. Bedankt dat je me 
hebt gestimuleerd en hebt laten groeien. 
Prof. dr. Judith Prins, beste Judith, jouw nuchtere, analytische kijk op 
wetenschappelijk onderzoek en jouw kennis over de psychosociale oncologie 
hebben mij geholpen om steeds een stap verder te komen.  
Dr. Olga Husson, beste Olga, jouw komst in het promotieteam was er een met een 
gouden randje. Het is een eer jouw eerste promovenda te mogen zijn. Ik kon altijd 
bij jou terecht voor hulp bij een statistische analyse, advies over de opbouw van een 
manuscript, een peptalk of gewoon even bijkletsen. Na een gesprek met jou (“het 
is toch bijna klaar?”) zag ik het weer zitten met de voortgang van mijn proefschrift. 
Ik vind het leuk dat je weer op Nederlandse bodem bent en kijk uit naar verdere 
samenwerking. Dank voor je begeleiding, steun en je aanstekelijke lach.    
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De leden van de manuscriptcommissie, Prof. dr. Anne Speckens, Prof. dr. Didi 
Braat en Prof. dr. Hans Gelderblom wil ik danken voor hun voortvarendheid in 
het lezen en beoordelen van dit proefschrift. 
De Raad van Bestuur van het Radboudumc  wil ik bedanken voor hun faciliterende 
rol in de opzet en ontwikkeling van AYA-zorg. Als ‘Radboudiaan’ ben ik trots dat 
de bakermat van AYA-zorg in het Radboudumc staat. 
Dr. Eveliene Manten-Horst, lieve Eveliene, als kwartiermaker en directeur van 
het Nationaal AYA ‘Jong & Kanker’ Platform weet jij als geen ander mensen te 
binden. Door jouw warme persoonlijkheid en tomeloze inzet en energie blijft dit 
Platform groeien en bloeien. Keep up the good work! 
Teamleden van het AYA-MDO, Rosemarie Jansen, Petra Servaes, Linde 
Bögemann en Desiree Dona. Lieve dames, de zorg voor AYA’s met kanker is 
soms zwaar, maar samen met jullie voelt het veel lichter. De combinatie van 
brede kennis en een stevige dosis ‘girlpower’ maakt ons clubje uniek. 
Een proefschrift volbrengen in combinatie met de taken van medisch-specialist 
lukt alleen met de steun van een getraind elftal met een solide basis, namelijk de 
afdeling Medische Oncologie. Een aantal spelers wil ik graag bij naam noemen. 
Prof. dr. ir. J.J.M. van der Hoeven, beste Koos, als aanvoerder (afdelingshoofd) 
heb je mij altijd gefaciliteerd en gesteund. Op de juiste momenten gaf je me een 
duwtje in de rug. Dank daarvoor. Drs. ing. Erik Lambeck, beste Erik, jouw tactisch 
inzicht is groot, jouw financieel inzicht nog groter en als spelverdeler weet jij ook 
wat er ècht gebeurt in de spreekkamer. Stafleden medische oncologie, jullie zijn 
een mooie, diverse club internist-oncologen met overlappende eigenschappen: 
zorgzaam, ambitieus en (prettig) eigenwijs. Jullie vormen de basis van het 
team. Ik kijk er naar uit die basis de komende jaren verder uit te bouwen. Prof. 
dr. Carla van Herpen, beste Carla, kamergenoot, wat krijg jij veel voor elkaar! 
Ondanks je drukke agenda maak je altijd tijd vrij om te informeren hoe het met 
me gaat. Dr. Sasja Mulder, ballenmaatje, met jou kan ik heerlijk lachen en stoom 
afblazen. Bijna (!) dr. Evelien Kuip, ik kijk er naar uit om jou te zien stralen bij de 
verdediging van jouw proefschrift. Collega’s van de afdeling medisch oncologie, 
fellows, arts-onderzoekers, verpleging, research, secretariaat en overige 
collega’s. Met velen van jullie deel ik al ruim 10 jaar de Nijmeegse werkvloer. 
Het hoge arbeidsethos, de goede onderlinge sfeer en betrokkenheid maakt dat 
ik elke dag met plezier naar mijn werk ga. En dat is veel waard! Dank daarvoor. 
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Sarcomenteam Radboudumc, beste collega’s, het is een genoegen om met jullie 
samen te werken. Jullie zijn een enthousiast en toegewijd team en ik kijk er naar 
uit om de sarcoomzorg en -onderzoek nog verder te verbeteren, zowel binnen 
als buiten de muren van het ziekenhuis. 
Rosemarie Jansen, lieve Roos, jij verdient een speciaal plekje in dit dankwoord, 
omdat jij ook een speciaal plekje in mijn hart hebt. Jij bent de eerste 
verpleegkundig specialist AYA in Nederland en hebt je de laatste jaren ingezet 
om AYA-zorg over Nederland uit te breiden. Jouw verdiensten zijn onlangs 
bekroond met een nationale AYA-award en die heb je enorm verdiend! Ik noem 
je altijd mijn “mattie”, wat vrij vertaald betekent maatje met wie je alles kan 
delen. In de spreekkamer zijn we er voor de patiënt en diens naasten. We vullen 
elkaar aan en vinden ook steun bij elkaar. Het is een voorrecht om samen met 
jou voor AYA’s te mogen zorgen. Ook buiten de muren van het ziekenhuis zijn 
we een goede match. Onder het genot van ons vaste recept, witte wijn met 
bitterballen, hebben we talloze mooie gesprekken gehad; vaak was een half 
woord al genoeg. Lieve Roos, dank je wel voor wie je bent.  
Dr. Ingrid Desar, lieve Ingrid, wij delen onze liefde voor het oncologie-vak, 
chocolade en witte wijn. Memorabel zijn onze congres-tripjes naar het buitenland 
met een aantal vaste elementen: uitstappen bij de verkeerde metrohalte, op 
hoge hakken door een bouwput lopen (dat bleek tòch niet de kortste route) en 
peperdure  wijn uit gesealde plastic glazen drinken. Ik heb het getroffen met jou 
als  sarcoom-maatje maar ook als vriendin. Nu op naar ons volgende project: 
een choco-to-go chocoladewinkel naast de espressobar in het restaurant van 
het ziekenhuis. 
Lieve vriendinnen en vrienden. Jullie zijn me heel dierbaar. Ik koester onze 
momenten van samenzijn, de latte macchiato’s, wijntjes, etentjes, tripjes, shop 
till you drop dagen, saunabezoeken en nog veel meer. Ook in moeilijkere tijden 
waren jullie er altijd voor mij en dat heb ik zeer gewaardeerd. Bijzondere dank 
aan de helpdesk-vriendinnen die in de eindspurt hebben bijgedragen aan het 
controleren van de inhoud van dit proefschrift.   
Lieve Roel, jij mag natuurlijk niet ontbreken in dit dankwoord. Ruim 21 jaar 
hebben wij lief en leed gedeeld. Onze levenspaden liepen uiteen, maar ik ben blij 
dat we nog steeds het beste met elkaar voor hebben. Jij hebt me altijd gesteund 
en gestimuleerd om mijn dromen te verwezenlijken. Dank je wel daarvoor. 
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Lieve familie, Rob & Margo, Mirian & Rob, Evert & Tjarda. Als klein meisje vond 
ik het al fijn dat ik 2 grote broers en 1 grote zus had. En dat vind ik nog steeds! Ik 
bof maar met jullie als directe familie en ik kan altijd terecht voor advies en hulp. 
Bij jullie is het altijd thuis komen. 
Lieve Veerle, Jort, Thijmen, Jasper, Lucas en Fenna, wat fijn dat jullie er vandaag 
(bijna) allemaal bij zijn. 
Lieve Pap en Mam, jullie hebben mij de basis gegeven om uit te groeien tot wie 
ik nu ben. En daar ben ik jullie heel dankbaar voor. Lieve Mam, jij volgt mijn wel 
en wee op de voet en enkele malen per week kletsen we even bij. Je bent niet 
alleen hofleverancier van Limburgse vlaai, maar vooral een voorbeeld voor mij. 
Lieve Hub, wat ben ik blij dat jij in mama’s leven bent gekomen. Samen is het 
mooier. Lieve Pap, wat zou je trots op me zijn. Ik koester de gedachte dat je er 
vandaag toch bij bent, op de eerste rij van het ‘balkon’.  
Lieve Okke en Lola, jullie zijn het grootste cadeau in mijn leven. Daar kan geen 
proefschrift tegenop. Lieve Okke, jouw energie is oneindig, je hockeytalent 
groot, je bent zorgzaam voor anderen, soms wat ondeugend en altijd een vrolijke 
noot. Lieve Lola, wat ben jij een lief en pienter meisje, een echte knuffelkont. Ik 
hou van jullie! 
Dankwoord
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Suzanne Elisabeth Jacqueline Kaal werd geboren op 11 mei 1977 in 
Venlo. In 1995 behaalde zij haar VWO-gymnasium diploma aan het 
St. Thomascollege te Venlo. Datzelfde jaar begon zij aan de opleiding 
Biomedische Gezondheidswetenschappen aan de Katholieke Universiteit 
Nijmegen (thans: Radboud Universiteit) met hoofdvak pathobiologie en bijvak 
geneesmiddelenonderzoek. In 1999 behaalde zij haar doctoraal examen en 
startte zij met de opleiding Geneeskunde aan dezelfde universiteit. In 2003 
behaalde zij haar artsexamen waarna zij werd aangenomen voor de opleiding 
Interne Geneeskunde onder supervisie van aanvankelijk prof. dr J.W.M. 
van der Meer en later prof. dr. J. de Graaf. Van 2003 tot 2007 werkte zij als 
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ElisabethTweeSteden Ziekenhuis) onder leiding van dr C. van der Heul en dr. P.L. 
Rensma. Daarna zette zij haar opleiding voort in het Radboudumc, aanvankelijk 
op de afdeling hematologie. In 2008 startte zij haar differentiatie Medische 
Oncologie met als opleider Prof dr W.T.A. van der Graaf. In 2009 rondde zij haar 
opleiding tot internist-oncoloog af. Sinds 2010 is zij verbonden als staflid aan de 
afdeling medische oncologie van het Radboudumc met als aandachtsgebieden 
zorg voor jongvolwassenen met kanker (AYA’s: Adolescents and Young Adults), 
bot en weke delen tumoren en zaadbalkanker. Vanaf die periode heeft zij een 
bijdrage geleverd aan de opzet en uitrol van AYA-zorg in het Radboudumc 
en daarbuiten. Zij is projectleider AYA-zorg van het Radboudumc en de regio 
Midden-Oost. Suzanne is de trotse moeder van Okke (2009) en Lola (2012). 
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